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Prostate cancer (PCa) is most commonly diagnosed cancer among men in the 
United States. Following PCa diagnosis, men often seek information about foods and 
supplements that may improve their response to therapies, quality of life and survival. 
Tomatoes and their primary bioactive (lycopene) are one of the most researched foods 
that have the potential to reduce prostate carcinogenesis. Currently, the majority of the 
literature has been observational epidemiological literature with inconsistent results. 
Although preventing PCa is preferable to treating PCa, patients seeking information about 
foods and supplements might already have cancer. Importantly, the prostate 
microenvironment is not the same prior to cancer initiation, during PCa promotion/ 
progression, and during treatment. As a result, we sought to clarify the epidemiological 
associations between tomatoes (and lycopene) and PCa incidence, and to evaluate the 
role of tomato feeding in an animal model that was undergoing two common treatment 
approaches.  
In Chapter 2, we evaluated the associations between tomatoes and PCa 
incidence. In this meta-analysis, we found that increased tomato consumption was 
associated with a reduced risk of PCa (RR=0.81, 95% CI =0.71-0.92, p=0.001). This 
finding was supported by dose-responses for several types of tomato products. In 
particular, it was observed that bioavailability of lycopene was important. Raw tomato 
consumption was not associated with a decreased risk of PCa (p=0.487), while cooked 
tomatoes and sauces (sources with high lycopene bioavailability) were associated with a 




In Chapter 3, we evaluated associations between lycopene and PCa incidence. 
Similar to the whole food product, increased lycopene consumption and blood 
concentrations were associated with a decreased risk of PCa. These associations were 
also supported by dose-response associations. From the dietary meta-analysis in 
Chapter 2, there was an estimated 9% reduced risk for 100 grams/week of cooked 
tomato. For an equivalent dose of lycopene (22 mg lycopene in 100 grams of tomato 
puree according to the USDA Nutrient Database), tomatoes were more effective than 
lycopene at reducing PCa risk (9% compared to 1.6%). The greater benefit from tomato 
products may be due to interactions between potentially beneficial bioactive compounds 
in tomatoes. These meta-analyses support the hypothesis that tomato products or 
lycopene reduce prostate carcinogenesis. 
In Chapter 4, we aimed to determine whether dietary lyophilized tomato powder 
(TP) or lycopene would be capable of affecting the growth of castration-resistant prostate 
cancer (CRPC). This aggressive and often lethal stage of PCa occurs after the prostate 
tumor acquires mutations to sustain growth despite androgen deprivation therapy (ADT). 
We hypothesized that tomato or lycopene products would reduce the emergence of 
CRPC. To test this hypothesis, TRansgenic Adenocarcinoma of the Mouse Prostate 
(TRAMP) mice were castrated at 12-13 weeks of age to model ADT, and the emergence 
of CRPC was monitored by ultrasound in two studies. In Study 1, TRAMP mice (n=80) 
were weaned onto an AIN-93G-based control diet (Con-L, n=28), a 10% TP diet (TP-L, 
10% lyophilized w/w, n=26), or a control diet followed by a TP diet after castration (TP-
Int1, n=26). In Study 2, TRAMP mice (n=85) were randomized onto a control diet with 




a control diet with lycopene beadlets (Lyc-Int, n=27) following castration (12 weeks of 
age). Tumor incidence and growth were monitored by ultrasound beginning at 10 weeks 
of age. Mice were euthanized 4 weeks after tumor detection or at 30 weeks of age if no 
tumor was detected. In contrast to studies of de novo carcinogenesis in multiple pre-
clinical models, tomato components following castration did not reduce CRPC incidence, 
time to tumor detection or final tumor weight.   
In Chapter 5, we hypothesized that dietary TP would not reduce apoptosis or cell 
death within the prostate tumor following external beam radiation therapy (EBRT) and 
would protect surrounding tissues from radiation-induced damage. Tomatoes contain 
carotenoids and other potent antioxidants. To evaluate this hypothesis, we conducted a 
pilot and dietary study. In the pilot study, male TRAMP mice (n=18) were provided a 
powdered AIN-93G diet. In the Diet study, male TRAMP mice (n=76) were provided a 
control diet or a modified AIN-93G diet containing 10% TP (w/w) beginning at 4 weeks of 
age. In both studies, prostates were monitored by ultrasound for in vivo tumor detection 
and 3-D volumetric measurement biweekly. Once tumors reached a volume of 1000 mm3 
or at 24 weeks of age, the caudal half of the mouse was irradiated with 7.5 gy (Rad) or 0 
gy (sham) with a Cobalt-60 source. In the pilot study, mice were euthanized after 0, 24, 
or 72 hours. Based on the results of the pilot study, mice in the main Diet study were 
euthanized 24 hours after radiation or sham treatment. Within the Diet study, prostate 
tumor scores for apoptosis and necrosis were not modified by tomato consumption; 
however, tomato consumption did not reduce acute changes in radiation-induced 




In conclusion, this work has revealed consistent associations between tomato 
products or lycopene and risk of prostate cancer incidence within published 
epidemiological studies. In our preclinical studies of tomato products and PCa treatments 
(ADT and EBRT), it was found that the responses to treatment were not modified by a 
diet containing 10% TP or lycopene. While further work in animal models and humans 
are needed, it is notable that these are the first studies to evaluate the interactions 
between tomato products on PCa treatments. Data from these epidemiological and 
preclinical studies highlight the importance of healthy dietary patterns throughout the 
lifespan. These data are very important for patients that are diagnosed with PCa and seek 
out information about the types of foods or supplements that can improve their clinical 
outcomes. Further studies should evaluate differences within the tumor microenvironment 
to determine if tomato products are more effective for specific subtypes or specific clonal 
populations of PCa. Additional epidemiological studies are also needed to determine if 
circulating lycopene concentrations are associated with specific stages of PCa and 
treatment-associated outcomes (such as biochemical recurrence and cachexia). In 
summary, this dissertation has contributed novel findings to our understanding of the 
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Chapter 1: Literature Review 
Prostate cancer biology, diagnosis, and treatment 
Prostate cancer (PCa) is the second most common cancer among men worldwide 
and is the fifth leading cause of cancer related deaths worldwide.1 PCa is a disease of 
aging.2 Clinical symptoms are rare in men younger than 50, with approximately 2/3 of 
cases occurring in men aged 65 and older. Incidence rates vary substantially across 
countries, primarily due to the advent of prostate specific antigen (PSA) testing.1,3 For 
example, PCa accounts for 21% of new cancer diagnoses among men in the United 
States compared to 15% worldwide.1,4 Guidelines for PCa screening vary between 
countries, medical organizations and guideline groups.5 Differences in screening intervals 
and guidelines may affect PCa detection and incidence rates.6 Racial and genetic profiles 
also modulate risk for PCa.4,7,8 Although these risk factors are largely based on genetics 
and location, only 15% of cancers are due to hereditary/genetic mutations. Approximately 
85% of cancers are driven by environmental factors that are mostly determined by 
lifestyle.  Diet and nutrition are drivers of nearly 40% of all cancers and modulates risk for 
PCa.9,10 
If PCa is detected early, common therapeutic options include: active surveillance, 
surgery (prostatectomy), external beam radiation therapy (EBRT) or chemotherapy.11-13 
In particular, EBRT has become more precise and novel methods of delivering the 
radiation dose have been proposed to improve patient outcomes. Despite improved 
treatment, approximately 60-69% of men who receive EBRT develop biochemical 
recurrence.14 The primary limitation for radiation therapy, is the potential for damage to 




limited the amount of radiation that a patient may endure and the therapeutic 
effectiveness of EBRT. For example, radiation therapy is typically accompanied with 
bowel and sexual dysfunction,15 and importantly (but less common), secondary tumors 
and PCa progression.16,17 Novel approaches are needed to improve the therapeutic 
effectiveness of EBRT and outcomes for PCa. 
In clinical practice, the maximal dose is typically limited by potential for damage to 
the surrounding (non-tumor) tissues. As the dose of 
radiation increases, oxidative damage within the 
tumor and surrounding tissue increases and the 
number of required doses (fractions) decrease 
(Figure 1.1). Acute and chronic toxic effects such 
as gastroenteritis, bowel dysfunction, sexual 
dysfunction, reduce the clinical effectiveness of 
EBRT. A low α/β ratio (1-3 gy range, ~1.8 on 
average)18,19 for PCa, indicates that PCa tumors 
may be highly responsive to lower doses of radiation that are delivered in multiple doses 
(fractions).19-21 Hypofractionation is hypothesized to improve tumor free recurrence, 
reduce biochemical recurrence, reduce treatment-associated trips to the hospital (~50% 
fewer trips), and reduce cost associated with treatment (~$1900 per patient).22-24 The 
surrounding tissues have a higher α/β ratio (~3.6-5 gy for bladder and rectum), which 
indicates that hypofractionation will not likely affect acute toxicity to normal surrounding 
tissue. Several clinical trials have investigated the clinical differences between these 
approaches. All have found that there are no differences between these two treatment 
Figure 1.1: Delivery of the total dose for 
radiation may be achieved through differing 
fractionation schemes. As fraction size 





schemes. This includes toxicity (acute or chronic) and relapse-free survival.25-30 Pending 
results from long-term follow up studies, hypofractionation will likely become the next 
standard of care for PCa treatment.   
Despite improvements to PCa detection and treatment, approximately 30% of men 
treated with curative interventions suffer tumor recurrence.31 These men, along with men 
diagnosed with advanced or metastatic cancer, usually undergo androgen deprivation 
therapy (ADT) to reduce systemic androgens.31,32 Huggins introduced the first strategies 
(castration) for reducing serum androgen levels as a treatment for PCa in the 1940s,33 
which led to a Nobel Prize in 1966. Since then newer androgen inhibitors have become 
safer and more specific toward targeting metabolites along androgen synthetic 
pathways.34 Despite these advances and initial success, most patients undergoing ADT 
progress to an advanced and lethal stage of PCa that responds very poorly to all known 
therapies. This is a condition known as castration resistant prostate cancer (CRPC).32,35-
37 CRPC is a lethal stage of PCa with a median survival of only 18 months.38,39 ADT has 
largely remained the standard for care among men with advanced and metastatic PCa. 
Recently, chemotherapy and hormonal therapeutic approaches have been integrated into 
the treatment regiments.39-42 This led to a 50% increase in survival from 12 months to 18 
months. Although progress has been made to improve life expectancy, the prognosis for 
CRPC is still very poor and accompanied by many negative adverse effects. Advances 







Tomatoes, carotenoids, and lycopene 
Tomatoes are the most consumed non-starchy vegetable in the United States, 
accounting for 19% of all vegetable consumption.43 Tomato consumption is generally 
divided into two forms—fresh tomatoes and processed tomato products. The average 
intake for tomatoes in America is a quarter of one cup per day, with 56% of typical 
consumption coming from tomato products and 44% from fresh tomatoes.43 Tomatoes 
are good sources of many nutrients and bioactive food components such as lycopene, 
carotenoids, flavonoids, potassium, folate, fiber, and vitamins that may improve health 
status.  
Lycopene is the dominant carotenoid and 
primary hypothesized bioactive in tomatoes.44,45 
Carotenoids are a family of compounds of over 600 lipophilic plant pigments that 
contribute the visible colors of many plants.44,46 As a carotenoid, lycopene is responsible 
for the red color of some fruits and vegetables. The structure of carotenoids is based on 
a C40 isoprenoid backbone that may be acyclic or have one or both ends modified into 
rings. In human sera, lycopene is a mixture of ~50% all-trans and cis lycopene.47 All-trans 
lycopene is a linear molecule that is constrained by a system of eleven conjugated double 
bonds (Figure 1.2). 5-cis lycopene is the second most common isoform in the serum.48 
Of the identified carotenoids, ~60 are found in the diet, with far fewer in detectible 
quantities in the blood.46 Dietary sources of each of the most common carotenoids can 
be found in Appendix A. Feeding synthetic (supplemental) lycopene can also provide 
lycopene isomers to tissues within a comparable range to the diet, but the whole food 




matrix contains additional carotenoids, polyphenols and bioactive components that might 
be important for disease management.  
Lycopene absorption, bioavailability, and metabolism 
Before carotenoids are able to be absorbed, they must be released from their food 
matrix, incorporated into lipid droplets, and then micelles must be taken into the 
enterocytes.49 In the duodenum, bile salts reduce the size of the lipid droplet and increase 
the surface area for lipolytic digestion. Carotenoids that are within the core of micelles 
may diffuse into the enterocyte.46,49 In addition to diffusion, lycopene, beta-carotene and 
lutein may also be actively absorbed through receptor-mediated transport in the 
duodenum. This transport requires the Class B Scavenger Receptor (SR-B1) membrane 
protein, which selectively uptakes cholesterol and other lipophilic substances.50,51 
Although SR-B1 has low substrate specificity, beta-carotene is absorbed more efficiently 
than lycopene through this transport mechanism.52  
 There is a wide intraindividual variation in carotenoid bioavailability. This may be 
due to a number of factors regarding genetic differences, food preparation procedure, 
and interactions with other foods during digestion. For example, carotenoids are generally 
more bioavailable as they are released from their respective food matrix. Food 
processing, such as heating (cooking/thermal processing), mechanical and enzymatic 
degradation facilitate the disruption of the cell wall and organelles that contain 
carotenoids, which allows for dispersal and absorption in the small intestine.53-55 Because 
of the highly lipophilic nature of carotenoids, lipid consumption is essential to the 
adequate absorption of carotenoids. Increased lipid consumption (particularly long chain 




Additionally, there is differential absorption of isoforms. Cis isoforms of lycopene are 
generally better absorbed than the all-trans isoform.47 Some soluble fibers disrupt 
micellization and can reduce the bioavailability of carotenoids. Notably, soluble fibers 
decrease cholesterol and lipid absorption, which reduces carotenoid bioavailability.46,49 
Genetic variability may play a large role in lycopene bioavailability. In one study, a 
combination of 28 single nucleotide polymorphisms (SNPs) in 16 genes accounted for 
72% of lycopene bioavailability variation.59 These differences in lycopene bioavailability 
may affect long-term blood lycopene status.59,60 
Lycopene is packaged into chylomicrons within the enterocyte and enters 
circulation.61 Once in circulation, the half-life for lycopene is 6.2 days (5.3 for trans-
lycopene and 8.8 days for cis-lycopene).62 Lycopene is deposited in a number of tissues 
where it can be metabolized. Two enzymes are thought to be involved in the initial 
cleavage of lycopene. The first enzyme, beta-carotene 15,15'-monooxygenase 1 (BCO1), 
is cytosolic, has limited substrate specificity, and cleaves at the central bond.63 It is 
currently under debate as to whether BCO1 actually cleaves lycopene,64-67 but BCO1 
knockout mice have altered accumulation of lycopene compared to wild type mice.68 The 
second enzyme, beta-carotene 15,15'-monooxygenase 2 (BCO2), catalyzes asymmetric 
cleavage of lycopene to form apo-lycopenals.69 These apo-lycopenals are also found in 
the diet, and are absorbed by a similar method to other carotenoids.70 Apo-lycopenals are 
metabolically active and may contribute to the potential health benefits in tomatoes.71,72 
BCO2 is located in the mitochondrial matrix and displays specificity for lycopene along 
with other carotenoids and xanthophylls.73,74 In BCO2 knockout mice, lycopene is not able 




Evaluation of safety for carotenoids 
Carotenoid supplementation is well tolerated by most people. Lycopene was assessed in 
a Phase I-II clinical trial for toxicity with daily supplementation of 15, 30, 45, 60, 90, or 120 
mg lycopene (provided as Lyc-O-Mato) per day.76 Of the 36 patients that were evaluated, 
one patient developed diarrhea (grade 2 toxicity), and the others did not develop any 
toxicities attributable to the supplementation. Another study evaluated the observed 
safety level through a risk assessment method for lycopene.77 Based on the literature, 
the observed safety level for lycopene consumption was 75 mg lycopene per day. As a 
reference, one serving of tomato sauce (half a cup or 120 grams) provides 6.9 mg of 
lycopene, and an average adult in the United States consumes 4.5 mg lycopene per day. 
In the same study, lutein was also assessed. The observed safety level in this risk 
assessment for lutein was 20 mg per day.77 For reference, one egg yolk has 
approximately 1 mg of lutein, and an average American adult consumes 1.5 mg of lutein 
and zeaxanthin per day. Although β-carotene was not directly evaluated for toxicity, it is 
generally recognized as safe (GRAS, 21CFR, Sect 182.5245, 184.1245) as a supplement 
and nutrient.78 
 
The Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model 
The transgenic adenocarcinoma of the mouse prostate (TRAMP) model was 
developed in the laboratory of Norman Greenberg during the 1990s. The TRAMP model 
is a transgenic line of mice that spontaneously developments of PCa in the prostatic 
epithelium. Prostate epithelium-specific expression of the simian virus 40 large and small 




prostate carcinogenesis in all TRAMP mice.79,80 Probasin expression is androgen 
dependent and stimulates growth upon puberty in these mice.81 The viral large T antigen 
inhibits the tumor suppressors p53 and Rb,80,82-84 two genes commonly lost in human 
PCa39, while the small t antigen inhibits protein phosphatase 2A, a negative regulator of 
the pro-proliferative MAP kinase pathway.80,83,84 
This model has been extensively used for investigation of pharmacological and 
nutritional preventative methods.79 This model has been used extensively as a model of 
PCa; at least 1000 original articles appear on PubMed (March, 2020). Primary,80,85 
metastatic,85,86 and castration-resistant PCa87-89 have been characterized in this model. 
Several aspects of the TRAMP model make it an appropriate model of human PCa, 
especially CRPC. The model demonstrates a progression from early low-grade 
hyperplasia through to metastasis, similar to human disease.  
Castration initially induces prostatic or tumoral regression before emergence of 
CRPC, and some tumors exhibit AR mutations.90 One concern with this model has been 
the presence of neuroendocrine (NE) differentiation. NE markers are indeed expressed 
in adenocarcinoma lesions of intact TRAMP mice and incidence increases with cancer 
grade.89 Tumors in castrated TRAMP mice also contain NE foci,89 which are not 
dependent upon circulating androgens.91 However, it is crucial to recognize that 
neuroendocrine differentiation in intact and castrated TRAMP mice reflect the pathology 
of advanced human PCa. NE differentiation is commonly found in many primary human 
PCa tumors and correlates with both tumor grade and Gleason score.92 Similarly, NE 
differentiation is found in human CRPC.93 Therefore, foci of NE differentiation appear to 




The interaction of diet and cancer is a very complex process that needs to be 
studied in the whole animal. We are primarily investigating the efficacy of a whole food 
(tomato powder) in cancer prevention; therefore, an animal model that digests and 
metabolizes the food and nutrients of interest is critical for any future translation/use for 
human trials. Animals must be used in order to collect data from serum and tissue 
analysis, particularly for pathologic tumor grade evaluation. There are no suitable 
alternatives currently in existence that would provide the unique tissue and cellular 
environmental and cytoarchitectural features that exist in the TRAMP mouse model that 
we are proposing to use. This animal model enables a focused and controlled 
environment for efficient dietary intervention studies to occur.  
 
Diet and the Tumor Microenvironment 
Although, tomato and lycopene consumption were found to be inversely 
associated with PCa progression among observational studies,94,95 it is not known if this 
correlation is due to lower overall cancer incidence, interactions with therapeutic 
approaches, or alterations in the trajectory of disease development. Very few clinical trials 
have evaluated the effect of lycopene or tomato-based supplementation on PCa 
progression. In general, the studies have suffered from methodological constraints such 
as short periods of supplementation and small sample sizes.96 This has limited the ability 
to assess the clinical effectiveness of these interventions, creating a knowledge gap 
regarding the effectiveness of tomatoes or lycopene as a nutritional intervention. While 
data suggest that tomato consumption may provide a benefit to men with advanced PCa, 




studies. Ultimately, a better delineation of these interventions may lead to novel nutritional 
strategies to improve PCa outcomes, positively influence treatment selection and improve 
recommendations for patients with advanced PCa. 
Currently, little is known about the impact of dietary tomato and its primary 
bioactive, lycopene, on PCa progression and the tumor microenvironment following 
treatment. We have previously demonstrated that tomato feeding reduced gene 
expression of cell cycle progression, proliferation, and androgen signaling markers in 
early carcinogenesis in TRAMP mice.97 In rodent models of PCa, dietary lycopene has 
been shown to downregulate gene expression of autocrine and paracrine growth factors, 
reduce carcinogenesis, and inhibit tumorigenesis.97-102 Lycopene and other tomato 
carotenoids accumulate in the prostate gland where they may protect DNA from oxidative 
damage and early carcinogenetic events.103,104  
Lycopene has been shown to upregulate interleukin (IL)-12 and interferon (IFN)-γ 
in cultured cells.101,105 IL-12 is a key negative regulator of angiogenesis by stimulating 
IFNγ, which mediates production of anti-angiogenic chemokines.106 Other studies have 
found that lycopene may be anti-angiogenic by inhibiting matrix metalloproteinase 2 
(MMP-2) and urokinase-type plasminogen activator (UPA) through vascular endothelial 
growth factor receptor (VEGFR)-2 mediated PI3K-Akt and ERK/p38 signaling pathways, 
leading to decreased vessel formation, invasion and metastasis.101,107-109 Within these 
studies, there was also down-regulated expression of ras-related C3 botulinum toxin 
substrate (Rac)-1 and upregulated expression of tissue inhibitors of metalloproteinase-2 
(TIMP-2) and plasminogen activator inhibitor-1 (PAI-1) which have been suggested to 




Current research and preliminary data suggest that feeding TP can reduce de novo 
androgen synthesis, which is critical for tumor growth and is the target of several PCa 
therapies such as ADT.97,110 Lycopene, and other tomato bioactives may improve the 
effectiveness of radiation therapy and ADT by improving inflammatory status,104 androgen 
and growth factor signaling,97,110 apoptosis,104,111,112 and cell cycle progression.104,111,112 
Recent evidence further supports that the whole food (tomatoes) is more effective than 
the individual bioactive (lycopene) as a potential adjuvant or chemopreventive 
agent.103,113-115 Even though lycopene has therapeutic potential, our lab has shown using 
a chemically-induced model of PCa that TP, but not lycopene, resulted in longer survival 
compared to a control diet in our lab.114 Additionally, our laboratory and others have 
revealed that tomato feeding reduces PCa incidence.113,116,117 We have also shown that 
a 10% TP diet was effective at reducing tumor weight and cellular proliferation, while 
increasing apoptosis in the Dunning transplantable tumor model.115 In addition to the anti-
carcinogenic properties of tomatoes and lycopene, our previous data also suggest that 
there is great potential of tomatoes and lycopene to improve therapeutic outcomes that 
have not been explored. 
Growth of primary PCa and CRPC tumors are driven by androgens. Tumors that 
relapse during ADT were originally believed to be “androgen independent”, but very low 
levels of androgens may still be detectable in tissue and serum of advanced 
patients.36,37,118 Alternative pathways have been discovered whereby androgens can 
arise and accumulate within the tumor despite ADT.36,37,118 Androgen receptors in patients 
with CRPC are expressed at similar levels to those in androgen-stimulated PCa and 




expressed in CRPC tumors despite the reduction in signals from androgen deprivation 




The gene that 





on the androgen 
receptor.121 Interestingly, tomato supplementation has been shown to reduce serum PSA 
levels.117,122 This lowered concentration of PSA consistent with a decrease in androgen 
concentration within the prostate tumors.121 Additionally, we have previously 
demonstrated that tomato or lycopene consumption reduces mRNA expression of 
enzymes that are important for de novo synthesis of androgens.97 Consistent with our 
preliminary data and other studies, tomato or lycopene consumption appears to have a 
beneficial effect on the androgen axis by reducing testosterone and dihydrotestosterone 
biosynthesis (Figure 1.3). These results suggest that tomato and lycopene may exert 
protective effects for primary PCa and CRPC through modulation of the androgen axis.  
Figure 1.3. Proposed benefit of tomato and lycopene consumption on the 




17β-hydroxysteroid dehydrogenase 3 (Hsd17b3) catalyzes the reduction of the 
inactive androstenedione to active testosterone and also acts on 5α-reduced androgens, 
converting androstanedione to the most potent androgen, 
dihydrotestosterone (DHT).123 Conversely, 17β-
hydroxysteroid dehydrogenase 2 (Hsd17b2) catalyzes the 
reverse reaction, oxidizing testosterone and DHT back to 
their inactive precursors (Figure 1.4). The balance between 
Hsd17b2 and Hsd17b3 activity may be critical, as Hsd17b2 
mRNA expression is low and Hsd17b3 expression is high 
in malignant prostate tissue.124 Thus, an elevated 
Hsd17b2:Hsd17b3 ratio may contribute to net inactivation of intratumoral androgens and 
a less aggressive disease phenotype. Unpublished data from a previously mentioned 
TRAMP study demonstrated that tomato feeding increased the ratio of Hsd17b2:Hsd17b3 
gene expression in primary tumors more than 2.5-fold (Figure 1.4).116 Additionally, tumor 
and prostate tissue weight was reduced 42% in tomato-fed animals compared to control-
fed mice (data not shown). These results suggest that tomato and lycopene may exert 
protective effects for primary PCa and CRPC through modulation of the androgen axis.  
 
Levels of evidence 
 Based on the epidemiological and preclinical evidence for PCa, many men with 
PCa might choose to consume lycopene supplements without evidence from definitive 
phase III human trials. One of the primary goals of evidence-based research is to provide 

































Figure 1.4. Gene expression 
ratio of Hsd17b2:Hsd17b3 in  
tumors of 18-week-old TRAMP 
mice fed control or 10% tomato 
powder diets for 14 weeks 





research is a hierarchical classification system known as the levels of evidence.125 
Clinicians and patients are encouraged to utilize information from the highest level of 
evidence possible to encourage their decisions.  
Systematic reviews of randomized control trials (RCTs) produce the highest level 
of evidence for therapeutic studies and are the most reliable source of determining causal 
relationships between dietary exposures and prostate carcinogenesis. Currently, the 
highest level of evidence for tomatoes and PCa are found in cohort studies, which are not 
capable of determining causal relationships. Importantly, most cohort studies did not 
report sources of tomatoes that were thermally processed or consumed with dietary fat.126 
The exclusion of these tomato products results in reporting of foods with low absorption 
of lycopene (such as seen with raw tomatoes)53-55 and other phytochemicals that might 
modify the growth and progression of a prostate tumor. Systematic reviews and dose-
response meta-analyses are needed to increase the reliability of the hypothesis that 
tomatoes and lycopene are associated with decreased prostate carcinogenesis. 
 Although reducing prostate carcinogenesis is preferable to treating PCa, studies 
have not evaluated the role of tomato feeding within therapeutic approaches for PCa.  
Following PCa diagnosis, patients often seek information about food and supplements 
that may improve their response to therapies, quality of life, and survival. Data regarding 
the interactions between tomato consumption and therapeutic approaches are critically 
needed because it is not currently known if tomatoes will improve or worsen the intended 
treatment. Lycopene and other carotenoids that are present within tomatoes are potent 
antioxidants that may improve natural defenses by scavenging free radicals generated 




but this same property could also reduce the effectiveness of the radiation therapy within 
the prostate tumor. More data are required to determine whether tomato products 
influence the efficacy of prostate cancer treatment. 
 
Aims of this Dissertation 
Following prostate cancer (PCa) diagnosis, men often seek information about food 
and supplements that may improve their response to therapies, quality of life and survival. 
If PCa is detected early, common therapeutic options include: active surveillance, surgery 
(prostatectomy), radiation therapy and/or chemotherapy.11,12 Despite primary treatment, 
approximately 30% of men suffer tumor recurrence.31 These men, along with men 
diagnosed with advanced or metastatic cancer, usually undergo ADT.31,32 While current 
therapies are initially successful for primary PCa, combinatorial dietary techniques are 
increasingly needed to protect against PCa progression and to alleviate adverse effects 
associated with from common therapies.  
The proposed studies include two dose response meta-analyses of the published 
literature associated with tomato or lycopene exposure and PCa risk. The proposed 
studies also include two preclinical studies utilizing the TRAMP mouse model to provide 
critical data on the ability of tomato or lycopene consumption to enhance clinical 
outcomes of PCa therapies (EBRT and ADT) that may reduce progression, improve 
quality of life, and increase survival. Elucidating whether these dietary approaches can 
improve therapeutic outcomes should positively affect treatment selection and 
recommendations for patients. Therefore, the aims of this dissertation are the following: 
1. Evaluate the epidemiological associations between the exposures of tomatoes or 




Hypothesis 1: We hypothesized that increased tomato consumption would be 
associated with a reduced risk of PCa incidence. 
Hypothesis 2: We hypothesized that increased lycopene exposure (dietary and 
blood) would be associated with a reduced risk of PCa incidence.  
2. Determine the potential of tomato or lycopene interventions to reduce the growth 
and progression of CRPC in the TRAMP model 
Hypothesis: We hypothesized that tomato and lycopene interventions would 
reduce the incidence of CRPC tumors and would reduce the growth of CRPC 
tumors over 5 weeks of ultrasound monitoring. 
3. Evaluate the potential for lyophilized tomato powder to reduce radiation-induced 
apoptosis and cell death in prostate tumors and surrounding tissues in the TRAMP 
model.  
Hypothesis 1: We hypothesized that dietary lyophilized tomato powder (TP) 
would not reduce apoptosis or cell death scores within the prostate tumor 
following external beam radiation therapy (EBRT). 
Hypothesis 2: We hypothesized that TP would reduce apoptosis and cell death 




Chapter 2: Processed and raw tomato consumption and risk of prostate cancer: a 




Background: Prostate cancer (PCa) is the second most frequently diagnosed cancer 
among men worldwide. Many epidemiological studies have found an inverse association 
between increased tomato consumption and PCa risk. This study aims to determine the 
associations between consumption of various types of tomato products and PCa risk and 
to investigate potential dose-response relationships.  
Methods: We conducted a systematic review and dose-response meta-analysis of dietary 
tomato in relation to PCa. Eligible studies were published before April 10, 2017 and were 
identified from PubMed, Web of Science, and the Cochrane Library. We estimated pooled 
risk ratios (RR) and 95% confidence intervals (CI) using random and fixed effects models. 
Linear and nonlinear dose-response relationships were also evaluated for PCa risk.  
Results: Thirty studies related to tomato consumption and PCa risk were included in the 
meta-analysis, which summarized data from 24,222 cases and 260,461 participants. 
Higher total tomato consumption was associated with a reduced risk of PCa (RR=0.81, 
95% CI: 0.71-0.92, p=0.001). Specifically, tomato foods (RR=0.84, 95% CI: 0.72-0.98, 
p=0.030) and cooked tomatoes and sauces (RR=0.84, 95% CI: 0.73-0.98, p=0.029) were 
associated with a reduced risk of PCa. However, no associations were found for raw 
                                               
a The content of this chapter has been published (Reference 127. Rowles JL, Ranard 
KM, Applegate CC, Jeon S, An R, Erdman JW. Processed and raw tomato consumption 
and risk of prostate cancer: a systematic review and dose–response meta-analysis. 




tomatoes (RR=0.96, 95% CI: 0.84-1.09, p=0.487). There was a dose-response 
association observed for total tomato consumption (p=0.040), cooked tomatoes and 
sauces (p<0.001), and raw tomatoes (p=0.037), but there was not a significant 
association with tomato foods (plinear=0.511, pnonlinear=0.289). 
Conclusions: Our data demonstrates that increased tomato consumption is inversely 
associated with PCa risk. These findings were accompanied with dose-response 
relationships for total tomato consumption and for cooked tomatoes and sauces. Further 
studies are required to determine the underlying mechanisms of these associations. 
Introduction 
Prostate cancer is the second most common cancer in men and is the fifth leading 
cause of cancer-related deaths worldwide.1 The development of PCa is complex and is 
influenced by a combination of genetic, hormonal and environmental factors.97 Diet is one 
of the most modifiable risk factors for PCa. Many epidemiological studies have 
investigated tomato products and their association with PCa carcinogenesis. Despite 
much positive data, studies have yielded mixed results. Lycopene, a lipophilic carotenoid 
that gives some fruits and vegetables their red color, is believed to be the primary 
bioactive component in tomatoes.44,45 Meta-analyses of observational studies indicate 
that increased lycopene exposure (diet or circulating blood concentrations) is associated 
with a reduced risk of PCa.128-132 In the United States, more than 85% of dietary lycopene 
comes from tomato products, which suggests that lycopene could be a surrogate 
biomarker of tomato consumption.44,45,133 In addition to lycopene, tomatoes contain other 
carotenoids (i.e., phytoene and phytofluene) and polyphenols that accumulate in the 




Three previous meta-analyses have investigated the association between tomato 
consumption and PCa risk.128,130,137 Among these analyses, none found an association 
with raw tomatoes,128,130 one found an association with cooked tomatoes,130 and one 
found an association by mixing risk estimates of multiple tomato products together.137 
However, previous analyses have not investigated the association between tomato 
consumption and advanced PCa risk. Additionally, none of the previous analyses 
investigated potential dose-response associations. The current study systematically and 
quantitatively evaluates the associations between dietary tomato and PCa risk. This 
meta-analysis enhances the existing literature about dietary tomato and its associations 
with PCa by investigating multiple forms of tomatoes (including tomato foods, cooked 
tomatoes, sauces, raw tomatoes and pizza), which provides a more comprehensive view 
of the associations between tomato consumption and PCa risk. This is also the first meta-
analysis that evaluates the relationship between tomatoes and advanced PCa. It is also 
the first to investigate trends over time through cumulative meta-analyses and potential 
dose-response associations.   
 
Materials and Methods 
Study selection criteria 
 This meta-analysis was conducted in accordance with the PRISMA guidelines and 
the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines.138,139 
Studies that met the following criteria were included in this meta-analysis: (a) evaluated 
the association between tomato products and PCa risk by using randomized control trials, 




was documented in replicable detail; (c) included relative risk ratio with 95% confidence 
intervals (CIs) for exposure categories; (d) articles were written in English; and (e) peer-
reviewed publications or theses. Additionally, studies that provided doses of tomato 
products, length of intervention, and relative risk for PCa were included in the dose-
response meta-analysis.   
Literature search  
We conducted a comprehensive literature search in PubMed, Web of Science and 
the Cochrane Library from their inception to April 10th, 2017 using the following key words: 
prostate cancer, prostate neoplasm, tomato, carotenoids, humans, case-control studies, 
follow-up studies, cohort, prospective studies and their variants. Titles and abstracts of 
articles that were identified by the keyword search were screened against the study 
selection criteria. Potentially relevant articles were independently retrieved for evaluation 
of the full text by two authors (JR3 and CA). We also conducted a reference list search 
(i.e., backward search) and cited reference search (i.e., forward search) from full text 
articles meeting the study selection criteria. Articles identified through this process were 
further screened and evaluated using the same criteria. We repeated searches on all 
newly identified articles until no further relevant articles were found. Two authors (JR3 
and KR) individually determined inclusion/exclusion of all articles retrieved in full text and 
discrepancies were resolved through discussion.  
Data extraction and quality assessment 
 The following information was extracted from each study: name of first author; year 
of publication; location of study; study period; number of cases, controls, total number of 




tomato sources consumed (raw tomato, cooked tomato, tomato sauces, 
multiple/undescribed sources, and pizza); relative risk ratios for prostate cancer; 
adjustments for covariates; and study type. Data extraction from each study was 
independently conducted by two authors (JR3 and SJ). Authors were contacted for 
additional data for studies that had missing values for tomato exposure, relative risk for 
PCa incidence, or the number of cases. The term RR (relative risk) will be used as a 
generic term for relative odds (cumulative incidence data), rate ratio (incidence-rate data), 
odds ratios (case-control data) and for hazard ratios (HR). The quality of each study was 
evaluated by two authors (JR3 and KR) using the Newcastle-Ottawa Scale, which is a 
validated scale for non-randomized cohorts in a meta-analysis.140 This tool judges the 
literature based on three broad categories: selection of cases and controls; comparability 
of studies; and exposure of the main variable. We regarded scores of 1-3, 4-6 and 7-9 as 
low, medium and high quality, respectively. The quality score helped to measure the 
strength of each study’s evidence and was not used to determine the inclusion of studies. 
Other aspects of study quality were analyzed in the subgroup analysis.  
Statistical analysis 
 RRs and 95% CIs were used as a measure of the effect size for all studies because 
HR and odds ratios (OR) are approximately equal to RR for low incidence of diseases.141 
Heterogeneity among studies was explored by using Cochran’s test and I2 statistic.142 
Fixed and random (DerSimonian-Laird) effects were applied based upon the I2 value as 
a marker of study heterogeneity.142 If there was low to moderate heterogeneity between 
studies (I2<50%) a fixed effect model was used to determine RR estimates. If 




model was applied. When results from fixed and random effects models were different 
with moderate heterogeneity (I2: 30-60%), we presented the latter as it represents a more 
conservative approach.143,144  
If tomato consumption was reported by the number of servings per unit time, we 
followed the U.S. Food and Drug Administration’s (FDA) Code of Federal Regulations 
(CFR) Title 21 Part 101 regulation for food labeling 
(http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=101) to 
approximate the number of grams per serving. The number of grams per serving were as 
follows: 148 grams per serving for raw tomato; 60 grams per serving for tomato sauces 
or cooked tomatoes; 104 grams per serving (1:1 ratio of raw and cooked tomato products) 
for tomato foods. Tomato foods were defined as exposure categories that did not indicate 
the source of tomato or combined multiple exposure categories (i.e., cooked and raw 
tomatoes). Details on the exact items included for each study can be found in Table B.1. 
We utilized the following hierarchy of lycopene bioavailability from tomato sources based 
on previous literature: tomato sauce = cooked tomatoes > tomato foods > raw tomatoes 
> pizza.53,54,57,58 Pizza was considered the lowest bioavailable group due to the 
heterogeneity of tomato sauce (if present) and differential preparation methods.  
The study-specific RR for the highest quantile was compared to the lowest quantile 
of each dietary tomatoes source because studies report different exposure categories as 
tertiles, quartiles and quintiles. Potential publication bias was assessed by using funnel 
plots145,146 with Egger’s linear regression test147 and Begg’s rank correlation test of 
asymmetry.148 If evidence of asymmetry was indicated, the trim-and-fill method was used 




performed sensitivity analyses to evaluate whether the pooled results could have been 
affected by excluding a single study at a time. Subgroup analyses were performed on 
study type, location of study and covariate adjustment. If the total number of cases or 
person-years were presented without distribution, we estimated the distribution by 
dividing by the number definitions of the quantiles.  
 For the meta-analysis of the dose-response association between tomato 
consumption and PCa risk, the method of generalized least squares for trend estimation 
proposed by Greenland and Longnecker was utilized.150,151 Based on data for each level 
of tomato consumption, study specific slopes (with 95% CIs) were generated. 
Additionally, we examined linear and nonlinear associations between tomato 
consumption and PCa risk by plotting linear and nonlinear dose-response curves using 
restricted cubic spines, with 3 knots at 10%, 50% and 90% of the distribution. A p-value 
for curve linearity and nonlinearity was calculated by testing that the coefficient of the 
second spline was equal to zero. All data were analyzed by STATA/IC version 14.2 




Literature search  
The initial abstract screening and reference list search yielded a total of 1,825 
articles after removing duplicates. After screening these titles and abstracts, 74 articles 
remained for full-text evaluation. Among the 44 excluded articles, 21 did not discuss 




data that were included in other studies/later follow-ups,191,192 and 2 had an irrelevant 
topic193,194. Among these articles, 30 were included and 44 were excluded. From the initial 
30 articles that were included in the meta-analysis, 19 studies investigated the association 
of tomato foods,179,195-212 10 investigated raw tomatoes,195,201,205,208,213-218 7 investigated 
tomato sauce,201,208,217,219-222 6 investigated cooked tomatoes,202,208,213,215,216,218  and 4 
investigated pizza201,208,217,223 (Figure 2.1). 
Study characteristics 
Table 2.1 summarizes the 30 studies that investigated the association between 
tomato consumption on PCa risk. Among these studies, 21 were case-control 
studies179,195,197-200,202,203,205-207,209,211,212,214-216,218,221-223 and 9 were cohort studies 
196,201,204,208,210,213,217,219,220. These studies had a combined total of 24,222 cases and 
260,461 participants. Twelve studies were from North 
America,179,195,199,201,202,204,208,211,216,217,219,220 8 were from Europe,196,197,205,212,214,215,218,223 
8 were from Asia,200,203,206,207,209,210,221,222 and 2 were from Australia.198,213 All studies that 
reported intake values utilized some form of a food frequency questionnaire. Many of the 
studies provided risk estimates that were adjusted for age (n=26),179,195-208,210,211,213-
217,219,220,222,223 energy (n=19),179,195-202,206,207,212,215-217,219,220,222,223 family history of 
prostate cancer (FHPC, n=17),179,195-198,200,201,206,208,211,214,216,217,219,220,222,223 body mass 
index (BMI, n=16),195,196,199-201,203,206,208,210,211,214-217,219,220 smoking 
(n=13),196,197,200,201,203,206,207,210,211,217,219,220,223 physical activity (n=7),196,201,214,217,219,220,223 
alcohol intake (n=8),196,203,206,210,217,219,220,223 or education (n=8).195,196,199,200,202-204,208  
The Newcastle-Ottawa Scale was utilized to assess quality of all included studies. 




average quality score was 6.24 (SD: 1.14) for case-control studies and 7.14 (SD: 1.46) 
for cohort and nested case-control studies. As a result, cohort studies were considered 
higher quality and case-control were considered medium quality.  
Tomato consumption and PCa risk 
All of these studies had complete relative risk information and were included in the meta-
analysis. Because several studies reported risk associations from more than one type of 
tomato food (i.e., raw or cooked tomatoes), we analyzed the RR from the type of tomato 
with the highest lycopene bioavailability. Figure 2.2 displays the pooled RR of PCa when 
comparing the highest tomato consumption category to the lowest. The pooled RR for 
this association was 0.81 (95% CI: 0.71-0.92, p=0.001, I2=73.1%). Specifically, the pooled 
RR was 0.68 (95% CI: 0.55-0.84, p<0.001, I2=77.4%) and 0.92 (0.86-0.98, p=0.013, 
I2=41.1%) for case-control and cohort studies, respectively (Figure B.1). Furthermore, we 
investigated publication bias by funnel plot (Figure B.2A), Begg’s correlation test and 
Egger’s linear regression test. Begg’s correlation test (p=0.003) and Egger’s linear 
regression test (p=0.011) for bias were significant. 
 We further stratified studies by the type of tomato consumption and evaluated 
associations with PCa risk. Studies that investigated tomato foods (RR=0.84, 95% CI: 
0.72-0.98, p=0.030, I2=76.7% [Figure 2.3]) or cooked tomatoes and sauces (RR=0.84, 
95% CI: 0.73-0.98, p=0.029, I2=57.4% [Figure 2.4]) were inversely associated with PCa 
risk. However, raw tomatoes (RR=0.96, 95% CI: 0.84-1.09, p=0.487 [Figure 2.5], 
I2=55.6%) and pizza consumption (RR=1.02, 95% CI: 0.85-1.22, p=0.850 [Figure 2.6]) 





Subgroup analysis of tomato consumption and PCa risk 
 Several subgroup and sensitivity analyses were conducted for total consumption 
of tomatoes. A statistically significant result was first achieved in 1999 and has remained 
unchanged after 22 additional studies were published (Figure B.3). There were no studies 
that strongly influenced the heterogeneity of the dataset. Table 2.3 describes the 
subgroup analyses for associations between tomato consumption and PCa risk. Studies 
conducted in North America were not significant (p=0.501), however studies conducted 
in Europe (p=0.029) and other continents (p=0.001) were significant. Interestingly, studies 
that did not adjust for BMI (p=0.002), smoking (p=0.002), FHPC (p=0.003), education 
(p=0.001), physical activity (p<0.001) and alcohol (p=0.001) were associated with a 
decreased risk of PCa.   
 For tomato foods, the pooled RR for case-control studies was 0.69 (95% CI: 0.53-
0.91, p=0.008, I2=80.3%) and 1.00 (95% CI: 0.87-1.15, p=0.963, I2=57%) for cohort and 
nested case-control studies. Publication bias was explored with a funnel plot (Figure 
B.2B). Begg’s correlation test (p=0.053) was not significant while Egger’s linear 
regression test (p=0.037) for bias was significant. No specific studies strongly affected 
the pooled RR, heterogeneity or publication bias. In the cumulative meta-analysis, the 
pooled RR fluctuated with time and remained significant after 2011 (Figure B.3). Studies 
conducted in North America (p=0.800) and Europe (p=0.424) were not significant, while 
studies conducted in other continents (p=0.010) were significant. Studies that did not 
adjust their model for age (p=0.005), BMI (p=0.006), FHPC (p=0.026), education 
(p=0.025), physical activity (p=0.010), or alcohol (p=0.032) were significantly associated 




 Regarding cooked tomatoes and sauces, the pooled RR was 0.63 (95% CI: 0.40-
1.00, p=0.052, I2=69.1%) for case-control studies and 0.92 (95% CI: 0.85-0.99, p=0.025, 
I2=0%) for cohort and nested case-control studies. Publication bias was explored by 
funnel plot (Figure B.2C). Begg’s correlation test (p=0.020) and Egger’s linear regression 
test (p=0.019) for bias were significant. No specific studies strongly impacted the pooled 
RR, heterogeneity or publication bias. Studies conducted in North America were 
significantly associated with PCa risk (p=0.033), however studies conducted in Europe 
(p=0.202) and other continents were not (p=0.064). Additionally, no significant trends 
were found in the cumulative meta-analysis (Figure B.4). Studies that adjusted for age 
(p=0.006), BMI (p=0.012), FHPC (p=0.028), and energy (p=0.008) were significantly 
associated with a reduced risk of PCa. 
 For raw tomatoes, the pooled RR was 0.95 (95% CI: 0.76-1.19, p=0.729, 
I2=55.9%) for case-control studies and 0.96 (95% CI: 0.81-1.14, p=0.557, I2=60.6%) for 
cohort and nested case-control studies. Publication bias was explored with a funnel plot 
(Figure B.2D). Begg’s correlation test (p=0.592) and Egger’s linear regression test 
(p=0.568) for bias were both not significant.  The pooled RR, heterogeneity and 
publication bias were not strongly affected by any specific studies. Although the pooled 
RR for raw tomato consumption was initially significant in 1995, this association has 
remained not significant since 2000 after the addition of 7 studies (Figure B.5). Studies 
conducted in North America (p=0.804) and other continents (p=0.889) were not 
associated with PCa risk, however studies conducted in Europe were significantly 
associated with a reduced risk of PCa (p=0.008). No specific adjustments were 




 For pizza consumption, the pooled RR was 1.12 (95% CI: 0.88-1.43) for one case-
control study and 0.97 (95% CI: 0.74-1.26, p=0.818, I2=72%) for cohort studies. 
Publication bias was explored with a funnel plot (Figure B.1E). Begg’s correlation test 
(p=0.734) and Egger’s linear regression test (p=0.568) for bias were both not significant. 
In the cumulative meta-analysis, pizza consumption was not significant in the first study 
and has remained not significant after 3 additional studies were published (Figure B.6). 
Due to the low number of studies that reported risk associations for pizza, subgroup and 
sensitivity analyses were not pursued.  
Tomato consumption and advanced PCa risk 
Four studies investigated the association between tomatoes and advanced 
PCa.179,202,208,219 Of these studies, one classified advanced PCa by stage,219 one by 
grade,208 and two used both stage and grade.179,202 Additionally, all studies that 
investigated associations between tomato consumption and advanced PCa were high 
quality. We explored publication bias with a funnel plot (Figure B.2F). Begg’s correlation 
test (p=0.089) and Egger’s linear regression test (p=0.112) for bias were both not 
significant. The pooled RR for this association was 0.89 (95% CI: 0.77-1.03, p=0.113, 
I2=35.3% [Figure 2.7]). Specifically, the pooled RR was 1.10 (95% CI: 0.84-1.44, p=0.493, 
I2=0%) for case-control studies and 0.81 (95% CI: 0.68-0.97, p=0.019, I2=16.3%) for 
cohort studies. Due to the low number of studies that reported risk associations for 
advanced PCa, subgroup and sensitivity analyses were not pursued. 
Dose response  
 Of the studies that were eligible for dose-response analysis, 19 investigated 




investigated raw tomatoes;195,201,205,213-218 and 7 investigated cooked tomatoes and 
sauces.201,202,213,215,216,218,220 Every study included in the dose-response contained 
relevant risk estimates with information for the dose of each quantile reported. Due to a 
lack of dose data, we did not conduct a dose-response meta-analysis on associations 
between pizza consumption and PCa and between tomato consumption and advanced 
PCa. Dose-response associations are described in Figure 2.8. Dose responses according 
to the type of study are described in Figure B.7. 
First, we investigated the dose-response association between total tomato 
consumption and PCa risk. One study that substantially increased the heterogeneity of 
the data was excluded from the dose response estimate (Figure B.8A).206 After this study 
was excluded, the error in the estimate was substantially decreased, and there was a 
significant nonlinear dose-response association between tomato consumption and PCa. 
As seen in Figure 2.8A, there was a significant nonlinear dose-response association 
between tomato consumption and PCa risk (plinear=0.099, pnonlinear=0.017). PCa risk 
decreased by 13% at 200 grams/week, 28% at 500 grams/week, 46% at 1,000 
grams/week, and 56% for 1350 grams/week. 
We investigated, but did not find any dose-response associations between 
consumption of tomato foods and risk of PCa (Figure B.8B, plinear=0.400, pnonlinear=0.173). 
In the sensitivity analyses, one study substantially increased the heterogeneity of the 
data206. After this study was excluded, the error in the estimate was substantially 





We investigated the dose-response associations between cooked tomatoes and 
sauces in relation to risk for PCa. We identified a significant dose-response association 
between cooked tomatoes and sauces and PCa risk (Figure 2.8C, plinear<0.001, 
pnonlinear<0.001). PCa risk decreased by 3% for 60 grams/week, 12% for 120 grams/week, 
19% for 240 grams/week, and 49% for 420 grams/week in the nonlinear model and 
decreased by 3.5% for each additional 30 grams/week. No studies significantly affected 
the heterogeneity of the data. 
Lastly, we investigated the dose-response associations between raw tomato 
consumption and risk of PCa. A significant linear dose-response association was 
observed between raw tomatoes and risk of PCa (Figure 2.8D, plinear=0.037, 
pnonlinear=0.099) such that PCa risk decreased by 2% for each additional 100 grams of raw 




The present systematic review and meta-analysis analyzed 30 studies, which 
included 24,222 cases with PCa reported from 260,461 participants. This analysis 
demonstrated inverse associations between PCa risk and consumption of tomatoes 
(total); tomato foods; and cooked tomatoes and sauces. No associations were found for 
raw tomatoes or pizza and PCa risk, nor were associations found between tomato 
consumption and advanced PCa risk. Due to a low number of studies investigating 
advanced PCa, associations may have been missed. These associations were further 




tomatoes and sauces. To our knowledge, this is the first meta-analysis to investigate 
potential dose-response associations of tomato consumption. Our data demonstrate that 
increased tomato consumption (particularly cooked tomatoes and sauces) could reduce 
PCa incidence. 
In a recently published pooled analysis, total tomato consumption was not 
associated with a reduced risk of PCa.126 Petimar, et al. elaborated that the vast majority 
of prospective cohort studies did not assess sources of bioavailable lycopene (i.e., 
cooked tomatoes and sauces).126 Associations in their study may have been missed if 
lycopene was not able to be adequately absorbed or metabolized. Generally, increased 
lipid consumption (particularly with long chain fatty acids) improves lycopene and 
carotenoid bioavailability by increasing solubility, and thermal food processing improves 
carotenoid bioavailability by disrupting cellular membranes, which allows lycopene to be 
released from the tissue matrix.53,54,56-58 Our review and others128,130 have failed to find 
an association between raw tomatoes and PCa risk. However our review and one other 
have found an inverse association between PCa risk and cooked tomatoes and 
sauces.130 We were unable to account for different preparation methods and the volume 
of tomato sauce (if present) on the pizza. As a result, associations with pizza may have 
been missed. Overall, these results further support the hypothesis that bioavailable 
lycopene and other tomato carotenoids are associated with a reduced risk of PCa.  
Tomatoes contribute up to 85% of dietary lycopene in the United States.44,45 In our 
recent meta-analysis of lycopene and PCa risk, lycopene consumption was associated 
with a 12% reduced risk of PCa and an estimated 1% reduced risk for each additional 14 




risk than our recent dose-response estimates for lycopene.132 From the current study, 
there was an estimated 9% reduced risk for 100 grams/week of cooked tomato. For an 
equivalent dose of lycopene (22 mg lycopene in 100 grams of tomato puree according to 
the USDA Nutrient Database), tomatoes were more effective than lycopene at reducing 
PCa risk (9% compared to 1.6%). The greater benefit from tomato products may be due 
to interactions between potentially beneficial bioactive compounds in tomatoes.44,45,134 
Additional research is needed to understand the benefit of tomato bioactives other than 
lycopene that may contribute to the reduced risk of PCa. 
The present analysis is the first to investigate the associations between tomato 
consumption and advanced PCa risk. Although increased tomato consumption was 
associated with a reduced risk of PCa, no association was observed for tomatoes and 
advanced PCa. Many studies did not include the grade or stage of PCa and contained 
only a small number of cases with advanced stages of PCa. Due to the small number of 
studies that investigated advanced PCa, an association may have been missed. A recent 
pooled analysis of prospective cohort studies found that pizza with tomato sauce was 
associated with a reduced risk of lethal PCa.126 As previously mentioned, lycopene is also 
a biomarker for tomato consumption.44,45,133 Another pooled analysis of prospective 
cohort studies found that increased circulating lycopene was associated with a reduced 
risk of advanced PCa.94 Combined, these pooled analyses suggest that tomato 
consumption may be associated with advanced PCa. A better understanding of the 
associations between the stage or grade of PCa and carotenoid status may lead to a 
reduced progression of PCa. More studies are needed in order to elucidate the 




Our analysis exhibits several strengths that contribute to the literature. Dose-
response meta-analyses along with meta-analyses for comparisons of high to low tomato 
consumption provides additional data points that were not considered in previous reviews. 
Our additions further strengthened the associations found in this study and those of other 
reviews. Cumulative meta-analyses assisted in evaluating trends over time and improved 
the interpretation of the data. Sensitivity and subgroup meta-analyses were conducted to 
examine the sources of heterogeneity and evaluate associations between tomato 
consumption and PCa risk.  
Despite these strengths, this study has several limitations that should be noted. 
First, the specific types of tomatoes consumed and the preparation methods varied in 
each study. A higher composition of raw tomatoes rather than cooked tomatoes may have 
reduced the bioavailability of lycopene and other carotenoids and may have reduced the 
association that was found. We were also somewhat limited in our ability to detect dose-
response associations because tomato consumption was inconsistently reported across 
studies. Some studies reported servings of tomatoes per week, while others reported 
grams per week. Next, guidelines for PCa screening varies between countries, medical 
organizations and guideline groups and may affect PCa detection and incidence rates.5,6 
Screening for PCa is an important factor of PCa diagnosis, especially of non-aggressive 
disease.3 Along these lines, stratified analyses of pre-PSA and post-PSA era in the United 
States and Europe may be useful. To this point, a recent pooled analysis of circulating 
lycopene found an inverse association with a reduced risk of PCa before the PSA era 
(1990).94 Unfortunately, only one study was conducted with a study period that ended 




studies had relatively modest inverse associations with PCa risk compared to case-
control studies. It is important to note that a single dietary assessment will have significant 
measurement error for both types of studies. To improve the estimate of the associations 
for tomato consumption and to further explore the associations of the different forms of 
tomato consumption, both types of studies were included.  
In conclusion, our data indicate an inverse association between tomato 
consumption and PCa risk. This study further supports the protective role of tomatoes 
and lycopene in prostate carcinogenesis. These data were further supported with dose-
response associations between total tomato consumption and cooked tomatoes and 
sauces and PCa risk. Our results, along with those of other meta-analyses, suggest 
potential health benefits from increasing tomato consumption. Promoting tomato 
consumption to achieve protective levels observed in this analysis is relatively easy. For 
example, our results suggest that 245 grams of tomato sauce per week would 
approximately provide a 30% reduced risk of PC. According to the USDA National 
Nutrient Database, 1 cup of tomato sauce weighs 245 grams. Our results support 
increasing tomato consumption in order to reduce PCa incidence. More high-quality 






Tables and Figures for Chapter 2 
Table 2.1: Characteristics of included studies. 
Source 
































Cooked tomatoes  
T1<60, T3>180 
Age, vegetable and 
























Raw tomatoes:  
T1<150.8, T3>345.8 
Age, study center, 
Edu, occupational 










Fat, energy, race, 
age, FHPC, BMI, 
PSA tests in last 5 
















France 139 3,313 13,017 Cases: 
63 
Cohort Tomato foods: 
T1<1,207.5; T3>1356.6 
Age, energy, trt 
group, number of 
diet records, SS, 
Edu, PA, height, PA, 



















Low ≤1040, high>1040 
Age, recruitment 





Table 2.1: Characteristics of included studies (continued). 
Source 




























T1 ≤0.25, T3 ≥ 1 serving 
Age, study center, 
Edu, BMI, SS, 










Q1<0.25 Q4≥2 servings 
Age, BMI, aspirin, 
marital status, 
ancestry, location, 
PA, vasectomy, SS, 






USA 3,029 ─ 51,525 40-75 Cohort Tomato sauce: 
Q1<15, Q4≥120 
 
Age, BMI, SS, 
height, PA, FHPC, 
diabetes, energy, 





USA 5,543 ─ 46,719 40-75 Cohort Tomato sauce: 
Q1<15, Q4≥120 
 
Age, time period, 
race, height, BMI, 
PA, SS, diabetes, 
FHPC, PSA, MV, 
energy, nutrients, 
alcohol, coffee, ERG 
Hardin, 2011 2001-
2004 











Hodge, 2004  1994-
1997 
Australia 858 905 1,763 <70 Case-
Control 
Tomato foods: 
T1<364, T3 ≥676 
Age, state, country 










Tomato foods:  
Q1<65.1, Q4≥767.2 
Age, energy, vas, 
SS, marital status, 
study area, BMI, 
Edu, MV, nutrients 
Jian, 2005 2001-
2002 








Age, location, Edu, 
SES, income, BMI, 






Table 2.1: Characteristics of included studies (continued). 
Source 






























Q1 ≤ 148, Q4 ≥ 740 
Cooked tomatoes: 




USA 1,338 ─ 29,361 55-74 Cohort Raw tomatoes: 
Q1<92.5, Q5>444 





Q1<0.50 Q4≥1 servings 
Age, energy, race, 
study center, FHPC, 
BMI, SS, PA, Vit E, 
intake, diabetes, 





1,619 1,618 3,237 Cases: 




Q1 ≤ 20.0 Q5 ≥ 108.1, 
Cooked tomatoes:  
Q1 ≤ 18.3 Q5 ≥ 92.7 











T1 < 104, T3≥312 
Edu, BMI, SS, 
alcohol, and food 
frequency (green 
vegetables, soy, 
milk, beef, and pork) 
Mazdak, 2012 2005-
2009 













180 ─ 15,000 Cases:  
~74 
Cohort Tomato foods: 







317 480 797 40-81 Case-
Control 
Raw tomatoes:  
Q1 < 91 Q4 >245 
Tomato foods: 
Q1 < 130.9, Q4 >449.4 
Age, height, total 
anti-inflammatory 
drugs, and SES 
Salem, 2011 2005-
2008 






Tomato foods:  
T1 ≤ 10 T3 >100 







Table 2.1: Characteristics of included studies (continued). 
Source 


























Q1<15.7 Q2 >15.7 









Q1 ≤199.5, Q4 ≥700 
Age, SS and energy 
Stram, 2006 1993-
1996 








Malaysia 112 112 224 50-86 Case-
Control 
Tomato foods†  
Takachi, 2010 1990-
2004 
Japan 339 ─ 43,475 45-74 Cohort Tomato foods: 
Q1< 42, Q4 >476 
Age, location, BMI, 
SS, alcohol, 
nutrients, MV, 
marital status, and 










Q1 <104, Q4 ≥728 
















Table 2.1: Characteristics of included studies. † signifies that study does not disclose dose for tomato consumption. Abbreviations: tertile (T), 
quartile/quintile(Q), years (yrs), body mass index (BMI), family history of prostate cancer (FHPC), Prostate Specific Antigen (PSA), physical activity (PA), 







1 indicates that cases are independently validated for case-control studies (0,1 star); 2, cases are from a 
representative population or drawn from the same community as the nonexposed cohort  (0,1); 3, 
community controls or structured interview for cohort studies (0,1); 4, controls have no history of prostate 
cancer (endpoint) (0,1); 5, study controls for most important factor (age) and family history of prostate 
cancer (0, 1, 2); 6, structured interview where blind to case/control status for case-control studies, record 
linkage or independent blind assessment for cohort studies (0,1); 7, same method of ascertainment for 
cases and controls or follow-up was long enough for outcomes to occur (4 years) (0,1); 8, same non-
response rate or <20% lost to follow up (0,1); 9, total: minimum equals 1; maximum equals 9 stars 
  
Table 2.2. Quality assessment of included studies 
Source Selection Comparability5 Exposure   Total9 
Author, Year Definition1   Representative2   Selection3   Definition4 
 




Ambrosini, 2008 0 ★ 0 0 ★ ★ ★ ★ 5 
Bonsetti, 2000 ★ ★ 0 ★ ★ 0 ★ 0 5 
Bonsetti, 2004 ★ ★ 0 ★ ★★ 0 ★ ★ 7 
Cohen, 2000 ★ 0 ★ 0 ★★ 0 ★ ★ 6 
Darlington, 2007 ★ 0 ★ 0 ★★ 0 ★ 0 5 
Diallo, 2016 ★ ★ 0 ★ ★★ ★ ★ ★ 8 
Er, 2014 ★ ★ 0 ★ ★★ ★ ★ ★ 8 
Gallus, 2006 ★ ★ 0 ★ ★ 0 ★ ★ 6 
Giovannucci, 1995  ★ ★ 0 ★ ★★ ★ ★ ★ 8 
Giovannucci, 2007 ★ ★ 0 ★ ★★ ★ ★ ★ 8 
Graff, 2016  ★ ★ 0 ★ ★★ ★ ★ ★ 8 
Hardin, 2011 ★ ★ 0 ★ ★★ ★ ★ 0 7 
Hodge, 2004  ★ ★ ★ 0 ★★ ★ ★ ★ 8 
Jain, 1999 ★ ★ ★ 0 ★ ★ ★ 0 6 
Jian, 2005 ★ ★ 0 ★ ★★ 0 ★ ★ 7 
Key,1997 0 ★ ★ ★ ★ 0 ★ ★ 6 
Kirsh, 2006 ★ ★ 0 ★ ★★ ★ ★ ★ 8 
Kolonel, 2000 ★ ★ ★ ★ ★ 0 ★ 0 6 
Li, 2008 ★ ★ ★ ★ ★★ 0 ★ ★ 8 
Mazdak, 2012 ★ ★ 0 ★ 0 0 ★ 0 4 
Mills, 1989 ★ ★ 0 0 ★ ★ ★ 0 5 
Norrish, 2000 ★ ★ ★ ★ ★ 0 ★ ★ 7 
Salem, 2011 ★ ★ 0 ★ ★★ 0 ★ ★ 7 
Shahar, 2011 ★ ★ 0 ★ ★★ 0 ★ 0 6 
Sonoda, 2004 ★ ★ 0 ★ ★ 0 ★ 0 5 
Stram, 2006 ★ ★ 0 ★ ★★ ★ ★ ★ 8 
Subahir, 2009 ★ ★ 0 ★ ★ 0 ★ 0 5 
Takachi, 2010 ★ ★ 0 ★ ★ ★ ★ ★ 7 
Villeneuve, 1999 0 ★ ★ ★ ★★ 0 ★ ★ 7 




Table 2.3: Subgroup analysis of tomato consumption and prostate cancer risk. 
 Total Tomato Consumption Tomato Foods Cooked Tomatoes and Sauces Raw Tomatoes 




P-value No. of 
studies 
RR 
 (95% CI) 









Overall model 26 0.81 
(0.71-0.92)† 
0.001 18 0.84  
(0.72-0.98)† 
0.030 10 0.84 
(0.73-0.98)† 
0.029 10 0.96 
(0.84-1.09)† 
0.487 
Study type             
Case-Control 19 0.68 
(0.55-0.84)† 
<0.001 13 0.69 
(0.53-0.91)† 
0.008 6 0.63 
(0.40-1.00)† 
0.052 8 0.95 
(0.76-1.19)† 
0.729 
Cohort/NCC 7 0.92 
(0.86-0.98) 
0.013 5 1.00 
(0.87-1.15)† 
0.963 4 0.92 
(0.85-0.99) 
0.025 2 0.96 
(0.81-1.14)† 
0.557 
Continent             
North America 9 0.95 
(0.83-1.10)† 
0.501 6 0.97 
(0.77-1.22)† 
0.800 5 0.92 
(0.86-0.99) 
0.033 5 1.02 
(0.88-1.18)† 
0.804 
Europe 7 0.82 
(0.68-0.98)† 
0.029 5 0.92 
(0.76-1.13)† 
0.424 2 0.70 
(0.40-1.21)† 
0.202  4 0.80 
(0.68-0.94) 
0.008 
Other 10 0.48 
(0.31-0.73)† 
0.001 7 0.55 
(0.35-0.87)† 
0.010 3 0.20 
(0.04-1.10)† 
0.064 1 1.04 
(0.60-1.80) 
0.889 
Adjustments              
High quality 13 0.86 
(0.76-0.98)† 
0.018 11 0.86 
(0.72-1.03)† 
0.093 3 0.93 
(0.86-0.996) 
0.039 5 0.91 
(0.77-1.08)† 
0.298 
Mid-quality 13 0.70 
(0.52-0.94)† 
0.017 7 0.79 
(0.54-1.15) 
0.211 7 0.66 
(0.45-0.96)† 
0.031 5 1.06 
(0.89-1.27)† 
0.519 
Adjusts for age 22 0.84 
(0.74-0.95)† 
0.006 16 0.88 
(0.75-1.03)† 
0.101 8 0.91 
(0.84-0.97)† 







0.044 2 0.49 
(0.30-0.80) 
0.005 2 0.25 
(0.01-4.24)† 







0.062 10 0.88 
(0.69-1.12)† 
0.293 5 0.91 
(0.85-0.98) 







0.002 8 0.80 
(0.68-0.94)† 
0.006 5 0.58 
(0.32-1.05)† 







0.111 9 0.88 
(0.72-1.07)† 
0.206 2 0.90 
(0.82-1.00) 







0.002 9 0.78 
(0.60-1.01)† 
0.062 8 0.74 
(0.55-0.98)† 







0.090 9 0.90 
(0.73-1.11)† 
0.323 5 0.92 
(0.86-0.99) 







0.003 9 0.85 
(0.73-0.98) 
0.021 5 0.65 
(0.41-1.02)† 







Table 2.3: Continued 
 Total Tomato Consumption Tomato Foods Cooked Tomatoes and Sauces Raw Tomatoes 




P-value No. of 
studies 
RR 
 (95% CI) 















0.020 11 0.82 
(0.64-1.04)†  
0.101 6 0.88 
(0.80-0.97) 







0.016 7 0.86 
(0.69-1.07)† 
0.169 4 0.74 
(0.45-1.16)† 







0.167 8 0.85 
(0.63-1.14)† 
0.270 2 0.95 
(0.85-1.06) 







0.001 10 0.83 
(0.70-0.98)† 
0.025 8 0.77 
(0.61-0.97)† 







0.326 2 1.14 
(0.80-1.62) 
0.479 2 0.91 
(0.82-1.00) 







<0.001 16 0.79 
(0.66-0.95)† 
0.010 8 0.74 
(0.55-0.98)† 











0.468 1 0.89 
(0.80-1.00) 







0.001 14 0.83 
(0.71-0.99)† 
0.032 9 0.80 
(0.64-0.99) 
0.056 9 1.01 
(0.94-1.09) 
0.283 
† signifies that results are estimated by DerSimonian-Laird random effects model. Bolded entries signify a significant result p<0.05. Abbreviations: relative 














Figure 2.2: Forest plot for association of highest vs lowest total quantile of tomato 
consumption on PCa risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 






Figure 2.3 Forest plot for association of highest vs lowest quantile of tomato foods on 
PCa risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure 2.4 Forest plot for association of highest vs lowest quantile of cooked tomatoes 
and sauces on PCa risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 







Figure 2.5 Forest plot for the association of highest vs. lowest quantile of raw tomatoes 
on PCa risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure 2.6 Forest plot for the association of highest vs lowest quantile of pizza on PCa 
risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure 2.7 Forest plot for the association of highest vs lowest quantile of tomato 
consumption on advanced PCa risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 






Figure 2.8 Dose-response analysis of tomato consumption and PCa risk.  
 
The solid black line is the nonlinear model curve for published relative risk and the two 
dotted lines are the corresponding 95% confidence intervals. The short-dashed line is 
the linear model curve for the published relative risks (RR); (A) total tomato 
consumption and risk of PCa after exclusion of one study; (B) tomato foods and risk of 
PCa after exclusion of one study (C) cooked tomatoes and sauces and risk of PCa (D) 




Chapter 3: Increased dietary and circulating lycopene are associated with 
reduced prostate cancer risk: a systematic review and meta-analysis 
 
b Abstract 
Background: Prostate cancer (PCa) is the fifth leading cause of cancer-related deaths 
worldwide. Many epidemiological studies have investigated the association between 
prostate cancer and lycopene; however, results have been inconsistent. We hypothesized 
that dietary and circulating concentrations of lycopene would be inversely associated with 
PCa risk.  
Methods: We conducted a systematic review and dose-response meta-analysis for the 
association between dietary and circulating lycopene and PCa risk. Eligible studies were 
published before December 1, 2016 and were identified from PubMed, Web of Science, 
and the Cochrane Library. We estimated pooled relative risk ratios (RR) and 95% 
confidence intervals using random and fixed effects models. Linear and nonlinear dose-
response relationships were also evaluated for PCa risk.  
Results: Forty-two studies were included in the analysis, which included 43,851 cases of 
PCa reported from 692,012 participants. Both dietary intake (RR=0.88, 95% CI: 0.78-
0.98, p=0.017) and circulating concentrations (RR=0.88, 95% CI: 0.79-0.98, p=0.019) of 
lycopene were associated with reduced PCa risk. Sensitivity analyses within the dose-
response analysis further revealed a linear dose-response for dietary lycopene and PCa 
risk such that PCa decreased by 1% for every additional 2 mg of lycopene consumed 
                                               
b The content of this chapter has been published (Reference 132. Rowles III JL, 
Ranard KM, Smith JW, An R, Erdman Jr JW. Increased dietary and circulating lycopene 
are associated with reduced prostate cancer risk: a systematic review and meta-analysis. 





(p=0.026). Additionally, PCa risk decreased by 3.5% to 3.6% for each additional 10 µg/dL 
of circulating lycopene in the linear and nonlinear models respectively (plinear=0.004, 
pnonlinear=0.006). While there were no associations between lycopene and advanced PCa, 
there was a trend for protection against PCa aggressiveness (RR=0.74, 95% CI: 0.55-
1.00, p=0.052). 
Conclusions: Our data demonstrate that higher dietary and circulating lycopene 
concentrations are inversely associated with PCa risk. This was accompanied by dose-
response relationships for dietary and circulating lycopene. However, lycopene was not 
associated with a reduced risk of advanced PCa. Further studies are required to 
determine mechanisms underlying these associations. 
 
Introduction 
Prostate cancer is the second most common cancer in men and is the fifth leading 
cause of cancer-related deaths worldwide1. The development of PCa is complex and 
influenced by a combination of genetic, hormonal and environmental factors, including 
diet97. Diet is a highly modifiable risk factors for PCa, and epidemiological evidence 
indicates that consumption of tomato products is associated with a reduced risk of 
PCa94,224,225. Lycopene, a lipophilic carotenoid that gives tomatoes their red color, is 
believed to be the primary bioactive component in tomatoes, and tomatoes are the source 
of more than 85% of dietary lycopene in the United States44,45. Despite potential benefits 
seen in the literature, epidemiological studies about lycopene and its role in prostate 




Previously, four meta-analyses have been conducted to investigate the 
associations between tomatoes or lycopene and the risk of PCa128-131. Of these analyses, 
three have shown an inverse association with elevated circulating lycopene129-131, and 
one showed an inverse association with dietary lycopene130. Since these studies were 
published, new evidence has surfaced that solicits a closer investigation of the 
association between lycopene and PCa risk. The current study aimed to update previous 
analyses by systematically and quantitatively evaluating the association between 
lycopene and PCa risk. Furthermore, we utilized dose-response meta-analyses to assess 
potential dose-responses, as well as cumulative meta-analyses to display trends over 
time.  
 
Materials and methods 
(Parallel statistical approaches were used in Meta-analysis 1 and 2. Only novel aspects 
of the methodology for this are described below) 
Study selection criteria 
 This meta-analysis was conducted in accordance with Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis of 
Observational Studies in Epidemiology (MOOSE) guidelines138,139. Studies that met the 
following criteria were included in the meta-analysis: (a) evaluated the association 
between lycopene and PCa risk by using randomized control trials, cohort, cross-
sectional, retrospective, prospective, and case-control studies; (b) methodology was 
documented in replicable detail; (c) evaluated the relationship between lycopene and 




for exposure categories; (e) were written in English; and (f) peer-reviewed publications or 
theses. Among studies that met the above criteria, those that provided information about 
doses of lycopene, length of intervention, and relative risk for primary or advanced PCa 
were included in the dose-response analysis.   
Literature search  
We conducted a comprehensive literature search of PubMed, Web of Science and the 
Cochrane Library using the following key words: prostate cancer, prostate neoplasm, 
lycopene, tomato, carotenoids, humans, case-control studies, follow-up studies, cohort 
studies, prospective studies and their variants (up to December 1st, 2016). Titles and 
abstracts of articles that were identified by the keyword search were screened against the 
study selection criteria. Potentially relevant articles were retrieved for evaluation of the 
full text. We also conducted a reference list search (i.e., backward search) and cited 
reference search (i.e., forward search) from full text articles meeting the study selection 
criteria. Articles identified through this process were further screened and evaluated using 
the same criteria. We repeated searches on all newly identified articles until no further 
relevant articles were found. Two authors (JR3 and KR) individually determined 
inclusion/exclusion of all articles retrieved in full text and discrepancies were resolved 
through discussion.  
Statistical analysis 
 STATA/IC version 14.1 (StataCorp LP, College Station, TX) was utilized to analyze 
the data. Because studies reported different exposure categories as tertiles, quartiles or 
quintiles, we used the study-specific RR for the highest quantile compared to the lowest 




concentrations. If the total number of cases or person-years were presented without 
distribution, we estimated the distribution by dividing by the number definitions of the 
quantiles. If the unit for circulating concentrations was reported as µmol/L, it was 
multiplied by 536.89 (molecular weight of lycopene) and adjusted to µg/dL. 
 For the meta-analysis of the dose-response relationship between lycopene and 
PCa risk, the method proposed by Greenland and Longnecker of generalized least 
squares for trend estimation was utilized150,151. Based on the dose of lycopene intake or 
circulating blood concentration provided for each quantile, study-specific slopes (with 
95% CIs) were generated. If a range was provided for lycopene exposure rather than a 
median, the lower boundary of the quantile was utilized. We examined linear and 
nonlinear associations between PCa risk and lycopene intake or circulating 
concentrations of lycopene by plotting linear and nonlinear dose-response curves using 
restricted cubic spines, with 3 knots at 10%, 50% and 90% of the distribution. A p-value 
for curve linearity and nonlinearity was calculated by testing that the coefficient of the 





The initial abstract screening and reference list search yielded a total of 2,208 
articles after removing duplicates. After screening these titles and abstracts, 95 articles 
remained for full-text evaluation. Among these articles, 41 were included and 54 were 




13 had an irrelevant topic96,153,179,181,193,233,249-254, 12 did not indicate lycopene 
status175,202,206,255-263, 3 studies had a shorter follow-up period compared to the included 
study191,217,220, and 2 used the same data found in other included studies94,200. From the 
initial 41 articles that were included in the meta-analysis, 42 studies evaluated 
associations between lycopene and prostate cancer (one article reported results from two 
cohorts264). Among these studies, 25 reported the dietary associations with 
lycopene8,95,152,154,159,162,163,198,199,201,205,208,214,216,218,222,265-273 and 18 reported associations 
with circulating lycopene60,171,264,268,274-286 on PCa (Figure 3.1).  
Study Characteristics 
 Table 3.1 summarizes the 25 studies that investigated dietary lycopene, and Table 
3.2 summarizes the 18 studies that investigated circulating lycopene. Among these 
studies, 19 were case-control154,159,162,163,198,199,205,214,216,218,222,265,267-269,271,275,285,286, 13 
were nested case-control171,264,266,274,276-279,281-284, 8 were cohort8,60,95,201,208,270,273,280, and 
2 were case-cohort studies152,272. These studies included a combined total of 43,851 PCa 
cases reported from 692,012 participants. Thirty-two studies were from North 
America8,60,95,152,154,159,163,171,199,201,216,222,264,266-271,273,275-279,282-286,  6 were from 
Europe205,214,218,272,280,281, 2 were from Australia198,274, 2 were from Asia (China and 
Singapore)162,222, and 1 was from South America (Uruguay)265. Many of the studies 
provided risk estimates that were adjusted for age 
(n=34)8,60,95,152,154,159,162,163,198,199,201,205,214,216,222,264-266,268-276,278-280,282,284-286, body mass 
index (n=24)8,95,152,154,159,162,163,171,199,201,208,214,216,264-267,276,277,279,281,282,286, smoking 
(n=19)8,60,95,154,163,171,199,201,264,267,268,270,273,275,278-281,286, education 




(n=18)8,95,171,198,201,208,214,216,222,265,267-272,277,280, physical activity 
(n=10)8,95,152,201,214,273,276,279-281, or alcohol intake (n=9)8,267,268,270,276,279-281. All studies that 
reported intake values utilized a food frequency questionnaire (1 study adapted a food 
frequency questionnaire that was used in the form of an interview218), and all studies 
reporting circulating lycopene values used high performance liquid chromatography 
(HPLC) for quantification of carotenoids. Three studies defined advanced PCa with 
Gleason scores266,277,282, 2 used stage208,272, and 6 used a combination of the 
two152,201,276,281,284,285.  
The Newcastle-Ottawa Scale was utilized to assess quality of all included studies. 
As described in Table 3.3, the highest quality score was 9 and the lowest was 6. The 
average quality score was 8.26 (SD: 0.81) for case-control studies, 8.70 (SD: 0.67) for 
cohort studies, and 8.46 (SD: 0.78) for nested case-control studies. Overall, the mean 
quality score was 8.41 (SD: 0.77), suggesting that the majority of included studies were 
of high quality.  
Dietary lycopene and PCa risk 
A total of 25 studies reported the relative risk of PCa with lycopene 
intake8,95,152,154,159,162,163,198,199,201,205,208,214,216,218,222,265-273. Of these studies, 16 were case-
control studies 154,159,162,163,198,199,205,214,216,218,222,265,267-269,271, 8 were cohort/case cohort 
studies8,95,152,201,208,270,272,273, and 1 was a nested case-control study266.  All of these 
studies had complete relative risk information and were included in the meta-analysis. 
Figure 3.2 demonstrates the pooled RR of PCa when comparing the highest lycopene 
intake to the lowest. The pooled RR for this comparison was 0.88 (95% CI: 0.78-0.98, 




pooled RR was 0.93 (95% CI: 0.87-0.99, p=0.030) for cohort studies and 0.82 (95% CI: 
0.68-0.999, p=0.049) for case-control studies. Furthermore, we investigated publication 
bias by funnel plot (Figure C.1A), Begg’s correlation test and Egger’s linear regression 
test. Begg’s correlation test (p=0.032) was significant, whereas Egger’s liner regression 
test (p=0.130) for bias was nonsignificant.  
We further conducted a series sensitivity and subgroup analyses. A statistically 
significant result was first achieved in 2005 and remained unchanged after 8 additional 
studies were published (Figure C.2). The heterogeneity between these studies was 
predominately due to one study from China162.  After this study was excluded, the overall 
heterogeneity I2 decreased from 54.1% to 31.3%. Begg’s correlation test (p=0.112) and 
Egger’s linear regression test (p=0.329) also became nonsignificant. Removal of this 
study from the dataset did not substantially affect the overall pooled RR (Figure C.3, RR= 
0.91, 95% CI: 0.83-0.99, p=0.034). We also investigated the influence of study type, 
location and covariate adjustments on the pooled RR. Table 3.4 describes subgroup 
analysis for dietary lycopene on PCa risk. Studies conducted in North America and 
continents other than Europe yielded an overall significant RR of 0.93 (95% CI: 0.87-0.99, 
p=0.036) and 0.59 (RR=95% CI: 0.35-0.99, p=0.046) respectively, while studies 
conducted in Europe (RR=0.93, 95% CI: 0.79-1.10, p=0.389) did not display an 
association between lycopene consumption on PCa incidence. High-quality studies also 
displayed a borderline significant protective association (RR=0.89, 95% CI: 0.79-1.00, 
p=0.051). Studies that adjusted their models for age (p=0.007) demonstrated protective 




by studies that prescribed supplements to their study population compared to studies that 
did not (Figure C.4, RR=0.88, 95% CI: 0.79-0.99, P=0.030). 
With respect to the associations of lycopene and advanced PCa, Figure 3.3 shows 
the pooled association for the highest intake of lycopene compared to the lowest. This 
association was not significant, (RR=0.93, 95% CI: 0.82-1.07, p=0.307) and had low 
within-study heterogeneity (I2=12.8%). Figure C.1C displays the funnel plot for publication 
bias in studies investigating advanced PCa. Begg’s correlation test (p=0.806) and Egger’s 
liner regression test (p=0.646) for bias were both nonsignificant.  There was no significant 
effect of time (Figure C.5) and there were no studies that prescribed supplements to their 
study.  
Circulating lycopene and PCa risk 
 There were 18 studies that investigated relationships between circulating blood 
concentrations of lycopene and PCa60,171,264,268,274-286. Of these studies, 2 were cohort 
studies60,280, 4 were case-control studies 268,275,285,286 and 12 were nested case-control 
studies264,274,276-279,281-284. All of these studies had complete relative risk information and 
were included in the meta-analysis. 
Figure 3.4 shows the pooled RR of the highest circulating lycopene quantile compared to 
the lowest quantile. The pooled RR of highest compared to lowest category of circulating 
lycopene was 0.88 (95% CI: 0.79-0.98, p=0.019). The RR for high vs. low circulating 
lycopene for cohort studies was 0.78 (95% CI: 0.37-1.65, p =0.516), case-control studies 
yielded a RR of 0.60 (95% CI: 0.32-1.13, p=0.115), and nested case-control studies 
yielded a RR of 0.91 (95% CI: 0.81-1.02, P=0.093). There was low heterogeneity between 




Begg’s correlation test, and Egger’s linear regression test. Begg’s correlation test 
(p=0.064) was nonsignificant and Egger’s linear regression test (p=0.013) was significant, 
indicating potential statistical publication bias.  
Next, we conducted several sensitivity and subgroup analyses. Cumulative meta-
analyses suggested that a statistically significant result was first achieved in 2001 and 
remained unchanged after 13 additional studies were published (Figure C.6). There were 
no studies that strongly influenced the heterogeneity of the dataset; however, one study 
had a substantially higher range of circulating lycopene284. Removal of this did not 
strongly affect Begg’s correlation test (p=0.115) and Egger’s linear regression test 
(p=0.017), but its exclusion improved the pooled RR (Figure C.7, RR= 0.85, 95% CI: 0.76-
0.95, p=0.006). Table 3.4 describes the subgroup analysis for associations between 
circulating lycopene and PCa risk. Studies conducted in North America displayed an 
inverse relationship between circulating lycopene and PCa (RR=0.87, 95% CI: 0.78-0.98, 
p=0.025), while studies in Europe (RR=0.94, 95% CI: 0.70-1.26, p=0.670) and other 
continents did not (RR=0.77, 95% CI: 0.40-1.48, p=0.431). High-quality studies found an 
association between high lycopene and PCa incidence (p=0.013), while lower-quality 
studies did not (p=0.946). Adjustments for BMI (p=0.013), smoking (p=0.022), family 
history of prostate cancer (p=0.005), education (p=0.025), physical activity (p=0.016), and 
alcohol (p=0.041) revealed associations between circulating lycopene and PCa 
incidence. The pooled RR was not affected by excluding studies that prescribed dietary 
supplements to their study population compared to studies that did not (Figure C.8, 




Figure 3.5 displays the pooled association for circulating lycopene in relation to 
advanced PCa. There was no significant association of lycopene on advanced PCa, 
(RR=0.77 95% CI 0.50-1.17, p=0.216) and there was considerable heterogeneity across 
studies (I2 = 64.1%). The funnel plot for publication bias is displayed in Figure C.1D. 
Begg’s correlation test (p=0.806) and Egger’s liner regression test (p=0.485) for bias were 
both not significant. There was no significant effect of time (Figure C.9). Additionally, the 
pooled RR was not affected by studies that prescribed dietary supplements to their study 
population compared to studies that did not (Figure C.10, RR=0.81 95% CI 0.49-1.34, 
p=0.416). 
Aggressiveness and Mortality 
 Figure 3.6 displays the pooled association of lycopene on PCa aggressiveness 
and Figure 3.7 displays the pooled association of lycopene on PCa mortality. There were 
2 studies that investigated associations between lycopene on aggressiveness60,154 and 2 
studies that investigated the associations of lycopene and mortality95,273. For PCa 
aggressiveness, patients with nonaggressive PCa (Gleason Score <7) were used as the 
reference group, to which patients with aggressive PCa (stage III or IV or Gleason score 
≥ 7) were compared. The pooled RR comparing the highest lycopene to lowest lycopene 
with respect to PCa aggressiveness approached statistical significance (RR=0.74, 95% 
CI: 0.55-1.00, p=0.052) with no heterogeneity between studies (I2=0%). The pooled RR 
for mortality was not significant (RR=0.85 95% CI 0.62-1.17, p=0.324) and displayed 







 Of the studies eligible for dose-response analysis, 
168,95,152,159,162,163,198,199,201,205,216,218,265,267,268,272 investigated dietary lycopene with 
respect to PCa incidence. As seen in Figure 3.8A, there were no significant associations 
with PCa risk (plinear=0.221, pnonlinear=0.153). During sensitivity analyses, one study 
significantly increased the heterogeneity of the data162. Removal of this study resulted in 
a significant linear dose-response relationship (Figure 3.8B, plinear=0.026, pnonlinear=0.096) 
such that PCa risk decreased by 1% for every additional 2 mg of lycopene consumed 
(95% CI 0.98-0.999).  
 Thirteen studies264,268,274,276-282,284,286 that investigated the association of circulating 
lycopene on risk of PCa were eligible for the dose-response analysis. Figure 3.8C shows 
the association between lycopene concentrations and PCa risk (plinear=0.105, 
pnonlinear=0.049). For each additional 10 µg/dL of circulating lycopene, there was a 
decrease in PCa risk by 3% (95% CI 0.94-1.00) in the nonlinear model. During sensitivity 
analyses, one study had a significantly higher range of circulating lycopene than the other 
included studies284. Removal of this study significantly improved the model for the dose-
response relationship resulting in a significant linear and nonlinear dose-response 
relationship (Figure 3.8D, plinear=0.004, pnonlinear=0.006). For each additional 10 µg/dL of 
circulating lycopene, there was a 3.5% and 3.6% (linear and nonlinear 95% CI 0.94-0.99) 
decrease in PCa risk for the linear and nonlinear models respectively.  
 Fewer studies investigated the association between lycopene and advanced PCa. 
Four studies152,201,266,272 that investigated dietary lycopene and 5 studies276,277,281,282,284 




was no significant association between dietary lycopene and advanced PCa (Figure 3.8E, 
plinear=0.585, pnonlinear=0.285). Additionally, no dose-responses were observed between 




 The present systematic review and meta-analysis analyzed 42 studies, which 
included 43,851 cases of PCa reported from 692,012 participants. We demonstrated an 
inverse association between PCa risk and higher exposures of both dietary and 
circulating lycopene. However, elevated exposure of dietary or circulating lycopene did 
not lower the risk for advanced PCa, mortality or aggressiveness. Cumulative meta-
analyses revealed associations between lycopene and PCa risk that had persisted over 
time. Sensitivity analyses within the dose-response analysis further revealed a significant 
and novel linear dose-response for dietary lycopene and PCa risk such that PCa 
decreased by 1% for every additional 2 mg of lycopene consumed. Additionally, we found 
that PCa risk decreased by 3.5% to 3.6% for each additional 10 µg/dL of lycopene in the 
circulation in the linear and nonlinear models respectively.  
 Due to large variation of lycopene content in foods, food frequency questionnaires 
(FFQ), diet records or diet histories may not be accurately estimate long-term dietary 
lycopene consumption287. There is also a large degree of diversity within questionnaires, 
and as a result, the lycopene consumption may not be precisely estimated across studies. 
Potentially due to these issues, the majority of previous meta-analyses have not found a 




inverse association between of dietary lycopene and PCa risk (p=0.017). Additionally, this 
is the first meta-analysis to find a dose-response with dietary lycopene and PCa risk. This 
may have resulted from a lack of power. The current analysis included an additional 12 
studies that investigated the association between dietary lycopene on PCa risk, nearly 
doubling the number of studies analyzed from previous analyses.  
Circulating blood concentrations of lycopene may be a more reliable and accurate 
estimation of lycopene intake compared to dietary questionnaires288. The majority of 
meta-analyses have demonstrated protective associations of circulating lycopene and 
PCa risk129-131. Similarly, the current study found an inverse association (p=0.018). 
Previous meta-analyses have also found a dose-response for circulating lycopene; PCa 
risk decreased by 2-3% for each additional 10 µg/dL of circulating lycopene129,131. In the 
current study, PCa risk decreased by 3% for each additional 10 µg/dL of lycopene in the 
circulation. After removing one study284 with a significantly higher range of circulating 
lycopene, this association became more significant. PCa risk decreased by 3.5% to 3.6% 
for each additional 10 µg/dL of circulating lycopene. Combined with previous work, these 
data support the hypothesis dietary and circulating lycopene reduce risk of PCa.  
Subgroup analysis revealed several nuances in the data. Several confounding 
factors, such as study type, location and adjustments in the regression model displayed 
significant associations. Cohort studies demonstrated the strongest correlation for dietary 
lycopene, but there was no difference between study types regarding for circulating 
lycopene. Additionally, high-quality studies revealed a reduced risk for PCa, whereas 
medium quality studies did not for studies investigating dietary and circulating lycopene. 




analysis. All of the medium quality studies investigating dietary lycopene did not utilize a 
validated FFQ, and medium quality studies that investigated circulating lycopene did not 
include proper covariates in their analyses. Studies that accounted for BMI, smoking, 
family history of prostate cancer, education, physical activity, and alcohol consumption 
were associated with a reduced risk of PCa. Studies that did not account for these 
covariates were not associated with PCa risk.  
 Although increased dietary and blood lycopene were predictive of reduced risk for 
total PCa, there was no association observed for advanced prostate cancer. A number of 
factors may have contributed to this lack of association. Most studies did not include the 
grade or stage of PCa and contained only a small number of cases with advanced stages 
of PCa. As a result, the true associations between lycopene and advanced PCa risk may 
not be identifiable. Key et. al. pooled individual data from several large cohort studies and 
found an inverse association between circulating and PCa risk94. Additionally, when 
investigating aggressiveness, the pooled effect was 0.74 (95% CI 0.55-1.00, p=0.052), 
indicating that lycopene may be related to the aggressiveness of PCa. Investigating the 
relationship between lycopene and PCa at different stages may provide further insight 
into the role of lycopene in PCa progression.  
 Our analysis exhibits several strengths that improve upon existing studies in the 
literature. First, compared to previous analyses, we included 16 additional studies that 
investigated PCa risk. Cumulative, sensitivity and subgroup analyses were conducted to 
examine the sources of heterogeneity and evaluate associations between lycopene and 
PCa. We had several concerns regarding studies that prescribed supplements to their 




retinyl palmitate and beta-carotene. Absorption of lycopene and beta-carotene occurs in 
the duodenum of the small intestine and is dependent on Class B Scavenger Receptor 
(SR-B1) membrane protein50,51. Beta-carotene is absorbed more efficiently than 
lycopene52, and supplementation may result in reduced lycopene bioavailability. 
Additionally, a consistent finding from studies that utilized beta-carotene and retinyl 
palmitate supplements was an increased risk of cancers in conjunction with other 
behavioral patterns such as smoking289-291. In light of this, we also analyzed the studies 
that did not prescribe supplements to their study. We found no differences between this 
analysis and the analysis of the studies that included these prescribed supplements.  
However, several limitations should be noted. Dietary measurements are limited 
by methods of ascertainment, food composition databases and differences in 
bioavailability292. Genetic variability may play a large role in lycopene bioavailability. In 
one study, a combination of 28 single nucleotide polymorphisms (SNPs) on 16 genes 
accounted for 72% of lycopene bioavailability variation59. These differences in lycopene 
bioavailability may affect long-term blood lycopene status and consequently PCa risk59,60. 
Next, guidelines for PCa screening vary between countries, medical organizations and 
guideline groups5. One of the largest risk factor of PCa diagnosis, especially of non-
aggressive disease, is screening. Differences in screening intervals and guidelines may 
affect PCa detection and incidence rates6. Additionally, the racial profiles of each study 
are different, which may contribute to differences in PCa risk. In the United States, 
African-Americans experience the highest incidence rates of PCa and have a 2.4-fold 




lowest incidence rates of PCa and have a 50% lower mortality rate compared to White 
Americans4.  
 This study further supports lycopene’s protective role in prostate carcinogenesis 
and progression. In conclusion, our meta-analysis demonstrates an inverse association 
between dietary and circulating lycopene on PCa risk. Our data also indicate dose-
responses between dietary and circulating lycopene and PCa incidence. Our results, 
along with those of other clinical and cohort studies, may suggest potential health benefits 
from improving lycopene status. In the dose-response for dietary lycopene, we found a 
1% decreased PCa risk for each additional 2 mg of lycopene consumed. Tomatoes 
provide the American diet with more than 85% of dietary lycopene and contain many other 
potentially beneficial carotenoids and phytochemicals that may protect against PCa. 
Improving lycopene status is easy to achieve. According to the USDA National Nutrient 
Database, ¼ cup of tomato paste contains 19 mg of lycopene, one slice of watermelon 
contains 13 mg of lycopene, and 1 cup of cherry tomatoes provide 3.8 mg of lycopene. 
More high-quality research is required in order to elucidate the associations between 
lycopene and advanced PCa risk and to determine the underlying mechanisms behind its 
associations with PCa. Overall, our results support the hypothesis that consumption of 
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USA 1,254 ─ 29,361 4.2 55-74 Q1 Intake: 
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Abbreviations: years (yrs); standard deviation (SD); tertile (T); quartile/quintile (Q); body mass index (BMI); family history of prostate cancer (FHPC); prostate specific antigen (PSA); 
physical activity (PA); education (Edu); smoking status (SS); multivitamin (MV); socioeconomic status (SES); treatment (trt); cardiovascular disease (CVD); diagnosis (diag); Auckland 
Prostate Study (APS); Cancer Prevention Study II Nutrition Cohort (CPS-II Nutrition Cohort); Markers of Prostate Cancer Study (MPC); Canadian Study of Diet, Lifestyle, and Health 
Cohort (CSDLH); Health Professionals Follow-Up Study (HPFS); Multiethnic Cohort Study (MEC);  Netherlands Cohort Study (NLCS); North Carolina-Louisiana Prostate Cancer Project 
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Abbreviations: years (yrs); standard deviation (SD); tertile (T); quartile/quintile (Q); body mass index (BMI); family history of prostate cancer 
(FHPC); vasectomy (vas); physical activity (PA); education (Edu); smoking status (SS); alcohol (alc); supplement (supp); treatment (trt); diagnosis 
(diag); Carotene and Retinol Efficacy Trial (CARET); Give us a CLUE to Cancer Study I (CLUE 1); Give us a CLUE to Cancer Study II (CLUE II); 
European Prospective Investigation into Cancer Study (EPIC); Health Professionals Follow-Up Study (HPFS); Kuopio Ischaemic Heart Disease 
Risk Factor Study (KIHD); Multiethnic Cohort Study (MEC); Prostate, Lung, Colorectal, and Ovarian Cancer Trial (PCPT); Physicians’ Health 





1 indicates that cases are independently validated (0,1star); 2, cases have prostate cancer, 
representative of population (0,1); 3, controls are selected from same population as cases (0,1); 4, 
controls have no history of prostate cancer (endpoint) (0,1); 5, study controls for most important factor 
(age) and other factors (0-2); 6, same method of ascertainment for cases and controls (0,1); 7, validated 
and comparable method for lycopene determination (0,1), 8, unbiased response between groups (0,1); 9, 
total: minimum equals 1; maximum equals 9 stars 
 
  
Table 3.3. Quality assessment of all studies investigating lycopene  
Source Selection Comparability5 Exposure   Total9 
Author, Year Definition1   Representative2   Selection3   Definition4 
 
Ascertainment6     Method7 Rate8 
 
Angalliu, 2011 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Antwi, 2016 ★ ★ ★ 0 ★★ ★ ★ ★ 8 
Beilby, 2010 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Bosetti, 2004 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Chang, 2005 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Cohen, 2000 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Deneo-Pellegrini, 1999 ★ ★ 0 ★ ★★ ★ 0 ★ 7 
Gann, 1999 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Gill, 2009  ★ ★ ★ ★ ★ ★ ★ ★ 8 
Goodman, 2003 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Goodman, 2006 ★ ★ ★ ★ ★★ 0 ★ ★ 8 
Hodge, 2004  ★ ★ ★ ★ ★★ 0 ★ ★ 8 
Hsing, 1990 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Huang, 2003 (CLUE 1) ★ ★ ★ ★ ★ ★ ★ ★ 8 
Huang, 2003 (CLUE 2) ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Jain, 1999 ★ ★ ★ ★ ★★ 0 ★ ★ 8 
Jian, 2007 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Karppi, 2009  ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Key,1997 ★ ★ ★ ★ ★ ★ ★ ★ 8 
Key, 2007 ★ ★ ★ ★ ★ 0 ★ ★ 7 
Kirsh, 2006 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Kristal, 2010  ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Kristal, 2011  ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Lewis, 2009 ★ ★ ★ ★ ★ ★ ★ ★ 8 
Lu, 2001 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
McCann, 2005 ★ ★ ★ ★ ★★ 0 0 0 6 
Meyer, 1997 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Nomura, 1997 ★ ★ ★ ★ 0 ★ ★ ★ 7 
Nordstrom, 2016 ★ ★ ★ 0 ★★ ★ ★ ★ 8 
Norrish, 2000 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Park, 2015  ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Parker, 1999 ★ ★ ★ ★ ★★ 0 0 ★ 7 
Peters, 2007  ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Sanderson, 2004 ★ ★ ★ ★ ★★ ★ 0 ★ 8 
Schuurman, 2002 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Shahar, 2011 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Stram, 2006 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Vogt, 2002 ★ ★ ★ ★ ★★ 0 ★ ★ 8 
Wang, 2016 ★ ★ ★ ★ ★★ ★ ★ ★ 9 
Wu, 2004 ★ ★ ★ ★ ★ ★ ★ ★ 8 
Zhang, 2007 ★ ★ ★ ★ ★★ 0 ★ ★ 8 






Table 3.4. Subgroup analysis between lycopene and prostate cancer risk 







P-value No. of 
studies 
Relative Risk 




Overall model 21 0.88 (0.78-0.98)† 55.8 0.017 17 0.88 (0.79-0.98) 26.2 0.019 
Study type         
Cohort/case 
cohort 
6 0.93 (0.87-0.99) 11.0 0.030 1 0.78 (0.37-1.65) 0.0 0.516 
Case-control 15 0.82 (0.68-0.999)† 63.7 0.049 4 0.60 (0.32-1.13)† 59.8 0.115 
Nested case-
control 
0 – – 0.657 12 0.91 (0.81-1.02) 3.6 0.093 
Continent         
North America 12 0.93 (0.87-0.99) 47.0 0.036 14 0.87 (0.78-0.98) 38.2 0.025 
Europe 4 0.93 (0.79-1.10) 0.0 0.389 2 0.94 (0.70-1.26) 0.0 0.670 
Other 5 0.59 (0.35-0.99)† 77.3 0.046 1 0.77 (0.40-1.48) – 0.431 
Adjustments          
High Quality 17 0.89 (0.79-1.00)† 53.7 0.051 15 0.86 (0.77-0.97) 32.9 0.013 
Mid Quality 4 0.81 (0.64-1.01) 48.4 0.058 2 0.99 (0.74-1.33) 0 0.946 
Adjusts for 
age 
18 0.85 (0.76-0.96)† 58.2 0.007 10 0.91 (0.80-1.04) 40.2 0.169 
No adj for age 3 1.12 (0.85-1.47) 7.8 0.405 7 0.81 (0.67-0.99) 0.0 0.034 
Adjusts for 
BMI 
12 0.89 (0.77-1.02)† 66.4 0.099 9 0.85 (0.75-0.97) 28.2 
 
0.013 
No adj for 
BMI 
9 0.84 (0.73-0.099) 11.5 0.033 8 0.96 (0.78-1.17) 27.2 0.656 
Adjusts for 
smoking 
8 0.93 (0.87-1.00) 46.8 0.046 10 0.80 (0.66-0.97) 35.9 0.022 
No adj for 
smoking 
13 0.81 (0.67-0.98)† 60.1 0.032 7 0.92 (0.80-1.05) 4.6 0.215 
Adjusts for 
FHPC 
14 0.94 (0.88-0.996) 30.7 0.038 4 0.66 (0.49-0.88) 41.8 0.005 
No adj for 
FHPC 
7 0.69 (0.51-0.93)† 72.6 0.015 13 0.92 (0.82-1.04) 1.7 0.163 
Adjusts for 
education 
10 0.95 (0.77 -1.17)† 67.9 0.627 7 0.80 (0.66-0.97) 23.1 0.025 
No adj for 
education 
11 0.88 (0.82-0.94) 29.3 <0.001 10 0.92 (0.82-1.04) 28.4 0.187 
Adjusts for PA 5 0.93 (0.87-0.998) 0.0 0.043 5 0.78 (0.63-0.95) 20.8 0.016 
No adj for PA 16 0.81 (0.67-0.98)† 63.0 0.030 12 0.92 (0.81-1.05) 25.3 0.213 
Adjusts for 
alcohol 
4 0.99 (0.72-1.36)† 52.4 0.930 5 0.80 (0.64-0.99) 39.9 0.041 
No adj for 
alcohol 
17 0.85 (0.75-0.96)† 54.9 0.008 12 0.91 (0.80-1.03) 21.5 0.132 
Adjusts for 
energy 
10 0.82 (0.66-1.00)† 72.2 0.051 0 – – – 










Figure 3.2 Forest plot for association of highest vs lowest intake of lycopene on PCa risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 






Figure 3.3 Forest plot for association of highest vs. lowest intake of lycopene on 
advanced PCa risk.  
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure 3.4 Forest plot for association of highest vs lowest circulating lycopene on PCa 
risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure 3.5 Forest plot for the association of highest vs. lowest circulating lycopene on 
advanced PCa risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 






Figure 3.6 Forest plot for the association of highest vs lowest lycopene concentrations 
on PCa aggressiveness. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 






Figure 3.7 Forest plot for the association of highest vs lowest lycopene concentrations 
on PCa mortality. 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure 3.8 Dose-response analysis of lycopene and PCa risk. 
 
The solid black line is the nonlinear model curve for published relative risk and the two 
dotted lines are the corresponding 95% confidence intervals. The short-dashed line is 
the linear model curve for the published relative risks (RR); (A) dietary lycopene 
(mg/day) and risk of PCa; (B) dietary lycopene (mg/day) and risk of PCa after exclusion 
of one study (C) circulating lycopene concentrations (µg/dL) and risk of PCa; (D) 
circulating lycopene concentrations (µg/dL) and risk of PCa after exclusion of one study 
E) dietary lycopene (mg/day) and risk of advanced PCa (F) circulating lycopene 




Chapter 4: Tomatoes or lycopene do not alter castration resistant prostate cancer 
progression in the TRAMP model 
 
c,d Abstract  
Background: Dietary tomato products or lycopene protect against prostate 
carcinogenesis, but their ability to reduce the emergence of castration-resistant prostate 
cancer (CRPC) is unknown. We hypothesized that tomato or lycopene products would 
reduce the emergence and growth of CRPC. 
Methods: Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice were 
castrated at 12-13 weeks of age and the emergence of CRPC was monitored by 
ultrasound in each study. In Study 1, TRAMP mice (n=80) were weaned onto an AIN-
93G-based control diet (Con-L, n=28), a 10% tomato powder diet (TP-L, 10% lyophilized 
w/w, n=26), or a control diet followed by a tomato powder diet after castration (TP-Int1, 
n=26). In Study 2, TRAMP mice (n=85) were randomized onto a control diet with placebo 
beadlets (Con-Int, n=29), a tomato diet with placebo beadlets (TP-Int2, n=29) or a control 
diet with lycopene beadlets (Lyc-Int, n=27) following castration (12 weeks of age). Tumor 
incidence and growth were monitored by ultrasound beginning at 10 weeks of age. Mice 
were euthanized 4 weeks after tumor detection or at 30 weeks of age if no tumor was 
                                               
c Joe L. Rowles primarily contributed to Study 2 and assisted with Study 1. Study 1 was 
primarily conducted by Joshua W. Smith. For congruency, both studies are reported 
together as Chapter 4. 
d The content of this chapter has been accepted by Journal of Nutrition (Rowles J.L. III, 
Smith J.W., Applegate C.C., Miller R.J, Wallig M.A., Kaur A., Sarol Jr J.N., Musaad S., 





detected. Tissue weights were compared by ANOVA followed by Dunnett’s test. Tumor 
volumes were compared using generalized linear mixed model regression.  
Results: Ultrasound estimates for the in vivo tumor volume were strongly correlated with 
tumor weight at necropsy (R2 =0.75 and 0.94, p<0.001 for both Study 1 and 2, 
respectively). Dietary treatments after castration did not reduce cancer incidence, time to 
tumor detection, or final tumor weight.  
Conclusions: In contrast to studies of de novo carcinogenesis in multiple preclinical 
models, tomato components did not reduce the emergence of CRPC in the TRAMP 
model. It is possible that specific mutant subclones of prostate cancer may continue to 
show some anti-proliferative response to tomato components, but further studies are 
needed to confirm this.   
 
Introduction 
Prostate cancer (PCa) is the second leading cause of cancer-related deaths 
among men in the United States.293 Androgen deprivation therapy (ADT) has been the 
primary therapy for advanced and metastatic PCa for over 70 years.294 Historically, ADT 
was performed by surgical castration following the discovery that testosterone was critical 
to prostate growth and function in laboratory models.33,295 In recent decades ADT 
increasingly has been accomplished by pharmacologic agents and integrated into 
effective multimodality treatment plans for locally advanced and high-grade localized 
prostate cancer, and in salvage regimens for local recurrence following prostatectomy.2, 




expectancy.294,296 Unfortunately, ADT alone is rarely curative as genetic instability within 
the cancer cells lead to the emergence of mutant sub-clones that progress in spite of 
castrate serum concentrations of testosterone.36 This late and often lethal phenotype is 
termed castration-resistant prostate cancer (CRPC).36  
Following PCa diagnosis, patients often seek information about food and 
supplements that may improve their response to therapies, quality of life, and survival. 
Tomatoes and lycopene are two of the most frequently mentioned foods or supplements 
by social media, lay press, and purveyors of alternative therapy as having a protective 
effect on prostate cancer activity. Consumption of tomatoes or their predominant 
carotenoid, lycopene, has been associated with lower PCa risk in many epidemiological 
studies.127,132 Interestingly, increased tomato or lycopene consumption in epidemiological 
cohorts appear to have a greater reductions in risk with lethal or aggressive PCa.94,95,285 
In agreement with the human epidemiological evidence, studies in multiple rodent models 
support the hypothesis that dietary tomato or lycopene reduce de novo prostate 
carcinogenesis.114,116,297 However, the potential efficacy of dietary tomato or lycopene as 
a component of an integrated treatment plan to reduce the progression of CRPC has not 
been thoroughly investigated in experimental systems.   
Based on the epidemiological and preclinical evidence for PCa incidence, many 
men with PCa undergoing ADT or with CRPC might choose to consume lycopene 
supplements without evidence from definitive phase III human trials. Although some 
groups have explored the activity of tomato carotenoids on the growth of androgen-
insensitive PCa xenografts,298-300 these short-term studies in models of tumorigenesis do 




from androgen sensitive to the castration-resistant state. Additionally, the use of 
pharmacological doses of lycopene, far beyond what is relevant to the diet, is a concern 
because little is known regarding the risks of such intake in humans.301,302 Although these 
data suggest that dietary tomato or lycopene may provide a benefit to men with advanced 
androgen-sensitive PCa, a lack of preclinical data on which to base more definitive trials 
remains a gap in the literature.  
We sought to address this hypothesis by investigating whether lifelong tomato 
consumption, a later dietary tomato intervention, or a later dietary lycopene intervention 
would be effective in reducing the emergence and growth of CRPC tumors in the 
transgenic adenocarcinoma of the mouse prostate (TRAMP) model. To investigate this 
hypothesis, we conducted 2 studies. Study 1 investigated the potential for lifelong or post-
castration tomato interventions to reduce CRPC incidence and progression in castrated 
TRAMP mice. Study 2 evaluated the potential for post-castration tomato or lycopene 
interventions to reduce CRPC incidence and progression in castrated TRAMP mice. To 
our knowledge, this is the first report to evaluate the efficacy of dietary tomato or lycopene 
combined with castration (as a model of ADT) to reduce the incidence and progression 
of CRPC in a rodent model. 
Materials and Methods 
Diets 
Tomato paste (Contadina®, San Francisco, CA) was purchased from a local 
supermarket in September 2014 and July 2015 for Study 1 and in April 2016 (Study 2); 




Scientific, Warminster, PA). Dried yield was ~25% of wet mass. Lyophilized tomato paste 
(TP) was ground to fine powder in a tabletop food processor, transferred to resealable 
gallon bags (air removed), and kept in the dark at -20˚C until diet mixing.  
Two experimental diets were used in Study 1: a powdered, AIN-93G-based control 
diet and the same diet modified to contain 10% (w/w) lyophilized tomato paste (TP). In 
Study 2, similar control and tomato diets were used with the addition of placebo beadlets 
(0.47 g/ kg diet, DSM, Netherlands). Study 2 also included a powdered AIN-93G-based 
control diet containing lycopene beadlets (Lyc) (0.47g of 10% lycopene beadlets/ kg diet, 
DSM, Netherlands). The composition of each diet is described in Table 4.1. Ingredients 
were mixed using a commercial mixer (Hobart, Illinois. USA). Proximate analysis was 
performed on the 100% tomato paste powder and diet formulas were balanced for total 
energy, carbohydrates, protein, fat, fiber, and moisture. New diets were formulated every 
1.5-2 months. Seven (Study 1) or six (Study 2) batches of the 10% tomato diet were made 
throughout the course of the study and each was analyzed for carotenoid content by high-
performance liquid chromatography (HPLC). 
Mouse breeding, genotyping, and housing 
The University of Illinois Laboratory Institutional Animal Care and Use Committee 
reviewed and approved all experimental procedures (Study 1 protocol number 14296; 
Study 2 protocol number 16078). Male C57BL/6-Tg(TRAMP)8247Ng/J (C57BL/6 
TRAMP+/-), female C57BL/6J, and female FVB/NJ mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME). A breeding colony was maintained with crosses of 
C57BL/6J females and C57BL/6 TRAMP+/- males. Male F1 offspring of FVB/NJ females 




with Extract-N-Amp™ Tissue PCR kits (Sigma-Aldrich, St. Louis, MO) and mice were 
genotyped to confirm transgene presence. Males carrying the probasin:SV40-Tag 
transgene (hereafter referred to as TRAMP mice) were weaned at 3 weeks of age and 
enrolled into the study via rolling admission. Mice were housed under controlled 
conditions (12-hour light/dark cycle, 22˚C, 55% humidity), weighed weekly, and diet was 
added 3 times per week.  
Study 1. Allotment of mice  
TRAMP mice were acclimated to the AIN-93G control diet from weaning at 3 to 4 
weeks of age and randomized to consume control diet (Con, n=54) or 10% TP (TP-L, 
n=26). Following castration between 12-14 weeks of age, mice were switched from the 
control diet to an intervention of 10% TP (TP-Int1, n=26) or remained on the control diet 
(Con-L, n=28).  
Study 2. Allotment of mice 
TRAMP mice were acclimated to the AIN-93G control diet from weaning at 3 weeks 
of age until castration at 12 weeks of age. Following castration, TRAMP mice consumed 
dietary treatments of control diet with placebo beadlets (Con-Int, n=29), an AIN-93G diet 
modified to contain 10% lyophilized tomato paste with placebo beadlets (TP-Int2, n=29), 
or the control diet with lycopene beadlets (Lyc-Int, n=27). 
Castration Surgery 
Mice were surgical castrated between 12 and 14 weeks of age under inhalation 
isoflurane for general anesthesia on a heated platform. The mean age at castration was 




mice exhibit nearly 100% incidence of high-grade prostatic intraepithelial neoplasia or 
microscopic well- to moderately-differentiated adenocarcinoma.88,135 Subcutaneous 
injections of an analgesic (buprenorphine, 0.05 mg/kg or carprofen, 5 mg/kg) was given 
pre- and post-surgery. Figure 4.1 displays the study designs with diet interventions, 
castration, and necropsy for both studies. 
In vivo ultrasound tumor screening and measurement 
Beginning at 10 weeks of age, biweekly (every 2 weeks) in vivo ultrasound imaging 
was used for longitudinal screening and tumor volume measurement. Inhalation 
isoflurane was used for general anesthesia. Ultrasonic scans were obtained through the 
ventral body wall while in dorsal recumbency on a heated table using the Vevo 2100 pre-
clinical ultrasonic imaging platform (VisualSonics, Inc., Toronto, Canada). Scans were 
conducted in 3D B-mode, and frames were collected in a caudal to cranial direction at 
intervals of approximately 0.152 mm. Serial 2D image slices were used to generate 
prostatic or tumor volume estimates as previously described.303 Mice with prostate tumors 
identified at 14 weeks of age or later were switched from biweekly ultrasound screening 
to weekly ultrasound scans in order to measure CRPC tumor volume.  
Necropsy 
Mice were euthanized for necropsy based upon the following criteria: (a) a 
moribund clinical status, (b) a four-week time period after a tumor mass was detected by 
ultrasound, (c) a tumor volume exceeding 5000 mm3, or (d) 30 weeks of age with no 
tumor detected by ultrasound. Study 1 mice were euthanized by CO2 asphyxiation under 




were exsanguinated by cardiac puncture under deep anesthesia followed by cervical 
dislocation. When possible, the prostate was dissected into individual lobes (anterior, 
dorsal, lateral and ventral). Suspected malignant prostate masses (tumors) were 
dissected from the remaining prostate. Individual prostate lobes, malignant prostate 
tumors, seminal vesicles, liver, lungs, and epididymal adipose tissue were weighed and 
snap frozen in liquid N2 and stored at -80˚C for future analysis. Gross metastases to the 
lungs, liver, kidneys, urethra, and regional lymph nodes (medial iliac and lumbar aortic, 
when present) were identified by visual inspection, and tissues were fixed in 10% neutral-
buffered formalin for 12 to 24 hours and held in 70% aqueous ethanol until paraffin 
embedding.  
Histopathology and immunohistochemistry 
 Tissues were embedded in paraffin and 4-μm-thick sections were stained with 
hematoxylin and eosin (H&E). A blinded examiner (SKC or MAW) evaluated the extent 
and severity of neoplasia in prostate and tumor sections as previously described.304 
Metastases were confirmed by H&E and SV-40 staining, and the emergence of poorly 
differentiated cancer exhibiting a stereotypic neuroendocrine phenotype was determined 
by staining against synaptophysin (ABCAM, Cambridge, MA). 
Carotenoid measurement 
 Diet and tissue carotenoids were extracted and analyzed by HPLC as previously 
described.62,305 Approximately 25 mg diet, 300 mg tumor tissue, 200 μL serum, and 100 
mg liver tissue were used for analysis. Carotenoids in the serum were analyzed by HPLC-




2.62,305 Due to castration, anterior prostates atrophied and were too small for individual 
assay. Thus, anterior prostates from 8-12 mice (one lobe per mouse) were pooled to 
achieve quantifiable signal. Anterior prostates from 8 and 12 mice (one lobe per mouse) 
in Study 1 were pooled into two individual replicates per treatment. Anterior prostates 
from 2-5 animals (one lobe per mouse) were pooled in Study 2.   
Statistical analysis 
Parallel statistical analyses were conducted for both studies. SAS (version 9.4, 
SAS Institute, Cary, NC) was used for statistical analyses. In total, 80 mice from Study 1 
(Con-L, n = 26; TP-L, n = 28; TP-Int1, n = 26) and 85 mice from Study 2 (Con-Int, n=29; 
TP-Int2, n=29; Lyc-Int, n=27) were included in the final analysis. Descriptive statistics of 
mouse characteristics such as enrollment age, age at castration, age at euthanasia, 
weight at euthanasia, occurrence and sites of lesions were obtained using means and 
standard error for quantitative variables and frequencies and percentages for 
dichotomous variables. Carotenoid accumulation was compared between carotenoid-
containing treatments by t-test. Body weight at necropsy and organ weights were 
assessed by ANOVA with multiple comparisons correction by Dunnett’s test. Cancer 
incidence was assessed by Fisher’s exact test between the control group and each 
treatment group. Survival curves were generated using product-limit estimation, with time 
from castration to appearance of ultrasound-detected tumor treated as the duration of 
tumor-free survival. We tested for significance of the differences in the survival rates 
between treatments by employing the log-rank test with PROC LIFETEST. To control for 





In both studies, 56 mice developed lesions that were detectable by ultrasound with 
weekly tumor volume measurements. Due to the rapid rate of weekly volume increase 
and heterogeneity of data, tumor volumes were transformed by natural logarithms. 
Generalized linear mixed model regression using PROC GLIMMIX was employed to 
examine differences between the treatment groups for rate of tumor growth during the 
five consecutive weeks of tumor volume monitoring. The model was fit to the data 
assuming a lognormal distribution of the outcome. A random intercept and slope, 
treatment effects as well as the interaction of treatment and time were included in the 
model. The latter term represented the differences in the rate of tumor growth (slopes) 
between treatment groups. Experimental units (mice) were nested within treatment group. 
Age and weight at castration were included in the model as covariates. Pairwise 
comparisons across treatment groups were conducted using the LSMESTIMATE 
statement and the p-values were adjusted for multiple comparisons using the Sidak 
test.307 We performed sensitivity analysis in the regression using generalized linear mixed 
models in two ways: 1) by considering a weighted least squares estimation of the 
parameter models, and 2) by removing influential observations based on studentized 
residuals. Differences in the tumor weight at euthanasia, week 0 tumor volume, week 4 
tumor volume, and the final non-missing tumor volume among the treatment groups were 
evaluated through generalized linear regression. Generalized linear regression was 
conducted using PROC GLMSELECT where age and weight at castration were 
considered as potential confounders. Sensitivity analyses were conducted for both 
studies by using a weighted least squares approach and by removing extreme 




to evaluate these endpoints. The primary outcomes for this study were cancer incidence, 
time to tumor detection, tumor growth rate, final tumor volume, and tumor weight. Unless 
otherwise stated, p<0.05 was considered significant. All values are reported as mean ± 
standard error of mean (SEM). 
 
Results 
Carotenoid content of diet and accumulation in tissues 
The carotenoid composition of the tomato and lycopene diets are shown in Figure 
4.2. Lycopene was the predominant carotenoid (~40 nmol/g, ~50% of total carotenoids) 
in the TP diets for both studies. Within the Lyc-Int diet, lycopene content was 139 nmol 
lycopene/g diet. No significant differences in tissue carotenoid accumulation were 
observed between tomato treatments in Study 1 (Table 4.2). Similarly, no significant 
differences in tissue lycopene accumulation were observed between Lyc-Int and TP-Int2 
interventions in Study 2. While the liver and serum carotenoid profile largely reflected the 
dietary carotenoid composition, we did not detect phytoene in prostate or tumor tissue, 
as our laboratory has previously reported for TRAMP mice.135 
Animal characteristics 
TRAMP mice were enrolled onto each study at 4.0 ± 0.1 and 4.2 ±0.1 weeks of 
age in Study 1 and 2, respectively. Mice in Study 1 were a week older at castration than 
Study 2 (13.1 ± 0.1 weeks compared to 12.1 ± 0.1 weeks). There were no differences 
between the body weights at euthanasia across treatment groups in either study (Figure 




epididymal adipose tissue, lungs, individual prostatic lobes and total prostate weight 
within studies (Table D.1).  
Tumor incidence and metastases  
 Cancer incidence is displayed in Table 4.3. 76% of the animals in Study 1 and 77% 
of the animals in Study 2 developed histologically confirmed moderately or poorly 
differentiated adenocarcinoma with no differences between treatment conditions (p=0.82 
in Study 1 and p=0.56 in Study 2). Expression of neuroendocrine features represented 
by synaptophysin immunohistochemistry, was expressed in 33% or 42% in the tumors 
from Studies 1 and 2 respectively, with no differences by treatment group. Metastatic 
spread was visually assessed at necropsy and lesions were confirmed by pathology. For 
both studies, the statistical analysis of distant metastatic disease was not possible for any 
site due to the low incidence of metastases observed (Table 4.4). The most common site 
of metastases was to the lymph node, which occurred in 4-30% of all animals. 
Approximately 78% of the metastases in Study 1 and 95% of the metastases in Study 2 
stained positive for SV-40.  
In vivo CRPC tumor growth 
 70% of mice in Study 1 and 66% of mice in Study 2 developed lesions that were 
detected by ultrasound and were eligible for in vivo growth analyses. Overall, ultrasound 
estimates for in vivo tumor volume were strongly correlated with tumor weight at necropsy 
(R2 =0.76 and 0.94, p<0.001 for both Study 1 and 2, respectively) (Figures 4.3A and 
4.3B). For both Study 1 and Study 2, no differences in tumor-free survival between the 




time of castration (12-14 weeks of age) were noted in Study 1 (log rank p=0.91) and Study 
2 (log rank p=0.70). These results remained the same even after using proportional 
hazards regression controlling for age and weight at castration. 
The initial tumor volume (week 0) was not different between treatment groups for 
mice on either study (p=0.22 and p=0.28 for Study 1 and 2, respectively). The mean tumor 
volume at detection was approximately 50 mm3 in Study 1 (Figure 4.3C) and 20 mm3 in 
Study 2 (Figure 4.3D). The differences between tumor volume by treatment in the final 
week of the analysis (week 4) were also not different in either study (p=0.07 and p=0.87 
for Study 1 and 2, respectively) compared to each respective control (Figure 4.3E and 
Figure 4.3F). Individual tumor growth curves can be found in Figure D.2. 
 Due to the large variability in the in vivo tumor volumes, tumor volumes were 
transformed by their natural logarithms. Regression analysis of in vivo log-transformed 
tumor volumes are shown in Table 4.5. In Study 1, a significant effect of time was noted 
(b=0.87, p<.0001), indicating that the log-transformed tumor volume increased with time 
(Table 4.5). The tests for interaction effects indicated that the slopes for TP-Int1 and TP-
L were not different from that of the control group (b=-0.04, p=0.73 and b=-0.03, p=0.76, 
respectively). The main effect of TP-Int1 treatment on log-transformed tumor volume was 
significant, with a beta coefficient of -0.43 (p=0.04), relative to Con-L. This corresponds 
to a 35% decrease in the actual tumor volume (mm3) in TP-Int1 compared to Con-L over 
the 5-week interval of tumor growth. The main effect of TP-L on log-transformed tumor 
volume and Con-L at Week 0 was not significant (b=-0.34, p=0.11). Tests of the 




TP-L were not different from Con-L (b=-0.04, p=0.73 and b=-0.03, p=0.76, respectively), 
indicating no differences in tumor growth rates. 
Similar to Study 1, a significant effect of time was noted (b=1.21, p<0.0001) in 
Study 2, indicating that the mean log-transformed tumor volume increased with time. 
Likewise, no interaction effects between treatment and time were found, indicating that 
the tumor growth rate for Con-Int did not differ from TP-Int (b=0.02, p=0.79) or Lyc-Int 
(b=0.01, p=0.83). Unlike Study 1, there were no main effects of dietary treatment, 
indicating that Con-Int did not differ from TP-Int2 (b=0.29, p=0.44) and Lyc-Int (b=0.35, 
p=0.38). Sensitivity analyses were conducted for both studies by using a weighted least 
squares approach and by removing extreme observations. However, the results of these 
analyses were unchanged. 
 
Discussion  
Men undergoing ADT as a component of curative multimodality therapy or for 
advanced or metastatic disease frequently consume supplements, many containing 
lycopene or tomato components, or increase their intake of tomato products, in hope of 
improving therapeutic outcome. There is currently a lack of quality pre-clinical research 
or clinical trials supporting the hypothesis that tomato products or lycopene enhance 
benefits of therapeutic interventions such as ADT. The present studies address this key 
gap in the scientific literature using a well-controlled and established TRAMP system with 
relevant physiological exposure to tomato components and lycopene to quantify their 




lycopene would reduce CRPC incidence and progression in the TRAMP model based on 
epidemiological and preclinical data. In contrast to the reduction of de novo murine 
prostate carcinogenesis accompanying tomato and lycopene consumption,114,116,297 the 
dietary treatments provided after castration did not affect incidence of histopathologic 
cancer, tumor weight at necropsy, final tumor volume by ultrasound, and duration of 
tumor-free survival (evaluated by ultrasound). 
Importantly, this study, like other murine experiments using similar dosages of 
lycopene or tomato products, resulted in blood concentrations that are relevant to what is 
observed in humans.97,116,135,297 Although the dose provided in the diet of mice for tomato 
powder interventions (~3 mg lycopene/kg body weight) may seem at first glance very 
excessive or pharmacologic (201 mg of lycopene per day for a 70 kg male), this 
concentration is necessary in a mouse to achieve blood concentrations similar to humans 
due to the poor absorption of carotenoids in rodents.308 The ranges of blood lycopene 
concentrations found in this and similar studies correlates well with blood concentrations 
in American males over the ranges that are associated with a significant reduction in risk 
for lethal PCa in the Health Professionals Follow Up Study (HPFS) prospective cohort 
trial and other studies.95,231,309 Importantly, this dose is easy to achieve through the diet. 
A human equivalent dose of 3 mg/kg in mice translates to 17 mg per day (0.24 mg/kg).310 
This could be achieved with a half serving of tomato sauce (1/4 cup, 60 grams) per day. 
Men accumulate carotenoids in the prostate and prostate lycopene concentrations 
increase similar to blood concentrations.311 This has been demonstrated in studies with 
daily intake of standard tomato products such as juice, soup, or sauce over several 




of lycopene after consuming tomato juice are related to specific genetic polymorphisms 
that can alter carotenoid absorption and metabolism.59,314 Together, these studies 
indicate that the mice in our studies achieve blood and tissue concentrations relevant to 
humans. As a result, these data are particularly relevant to human dietary interventions 
and adds confidence to our findings.  
Experimental models that closely recapitulate the physiology, molecular biology, 
and natural selective pressures of CRPC development more reliably estimate the efficacy 
of preventative or therapeutic strategies. The TRAMP model exhibits castration sensitivity 
similar to humans,88 is immunocompetent, exhibits a predictable histological progression 
from low-grade hyperplasia to poorly differentiated adenocarcinoma (ultimately with clear 
neuroendocrine features) and local as well as distant metastasis.89,315,316 Furthermore, 
transcriptional signatures of human and TRAMP prostate cancer are similar.97,317  The 
TRAMP model is also characterized by dysfunction of Rb and p53 due to the SV40 
transgene, thereby disrupting cell cycle control and promoting genomic instability; 
aberrations in TP53 and RB are transcriptional signatures of human CRPC.316 These 
features of the TRAMP model, both in de novo carcinogenesis and in response to 
castration, fortify our confidence that our new findings are relevant to human CRPC.  Our 
data suggest caution in advising men undergoing ADT that increased tomato or lycopene 
consumption will likely reduce the severity of their disease. 
Ultrasound evaluation of the emergence of individual castrate-resistant tumors 
over five weeks provided a unique and insightful dimension to our studies. The plots of 
individual ultrasound-derived tumor volumes (Figure D.2) displayed extreme 




of dietary treatment and ranged between 10- and 100-fold. Remarkably, this 
heterogeneity is similar to the over 10-fold variation that is seen in the rate of progression 
for men failing initial ADT.318 Although the sample sizes of the present experiments are 
large compared to other preclinical studies, this observed variation in tumor growth rates 
makes it difficult to detect modest changes in tumor growth rate due to dietary treatments. 
CRPC tumors that grow despite ADT typically maintain activity of androgen-mediated 
pathways, often through sustained androgen receptor signaling.36 There are many 
pathways for PCa to progress to CRPC such as mutations affecting the function of the 
androgen receptor, affinity for alternative ligands, activation complementary growth 
promoting signaling pathways, and others.36,319 It is likely that the specific mutational 
spectrum of individual CRPC lesions underlies the large variation in progression rates. 
 Of the very few studies of PCa progression227,320 or CRPC244,253,321, none have 
been sufficiently powered or adequately controlled. A recent systematic review of 
preclinical studies found that most eligible studies reported inhibitory effects of tomato or 
lycopene treatment on androgen-related outcomes.322 Lycopene, in addition to other 
tomato bioactives, may affect tumor progression after castration by modifying 
inflammatory status; 103,104 androgen and growth factor signaling;97 apoptosis;104,111,112 
and cell cycle progression.104,111,112 Tomatoes contain other potentially beneficial 
carotenoids, and bioactive compounds that may reduce prostate tumorigenesis,31 and 
some studies suggest that the whole fruit may be more effective than lycopene alone.14 
Further studies are needed that investigate the molecular profiles of CRPC tumors to 





In conclusion, our studies of tomato products in a well-characterized murine model 
of prostate carcinogenesis are relevant to a key issue for men with PCa undergoing ADT. 
The emergence and progression of CRPC was not altered by tomato or lycopene 
consumption. As science progresses, the role that dietary tomato or lycopene has on the 
growth and progression of specific molecular subtypes of CRPC may be explored with 
the rise of personalized nutrition and cancer treatment plans. Although data from these 
studies did not display a benefit from tomato consumption following castration (ADT), a 
recent single-blind, randomized, pilot trial of 32 men on ADT found that adherence to a 
diet and exercise-based lifestyle intervention shows promise for countering and/or 
reversing adverse effects of ADT.323 Our findings in a model that is relevant to the 
evolution of human PCa with blood concentrations similar to human epidemiological 
literature suggest that men should focus on other fitness and healthy dietary guidelines 
(such as the Dietary Guidelines for America 2015) as they begin ADT rather than focus 
upon supplements of nutrients or other bioactives until a benefit has been demonstrated 





Figures and tables for Chapter 4 
Figure 4.1: Study designs 
 
TRAMP mice were randomized onto a dietary treatment groups after weaning (4 weeks) 
or after castration. In Study 2, Con-Int and TP-Int2 mice received diets containing placebo 
beadlets. Prostates were monitored biweekly for tumor occurrence by ultrasound 
beginning at 10 weeks of age. After tumor detection, mice were scanned four additional 
times (+4 weekly ultrasound scans) to track changes in tumor volume. Mice without 
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Carotenoid composition of the tomato (TP) and lycopene (Lyc) diets. Data are mean 
concentration ± SEM across 6-7 diet batches with 2-3 replicates/batch. Data are 
presented as nmol/g diet. nd, not detected, carotenoid concentration was below the limit 
of detection (0.005 nmol carotenoid/ g diet); na, not analyzed. Lycopene content was 
compared between Study 2 TP and Study 2 Lyc by t-. test. * indicates statistical 
significance (p<0.001). Control diets were not included due to their lack of carotenoids in 










Figure 4.3: Tumor volume correlations and means  
 
  
Correlation of tumor weight at necropsy vs. tumor volume at final ultrasound scan in vivo. 
A, Study 1; B, Study 2. C-F, in vivo tumor volume. C. Study 1, week 0 (tumor detection); 
D, Study 2, week 0 (tumor detection); E, Study 1, week +4; F, Study 2, week +4. G, Study 
1 in vivo tumor volumes. Week of tumor detection is set at 0. H, Study 2 in vivo tumor 
volumes. Week of tumor detection is set at 0. Data are expressed as means ± SEM. For 





Table 4.1. Composition of experimental diets. 
 
             g/kg diet 
  Control 10% Tomato Lycopene 
Cornstarch 390 363 390 
Maltodextrin 130 105 130 
Sucrose 98 97 98 
Casein 196 177 196 
Cellulose 49 41 49 
AIN-93G mineral mix 34 34 34 
AIN-93G vitamin mix 10 10 10 
L-Cystine 3.0 3.0 3.0 
Choline bitartrate 2.5 2.5 2.5 
Soybean oil 70 68 70 
Lyophilized tomato paste 0 100 0 
10% Lycopene beadlets 0 0 0.47 
Placebo beadlets1 0.47 0.47 0 
Water 18 0 18 
kcal/g diet 2 3.9 3.8 3.9 
 





Table 4.2. Carotenoid accumulation in castrated TRAMP mice fed experimental diets. 
 
 n Lycopene1 Phytoene Phytofluene ζ-Carotene -Carotene 
Serum TP-L 6 569.1 ± 97.62 69.1 ± 10.7 141.5 ± 44.4 n.a.3 n.a. 
nmol/L TP-Int1 6 551.1 ± 96.8 59.1 ± 12.3 135.7 ± 8.6 n.a. n.a. 
 TP-Int2 23 285.4 ± 21.8 109.9 ± 7.4 242.4 ± 26.5 n.a. n.d. 
 Lyc-Int 21 345.8 ± 35.0 n.d.4 n.d. n.a. n.d. 
Liver TP-L 12 15.7 ± 2.1 5.6 ± 0.9 10.5 ± 1.5 1.7 ± 0.2 0.03 ± <0.01 
nmol/g TP-Int1 11 17.4 ± 2.1 5.7 ± 0.7 11.2 ± 1.5 1.6 ± 0.2 0.03 ± <0.01 
 TP-Int2 29 10.1 ± 0.5 4.7 ± 0.5 13.8 ± 1.1 n.a. n.d. 
 Lyc-Int 25 8.5 ± 1.1 n.d. n.d. n.a. n.d. 
Prostate TP-L 25 0.38 ± 0.09 n.d. 0.15 ± 0.02 0.34 ± 0.07 n.d. 
nmol/g TP-Int1 2 0.37 ± 0.04 n.d. 0.12 ± 0.01 0.32 ± 0.03 n.d. 
 TP-Int2 15 0.68 n.d. 0.51 n.a. n.d. 
 Lyc-Int 1 1.50 n.d. n.d. n.a. n.d. 
Tumor TP-L 3 0.09 ± 0.01 n.d. 0.04 ± 0.01 0.04 ± <0.01 n.d. 
nmol/g TP-Int1 4 0.12 ± 0.02 n.d. 0.13 ± 0.04 0.06 ± 0.01 n.d. 
 TP-Int2 6 0.05 ± 0.02 n.d. 0.14 ± 0.02 n.a. n.d. 







Table 4.2. (Continued) 
1Total lycopene (sum of all trans and cis stereoisomers).  
2All values represent the mean ± SEM. By t-test, there were no significant differences between TP treatments (Study 1, TP-L and TP-
Int1) in tissue accumulation of any carotenoid. In Study 2 (TP-Int2, Lyc-Int), no significant differences were observed between lycopene 
concentrations TP-Int2 and Lyp-Int.  
3n.a., not analyzed.  
4n.d., not detected. Concentration was below the limit of detection. The limit of detection was 0.015 nmol of each carotenoid per gram 
tissue. Lutein and β-Carotene were analyzed, but not detected in any tissue.  
5Prostate concentrations from Study 1 (TP-L and TP-Int1) are means of two pools of 8 to 12 mice each, while prostates for Study 2 









Prostatic Lesion Score (% total)2 
Neuroendocrine 
carcinoma1  
Treatment + / total n % NSL PIN WD MD  PD + / total n % 
Study 1          
Con-L 19/25 76 16 8 8 4 64 4/16 25 
TP-Int1 18/23 78 17 4 4 13 61 5/13 38 
TP-L 17/22 77 18 5 5 27 45 4/10 40 
Study 2          
Con-Int 21/27 78 22 0 0 4 74 9/21 29 
TP-Int2 22/28 79 18 4 0 0 79 14/22 55 
Lyc-Int 20/27 74 26 0 0 11 63 8/19 44 
 
1Fisher’s exact test between control and respective treatment were not significant for 
adenocarcinoma and neuroendocrine incidence in Study 1 (Con-L, TP-Int1, TP-L) or Study 2 
(Con-Int, TP-Int2, Lyc-Int). 
2Cancer incidence was evaluated by stage by a trained veterinary pathologist. NSL, no significant 
lesion; PIN, prostatic intraepithelial neoplasia; WD, well differentiated adenocarcinoma; MD, 
moderately differentiated adenocarcinoma; PD, poorly differentiated carcinoma.  
3n, total mice available for comparison within each treatment group. Data are provided as the 










Liver Lungs Kidney 
 n1 +2 % + % + % + % 
Study 1          
Con-L 25 5 20 2 8 7 28 5 20 
TP-Int1 23 1 4 0 0 1 5 1 5 
TP-L 23 7 30 0 0 1 4 1 4 
Study 2          
Con-Int 29 5 17 1 3 2 7 1 3 
TP-Int2 29 8 28 1 3 2 7 2 7 
Lyc-Int 28 7 25 1 4 3 11 4 14 
 
1n, total mice available for comparison within each treatment group.  
2Data are provided as the number (+) and percent (%) of mice positive for a designated 





Table 4.5. Generalized linear mixed model regression analyses of in vivo tumor growth. 
 Estimate1 SE t p 
Study 1     
Intercept 3.89 0.14 27.45 <0.0001 
Time 0.87 0.07 12.54 <0.0001 
Treatment     
TP-L -0.34 0.21 -1.65 0.105 
TP-Int1 -0.43 0.20 -2.13 0.038 
Time*Treatment     
TP-L*time -0.03 0.10 -0.31 0.760 
TP-Int1*time -0.04 0.10 -0.35 0.726 
Study 2     
Intercept 2.44 0.27 9.11 <0.0001 
Time  1.21 0.05 22.27 <0.0001 
Treatment     
TP-Int2 0.29 0.37 0.78 0.440 
Lyc-Int 0.35 0.40 0.89 0.380 
Time*Treatment     
TP-Int2*time 0.02 0.08 0.26 0.792 
Lyc-Int*time 0.02 0.08 0.21 0.832 
 
1Estimates and standard errors (SE) are expressed as: Intercept, the natural log of tumor volume 
(in mm3) at detection (week 0); Time, the natural log of the relative increase in tumor volume in 
one week in the control group; Treatment, the natural log of the relative difference between the in 
vivo tumor volume at week 0 of a respective treatment group and the control group; 
Time*Treatment, the natural log of the relative difference between the tumor growth rate of a 









Chapter 5: Radiation efficacy was not altered by a 10% tomato powder diet in 
TRAMP mice 
eAbstract 
Background: Tomatoes contain carotenoids and other potent antioxidants that may 
protect the surrounding tissue from the detrimental effects of external beam radiation 
therapy (EBRT), while reducing rates of prostate carcinogenesis. We hypothesized that 
a diet containing lyophilized tomato paste (TP) would not reduce apoptosis or cell death 
within the prostate tumor following EBRT, while reducing apoptosis and cell death within 
surrounding tissues.  
Methods: To evaluate this hypothesis, we conducted a Pilot and Diet study. In the Pilot 
study, male TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice (n=18) 
were provided a powdered AIN-93G diet at 4 weeks of age. In the Diet study, TRAMP 
(n=76) were provided a control diet or a modified AIN-93G diet containing 10% TP (w/w) 
at 4 weeks of age. In both studies, prostates were monitored by ultrasound. Once tumors 
reached a volume of 500 mm3 (Pilot study), 1000 mm3 (Diet study) or at 24 weeks of age, 
the caudal half of the mouse was irradiated with 7.5 Gy (Rad) or 0 Gy (sham) with a 
Cobalt-60 source. In the Pilot study, mice were euthanized after 0, 24, or 72 hours 
following radiation or sham treatment. Based on the Pilot study, mice were euthanized 24 
                                               
e Please note that additional experiments and analyses are delayed due to COVID-19 
related closures or are currently underway that might alter the final results and 





hours after radiation or sham treatment in the Diet study. Antioxidants (carotenoids and 
α-tocopherol) were measured by high performance liquid chromatography (HPLC). 
Tissues were assessed by a pathologist for radiation-induced changes (hematoxylin and 
eosin) and apoptosis (cleaved caspase-3). Inflammatory markers (C-reactive protein, IL-
6, IL-17A, TNFα, IFNγ, and IL-10) in serum and selected tissues were evaluated by ELISA 
or a Bio-Plex multiplex immunoassay. 
Results:  The caudal half of the animal received a dose of 7.3 Gy of radiation, while the 
cranial half of the animal received 0.6 Gy. Cell death and apoptosis scores within the 
tumor increased with radiation treatments compared to sham-treated mice, while no 
changes occurred in the surrounding prostate. Following radiation treatment, circulating 
levels of lycopene (52% lower), phytoene (26% lower), and α-tocopherol (22% lower) 
were lower compared to sham treated mice (p<0.05). Likewise, serum levels of TNFα 
(50% lower), INFγ (35% lower), IL-6 (35% lower), IL-17a (35% lower), and IL-10 (22% 
lower) were reduced with radiation compared to sham-treated mice (p<0.05). However, 
tissue levels of carotenoids and α-tocopherol were not modified by radiation.  
Conclusions: Collectively, these data indicate that radiation therapy with TP was not 
inferior to radiation alone; however, TP did not improve any of the measured endpoints. 
 
Introduction 
Prostate cancer (PCa) is the second leading cause of cancer related deaths 
among men in western countries.4 If PCa is detected early, common therapeutic options 




(EBRT) or chemotherapy.11-13 In particular, EBRT has become more precise and novel 
methods of delivering the radiation dose have been proposed to improve patient 
outcomes. Despite improved treatment, approximately 60-69% of men who receive EBRT 
develop biochemical recurrence.14 In clinical practice, the maximal dose is typically limited 
by potential for damage to the surrounding (non-tumor) tissues. As the dose of radiation 
increases, oxidative damage within the tumor and surrounding tissue increases and the 
number of required fractions (doses) decreases.18-21 Acute and chronic toxic effects such 
as gastroenteritis, bowel dysfunction, sexual dysfunction, decrease the clinical 
effectiveness of EBRT. For example, radiation therapy is typically accompanied with 
bowel and sexual dysfunction,15 and importantly (but less common), secondary tumors 
and PCa progression.16,17 
Following PCa diagnosis, patients often seek information about food and 
supplements that may improve their response to therapies, quality of life, and survival. 
Tomatoes and lycopene are two of the most frequently mentioned foods or supplements 
by social media, lay press, and purveyors of alternative therapy as having a protective 
effect on prostate cancer activity. Lycopene, in addition to other tomato bioactives, may 
affect tumor progression after castration by modifying inflammatory status; 103,104 
androgen and growth factor signaling;97 apoptosis;104,111,112 and cell cycle 
progression.104,111,112 Lycopene and other carotenoids that are present within tomatoes 
are potent antioxidants that may improve natural defenses and scavenge free radicals 
generated during radiolysis. Anti-oxidants may quench singlet molecular oxygen (reactive 
oxygen species, ROS). Reducing ROS may suppress the highly pro-inflammatory 




ROS in normal tissues is radioprotective and may lead to fewer adverse effects and 
protection from oxidative damage that is caused by radiation therapy.324,325 Although 
these data suggest that PCa may provide a benefit to men who are undergoing treatment 
for radiation therapy, the lack of pre-clinical data prevent more definitive trials from 
occurring and remains a gap in the literature.  
The goal of this study was to address the hypothesis that tomato feeding would 
protect surrounding tissues from inflammatory damage, without affecting radiation-
induced damage in the tumor in the TRansgenic Adenocarcinoma of the Mouse Prostate 
model. To evaluate this hypothesis, we conducted 2 studies. The first study was a pilot 
study, which established the timing for termination of mice following radiation and to 
establish the radiation dose that would be used in a dietary study. The second study 
aimed to evaluate the potential of lifelong consumption of tomato powder to alter 
radiation-induced damage (apoptosis and double-stranded DNA-breaks) in the prostate 
tumor and surrounding tissues. To our knowledge, this is the first study to evaluate the 
efficacy of dietary tomato or lycopene on inflammatory-induced changes to the tumor and 
surrounding organs within an animal model.  
 
Materials and Methods 
Diets  
Many of the methods used for this section are similar to the Materials and Methods 
for Chapter 4 (pages: 87-94). Briefly, tomato paste (Contadina®, San Francisco, CA) was 
purchased from a local supermarket in September 2014, July 2015, and in April 2016 and 




Warminster, PA). Dried yield was ~25% of wet mass. Lyophilized tomato paste (TP) was 
ground to fine powder in a tabletop food processor, transferred to resealable gallon bags 
(air removed), and kept in the dark at -20˚C until diet mixing.  
Two experimental diets were used in this study: a powdered, AIN-93G-based 
control diet and the same diet modified to contain 10% (w/w) lyophilized tomato paste 
(TP). Ingredients were mixed using a commercial mixer (Hobart, Illinois. USA). Proximate 
analysis was performed on the 100% tomato paste powder and diet formulas were 
balanced for total energy, carbohydrates, protein, fat, fiber, and moisture. New diets were 
formulated every 2 months. Each batch of diet was analyzed for carotenoid content by 
high-performance liquid chromatography (HPLC). 
Mouse breeding, genotyping, and housing 
The details for breeding, genotyping, and housing are the same as Chapter 4 
(pages 88-89). The University of Illinois Laboratory Institutional Animal Care and Use 
Committee reviewed and approved all experimental procedures (Protocol 18029). Male 
C57BL/6-Tg(TRAMP)8247Ng/J (C57BL/6 TRAMP+/-), female C57BL/6J, and female 
FVB/NJ mice were purchased from The Jackson Laboratory (Bar Harbor, ME). A breeding 
colony was maintained with crosses of C57BL/6J females and C57BL/6 TRAMP+/- 
males. Male F1 offspring of FVB/NJ females and C57BL/6 TRAMP+/- males were used 
for the study. Tail DNA of pups was isolated with Extract-N-Amp™ Tissue PCR kits 
(Sigma-Aldrich, St. Louis, MO) and mice were genotyped to confirm transgene presence. 
Males carrying the probasin:SV40-Tag transgene (hereafter referred to as TRAMP mice) 




were housed under controlled conditions (12-hour light/dark cycle, 22˚C, 55% humidity), 
weighed weekly, and diet was added 3 times per week. 
Pilot study  
TRAMP mice will be randomized onto an AIN-93G control diet (n=18) at four weeks 
of age. Power analyses (power=0.80 and α=0.05) have indicated that 15 animals per 
group will be sufficient to detect a 40% change in oxidative damage in surrounding 
tissues.326 Beginning at 10 weeks of age, weekly in vivo ultrasound imaging was used for 
longitudinal screening and tumor volume measurement. Inhalation isoflurane was used 
for general anesthesia. Ultrasonic scans were obtained through the ventral body wall 
while in dorsal recumbency on a heated table using the Vevo 2100 pre-clinical ultrasonic 
imaging platform (VisualSonics, Inc., Toronto, Canada). Scans were conducted in 3D B-
mode, and frames were collected in a caudal to cranial direction at intervals of 
approximately 0.152 mm. Serial 2D image slices were used to generate prostatic or tumor 
volume estimates as previously described.303 
Once tumors reached a volume of 500 mm3 or at 24 weeks of age without a 
detected tumor by ultrasound, mice were irradiated with 7.5 Gy by a Cobolt-60 source at 
a dose rate of 0.22 Gy/min (Theratron-780 Isocentric teletherapy) (n=12) or 0 Gy (sham 
treatment – Sham, n=6). The radiation was collimated to protect the cranial half of the 
mouse. Inhalation isoflurane was used for general anesthesia. 7.5 Gy of radiation was 
selected to be equivalent to one quarter of a human patient’s hypofractionated therapeutic 
dose. The dose was calculated to be equivalent to 3.5 Gy that was delivered in 5 fractions 
(equivalent to 25% of a human’s hypofractionated total dose).327-330 This dose was 




animal. The prostate received 7.3 Gy of radiation, while the cranial half of the animal 
received a dose of 0.6 Gy (Figure E.1). Non-radiated sham animals underwent the same 
procedure as the radiation treated animals without radiation exposure. Animals were 
euthanized 0, 24, or 72 hours after radiation or sham treatments. The study designs for 
the pilot and diet studies can be found in Figure 5.1.  
Diet study 
TRAMP mice were acclimated to the AIN-93G control diet from weaning at 3 to 4 
weeks of age and randomized to consume control diet (Con, n=35) or 10% TP (n=39). 
Similar to the pilot study, prostates were scanned by ultrasound beginning at 10 weeks 
of age, biweekly (every 2 weeks) for longitudinal screening and tumor volume 
measurement. Inhalation isoflurane was used for general anesthesia. Mice with prostate 
tumors identified were switched from biweekly ultrasound screening to weekly ultrasound 
scans in order to measure tumor volume. Once tumors reached a volume of 1000 mm3 
or at 24 weeks of age without a detected tumor by ultrasound, mice were irradiated with 
7.5 Gy by a Cobolt-60 source at a dose rate of 0.22 Gy/min (Rad, n=19; TP-Rad, n=18) 
or 0 Gy (sham treatment – Sham, n=16; TP-Sham, n=20). Animals were euthanized 24 
hours after radiation or sham treatments.  
Necropsy 
TRAMP mice were exsanguinated by cardiac puncture under deep anesthesia 
followed by cervical dislocation. When possible, the prostate was dissected into individual 
lobes (anterior, dorsal, lateral and ventral). Suspected malignant prostate masses 




prostate tumors, seminal vesicles, liver, lungs, and epididymal adipose tissue were 
weighed and snap frozen in liquid N2 and stored at -80˚C for future analysis. Gross 
metastases to the lungs, liver, kidneys, urethra, and regional lymph nodes (medial iliac 
and lumbar aortic, when present) were identified by visual inspection, and tissues were 
fixed in 10% neutral-buffered formalin for 12 to 24 hours and held in 70% aqueous ethanol 
until paraffin embedding.  
Histopathology and immunohistochemistry 
 Tissues were embedded in paraffin and 4-μm-thick sections were stained with 
hematoxylin and eosin (H&E). A blinded examiner evaluated the bladder, urethra, each 
lobe of the prostate, the prostate lesion (tumor), small intestines, kidney, and liver for 
morphological changes including cell death, edema, and infiltration of macrophages. 
Additionally, this blinded examiner (MAW) also evaluated the extent and severity of 
neoplasia in prostate and tumor sections as previously described.304 Metastases were 
confirmed by H&E and SV-40 staining. Apoptosis was quantified by cleaved caspase-3 
staining (Cell Signaling Technology, MA). Double-stranded DNA damage was quantified 
by γ-H2A.X (ABCAM, MA). 
Carotenoid measurement 
 Diet and tissue carotenoids were extracted and analyzed by HPLC as previously 
described.62,305 Approximately 25 mg diet, 300 mg tumor tissue, 200 μL serum, and 100 
mg liver tissue were used for analysis. Anterior prostates from 10 mice per treatment 






 All samples were stored at −80°C until the day of the assay .The serum levels of 
IL-1β, IFNγ, TNFα, IL-6, IL-10, and IL-17A cytokine profiles were measured using a Bio-
Plex multiplex assay (Bio-Rad, Hercules, CA) as previously described.331 Serum levels of 
C Reactive Protein (CRP) was assessed by an ELISA following the manufacturer’s 
instruction (ABCAM, MA). Portions of the liver, epididymal adipose tissue, anterior 
prostate, and prostate tumor were homogenized in PBS and frozen at -20°C overnight. 
Samples were thawed and centrifuged at 2000 x g for 15 minutes. The supernatant was 
transferred to a new tube, and TNFα was quantified by an ELISA following the 
manufacturer’s instructions (Thermo-Fisher, MA). 
Statistical Analysis 
Statistical analyses were performed in SAS version 9.4 (SAS Institute, Inc., Cary, 
NC) and GraphPad Prism 8.4 for Windows. Tissue weights, serum and tissue cytokines, 
and gene expression were compared using one or two-way ANOVA with multiple-
comparison adjustments by Tukey’s method. Data were log transformed when 
assumptions of normality were not met. Histological scores were assessed by Wilcoxon’s 
Rank-Sum Test whenever two samples were present at a given time point. Otherwise, 
the nonparametric Kruskal-Wallis test was performed with multiple-comparisons by 
Dunn’s test. Unless otherwise stated, a p-value < 0.05 was considered statistically 








Animal characteristics of the Pilot study 
 There were no differences between the body weights at euthanasia across time 
points that were evaluated in (Figure E.1). Additionally, there were no differences in the 
epididymal adipose tissue, lungs, heart, and total prostate weight within studies (Table 
E.1). Following radiation treatment (24- or 72-hours following radiation), the mean weight 
of the spleen decreased by 50% (p<0.001). Mean testicular weight also decreased by 
10% after 72 hours (p<0.01). Interestingly, mean PCa tumor weight appeared to be 68% 
lower than sham-treated mice 72 hours following irradiation compared to sham-treated 
mice; however, the number of tumors for this comparison were low (Table E.2). 
 By 24 weeks of age, 100% of mice developed histologically-confirmed prostate 
adenocarcinoma Table 5.1. Histological evaluation of tumors suggests that radiation 
increased the median necrosis and apoptosis scores within the tumor from 0-1% in sham 
treated mice to 25-50% (24 and 72 hours post radiation) (Table 5.2). Statistical evaluation 
of these scores were not appropriate because of the low number of mice with tumors in 
the 72-hour group (n=2). No significant lesions or morphological changes were noted in 
the small intestine, bladder, urethra, prostate, or liver with radiation exposure (data not 
shown). 72 hours after radiation, serum C-reactive protein levels were 50% lower than 
the sham-treated and 24-hour post radiation groups (Figure 5.2A). Based on this 
information, we selected 24 hours for the Diet study.  
Animal characteristics of the Diet study 
 Unlike the Pilot Study where 100% of mice developed histologically-confirmed 




developed PCa by 24 weeks of age (Table 5.1). There were no differences between the 
body weights at euthanasia across in any dietary or treatment condition (Figure E.1). 
There also were no differences in the liver, epididymal adipose tissue, lungs, heart, testes, 
prostate tumor weight, individual prostatic lobes and total prostate weight within studies 
(Table E.2). For the spleen, there was a main effect of radiation such that irradiated mice 
had lower mean spleen weights compared to sham-treated mice (p<0.0001). 
Tumor apoptosis and cell death 
 Apoptosis and necrosis were evaluated by a trained veterinary pathologist 
(M.A.W.) within the PCa tumor and surrounding prostate tissue. There were no significant 
lesions or morphological changes within the urethra, bladder, small intestine, or liver as 
a result of diet or radiation treatments (data not shown). Cell death scores within the tumor 
are described in Table 5.2, and cleaved caspase-3 scores for apoptosis are described in 
Table 5.3. Within the tumor, the median score for cell death (necrosis and apoptosis) was 
between 1.5 and 2.5 for all treatment conditions representing that 10-25% of the tumor 
was necrotic or apoptotic. Neither diet nor treatment altered cell death within the tumor 
(p=0.33).  
Within the tumor, the median cleaved caspase-3 score (apoptosis) increased from 
3 in sham-treated mice to 4 in irradiated mice. A score of 3 indicates that <50% of lobules 
have positively stained cells, while a score of 4 indicates that > 50% of cells lobules have 
positive cells. Apoptosis was not modified by treatment or diet within the anterior (p=0.85) 
or ventral prostates (p=0.35). Interestingly, the median score for cleaved caspase-3 
(apoptosis) was altered in the dorsolateral prostate by diet. The median score for control-




mice was 1 (Table 5.3) (p=0.0017). This might be an important finding due to the fact that 
most PCa tumors arise within the dorsolateral lobes of the prostate.89 Future studies are 
needed to confirm if apoptosis in specifics lobes of the prostate are sensitive to the effects 
of tomato carotenoids.  
Carotenoid and α-tocopherol content of diet and accumulation in tissues 
The ingredients for each diet are described in Table E.1. The carotenoid 
composition of the tomato diet is shown in Figure 5.3, while carotenoid accumulation is 
shown in Table 5.3. Lycopene was the predominant carotenoid (39 nmol/g, 21 mg/kg, 
49% of total carotenoids) in the TP diet. The AIN-93G base for both diets also provided 
~120 nmol/g (75 IU) of α-tocopherol. The profile of carotenoids in the liver and serum 
largely reflected the composition of the tomato diet for sham treated mice. Radiation 
decreased serum concentrations of lycopene (p<0.0001), phytoene (p<0.01), and α-
tocopherol (p<0.01) compared to sham treated mice by 48%, 26%, and 22% respectively 
(Table 5.3). Although lycopene and other antioxidants were lowered following radiation in 
the serum, tissue concentrations in the liver and tumor were not modified by radiation. 
Antioxidants in the prostate was not statistically compared; however, mean α-tocopherol 
concentrations within the prostate were numerically 42% lower in irradiated mice 
compared to sham-treated mice. 
Inflammatory markers 
Four pro-inflammatory (TNFα, IFNγ, IL-17a, and IL-6) cytokines and one anti-
inflammatory (IL-10) cytokine were measured in the serum. There were no main effects 




(p<0.0001), IFNγ (p<0.001), IL-6 (p<0.01), IL-17a (p<0.01), and IL-10 (p=0.01) 
concentrations by 50%, 35%, 35%, 35% and 22%, respectively (Figure 5.4). TNFα 
concentrations within the liver (p=0.30), adipose tissue (p=0.22), prostate (p=0.27), and 
tumor (p=0.63) were not significantly modified by diet or radiation (Figure 5.4). C-reactive 




Males that undergo treatment for PCa often consume supplements containing 
lycopene or tomato components with the goal of improving their therapeutic outcomes. 
However, no epidemiological, pre-clinical, or clinical trials have evaluated the potential for 
tomato consumption to modify the tumor and surrounding tissues’ response to therapy. 
The current study addresses a gap in the literature by evaluating the hypothesis that 
tomato feeding can protect the tissues surrounding the prostate tumor from radiation-
induced damage. The current studies are the first to evaluate the interactions between 
tomatoes and radiation within a pre-clinical model. We hypothesized that a diet containing 
lyophilized tomato paste (TP) would not reduce apoptosis or cell death within the prostate 
tumor following EBRT, while reducing apoptosis and cell death within surrounding tissues.  
The data from this study indicates that radiation therapy in TRAMP mice consuming TP 
was as effective at destroying tumor tissue as radiation therapy in mice receiving no TP. 





Life-long tomato consumption is hypothesized to prime a tumor to be more 
radiosensitive by initially stimulating changes that make tumors less aggressive and by 
altering pathways involved in cancer progression (halting cell cycle status,104,111,112 
increasing apoptosis,104,111,112 reducing growth factor signaling,97 and reducing 
angiogenesis).95,107,108 There is currently only one small study in humans (n=17) to our 
knowledge that evaluated the interactions between tomato consumption and EBRT.332 
The aforementioned study supplemented men with 0 oz (control) of tomato juice, 4 oz, 8 
oz, or 12 oz of tomato juice during radiation therapy.332 The goal of that study was to 
evaluate the tolerance and adverse events associated with tomato supplementation. No 
adverse events were noted with lycopene consumption indicating its safety. Although the 
sample size was small, an interesting finding from this study was that higher serum 
lycopene concentrations were associated with less cachexia and improved therapeutic 
outcomes among patients treated with EBRT.332 In the United States, more than 85% of 
dietary lycopene comes from tomato products, which suggests that lycopene could be a 
surrogate biomarker of tomato consumption.44,45,133 Larger clinical and pre-clinical studies 
are necessary to determine the role that tomato consumption might have on EBRT.  
Tomato consumption increases circulating carotenoid concentrations, which may 
result in increased antioxidant protection and decreased inflammation.102,333 Radiation 
either damages DNA directly or indirectly by forming reactive oxygen species (ROS) that 
react with organelles to disrupt normal cellular metabolism. About two-thirds of damage 
by irradiation is caused indirectly through action of ROS.334 Lycopene and other tomato 
carotenoids are potent antioxidants that may act as a buffer against ROS caused by 




carotenoids may decrease the efficacy of EBRT by quenching ROS in the tumor before 
substantial damage occurs to the DNA.334,335 In the current study, circulating levels of 
antioxidants (such as lycopene and α-tocopherol) were lowered by 35-50% radiation after 
24 hours. Without an adequate supply of antioxidants from the diet, such as lycopene and 
α-tocopherol, serum and tissue concentrations would rapidly become depleted. It is likely 
that surrounding tissues would be more heavily damaged through indirect activity of ROS. 
As injuries in these tissues accumulate, clinical acute and late stage toxicities may occur 
leading to digestive, urinary, bowel, or sexual dysfunction.15  
Cell death and apoptosis scores after radiation were not altered by the 
consumption of TP. This suggests that radiation therapy with TP consumption was not 
inferior to radiation alone. The use of antioxidants during radiation therapy is controversial 
because it is hypothesized that antioxidants can also protect the targeted tissue from the 
effects of radiation.336-339 This is important because many men who are diagnosed with 
PCa choose to improve their diet after diagnosis. Although consumption of fruits and 
vegetables generally increase following PCa diagnosis, tomato consumption remains 
relatively constant (<15% increase after diagnosis) following diagnosis.187 Studies such 
as this are important for men who are being treated with treatments such as EBRT. The 
amount of lycopene that was consumed in this study is easy to achieve through the diet. 
A human equivalent dose of 3 mg/kg in mice translates to 17 mg per day (0.24 mg/kg).310 
This could be achieved with a half serving of tomato sauce (1/4 cup, 60 grams) per day. 
Men accumulate carotenoids in the prostate and prostate lycopene concentrations 
increase similar to blood concentrations.311 The range of blood lycopene concentrations 




the Health Professionals Follow Up Study (HPFS) prospective cohort trial and other 
studies.95,231,309  
Mice were irradiated with 7.5 Gy of half-body radiation. This dose is potentially 
lethal to cells in the bone marrow and spleen due to substantial increases in apoptosis 
and cell death.340-343 Likewise, mice that were irradiated in the current studies displayed 
a 36% lower spleen weight compared to sham-treated mice after 24 hours. This decrease 
might be indicative of the hematopoietic and lympohcytic cells that have undergone 
apoptosis within the spleen. Reductions in spleen volume/weight are also noted in people 
who have their spleen irradiated for cancer or other reasons.344 The spleen and bone 
marrow are both components of the lymphatic system.345,346 Circulating concentrations of 
cytokines within the serum were lower in mice that were treated with radiation compared 
to sham-treated mice in this study. This has been observed in other studies.343,347 We 
hypothesized that the observed decrease in cytokines are due to the effect of radiation 
on the lymphatic system (e.g. spleen, bone marrow, and lymph nodes) that were exposed 
to radiation.  
These studies exhibit strengths that contribute to the literature. Among the possible 
animal models that were available, we selected the TRAMP model. This model is well 
established and exhibits a predictable histological progression from low-grade 
hyperplasia to poorly-differentiated adenocarcinoma (many with clear neuroendocrine 
features) and local as well as distant metastasis, resembling development of the human 
PCa.89 Carotenoids and other dietary compounds also are distributed to organs in a 
similar manner to humans. In this study, we used lyophilized tomato paste (TP), which 




potential for greater synergistic effects of each nutrient present within the whole food. 
Tomato paste is readily available, convenient, and safe for a consumer to purchase and 
consume during radiation therapy. To monitor tumor emergence in this study, ultrasound 
provided us with a more precise in vivo estimation of tumor emergence and growth. In 
Chapter 4, tumor weight and volume were tightly correlated, and within the current study, 
we were able to detect tumors as small as 10 mm3.  
Despite these strengths, this study also has several limitations that should be 
considered. This study used a single dose of 7.5 Gy of radiation. While this dose was 
calculated to be equivalent to 25% of a patient’s total dose of hypofractionated EBRT (3.5 
Gy for 5 days),327,329,330,348 many acute toxicities occur following weeks after the onset of 
the treatment.349,350 It is possible that the accumulation of damage from several doses 
might have a different effect on damage to the tumor and surrounding tissue compared 
to a single dose. Future studies will be needed to determine if TP alters tumor cell death 
over a prolonged period of time. Additionally, this study only tested a single level of dietary 
TP throughout the lifespan. The results of this study are more generalizable to a man that 
consumes TP through their lifespan than one that changes their dietary pattern following 
PCa diagnosis. Although multiple doses were not evaluated, men accumulate lycopene 
in the prostate with moderate doses and short periods of tomato consumption.312 A 
randomized clinical trial (RCT) of 66 men found that one serving of tomato dishes 
containing 200 g of Hunt’s Spaghetti Sauce (providing 30 mg of lycopene per day) was 
sufficient to increase plasma and prostatic lycopene concentrations in 3 weeks.122 
To our knowledge, this is the first pre-clinical study to evaluate the potential for 




surrounding tissues. This study provides preliminary data that suggest that tomato 
consumption with radiation therapy does not affect the damage occurring within the tumor 
or surrounding tissue. This study suggests that tomato consumption does not inhibit the 
main treatment effects of EBRT in prostate tumors; however, this study does not support 
the hypothesis that TP protects the surrounding tissues from the harmful effects of EBRT.  
As a result, improving tomato consumption can safely serve as a low-cost method of 
decreasing the risk of developing PCa without affecting the efficacy of subsequent 
treatment regiments.127,132  Future clinical studies should evaluate the concentration of 
lycopene in the blood as a potential biomarker of tomato consumption to determine 
whether increased circulating lycopene correlates positively or negatively with treatment-





Figures and tables in Chapter 5 




TRAMP mice were randomized onto a dietary treatment groups after weaning (4 
weeks). Prostates were monitored weekly (Pilot Study – Figure A) or biweekly (Diet 
study – Figure B) for tumor occurrence by ultrasound beginning at 10 weeks of age. 
After tumor detection, mice were scanned weekly by ultrasound until tumors reached a 
volume of 500 (Pilot Study) mm3 or 1000 mm3 (Diet study). At this volume, the caudal 
half of the animal was irradiated with 7.5 Gy by a Co-60 source. Mice were euthanized 



















Data are represented as mean ± SEM. Means with different letters signify that means 
differ (one-way ANOVA followed by Tukey’s post hoc test, p<0.05). A) Serum 
concentrations of C-reactive protein (CRP) in the Pilot Study (n=6 per group, performed 
in duplicate). B) Serum concentrations of CRP in the Diet study (n=8-13 per group, 

































































































































Data are mean concentration ± SEM across 3 diet batches with 2 replicates/batch. Data 
are presented as nmol/g diet. Control diets were not included due to their lack of 
























Data are represented as mean ± SEM. Means with different letters signify that means 
differ (one-way ANOVA followed by Tukey’s post hoc test, p<0.05). A) Serum 
concentrations of cytokines (n=8-13 per group). B) Tissues levels of TNFα (n=6 per 
group).  




































































Prostatic Lesion Score (% total) 
Treatment + / total n % NSL PIN WD MD  PD 
Pilot 
Study 
14/14 100      
Sham 4/4 100 0 0 50 0 50 
24 Hours 6/6 100 0 0 33 17 50 
72 Hours 4/4 100 0 0 50 50 0 
Diet Study 41/70 59      
Sham 11/14 79 0 21 21 7 50 
TP-Sham 12/20 60 0 40 15 0 45 
Rad 8/19 42 0 58 11 11 21 
TP-Rad 10/17 59 0 41 24 0 35 
 
Data are provided as the number (+) and percent (%) of mice positive for a designated 
pathology within each treatment group. Cancer incidence was evaluated by stage by a 
trained veterinary pathologist. NSL, no significant lesion; PIN, prostatic intraepithelial 
neoplasia; WD, well differentiated adenocarcinoma; MD, moderately differentiated 
adenocarcinoma; PD, poorly differentiated carcinoma. Histologically confirmed 






Table 5.2 Tumor apoptosis and necrosis within TRAMP tumors 
 
eval/total n1 Mean ± SEM Median 
preliminary 
p-value* 
Pilot Study     
Sham 3/3 1.7 ± 1.2 1 0.5667 
24 hours 4/4 3.0 ± 0.9 3  
72 hours 2/2 3.0 ± 1 3  
Diet Study     
Sham 7/9 1.6 ± 0.3 2 0.3264 
TP-Sham 8/9 1.6 ± 0.3 1.5  
Rad 4/6 2.3 ± 0.9 2.5  
TP-Rad 7/7 2.4 ± 0.4 2  
 
Data are expressed as means ± standard error and as a median. There were no 
significant differences in medians (Kruskal-Wallis test). A score of 0 represents 0-1% 
cell death (apoptosis and necrosis); a score of 1 represents up to 10% cell death; a 
score of 2 represents 10-25% cell death; a score of 3 represents 25-50% cell death; and 
a score of 4 represents greater than 50% of the cells are dead. 
1the eval/total n represents the number of slides that have been completed of the total 
number of slides that exist for this endpoint. Due to the closures from COVID-19, data 





Table 5.3 Cleaved caspase-3 evaluation for apoptosis 
 
Eval/total n1 Mean ± SEM Median 
preliminary 
p-value* 
Tumor     
Sham 1/9 3 3 0.2557 
TP-Sham 5/9 2.8 ± 0.5 3  
Rad 5/6 4.2 ± 0.5 4  
TP-Rad 7/7 4.0 ± 0.4 4  
Dorsolateral Prostate     
Sham 5/12 1.6 ± 0.2 2a 0.0017 
TP-Sham 10/17 0.8 ± 0.1 1b  
Rad 8/19 1.6 ± 0.2 2a  
TP-Rad 9/17 1.0 ± 0.0 1ab†  
Ventral Prostate     
Sham 4/7 0.5 ± 0.3 0.5 0.8283 
TP-Sham 7/12 0.3 ± 0.2 0  
Rad 6/13 0.3 ± 0.3 0  
TP-Rad 4/12 0.3 ± 0.3 0  
Anterior Prostate     
Sham 14/16 1.4 ± 0.4 1 0.3514 
TP-Sham 17/20 1.2 ± 0.2 1  
Rad 14/19 1.2 ± 0.3 1  
TP-Rad 13/18 0.8 ± 0.2 1  
 
Data are expressed as means ± standard error and as a median. Medians with different 
letters are significantly different from each other (Kruskal-Wallis test followed by Dunn’s 
multiple comparisons test; p-value <0.05).  † signifies that TP-Rad compared to Rad in 
the dorsolateral prostate was trending toward significance (p=0.068). A Cleaved caspase-
3 score of 0 represents no increase over background (0-1 positive cell/lobular profile); a 
score of 1 represents a focal increase above background (<25% lobular profiles with 2-
5); a score of 2 represents “widespread” increases above background (>25% lobular 
profiles with 2-5); a score of 3 represents a “massive” increase above background (>25% 
lobular profiles with >5 positive cells per profile); a score of 4 represents that 50% lobules 
affected, with > 50% having 6-10 or more positive cells, generally associated with foci of 
cell death; occasional aggregates of positive cells; and a score of 5 represents 50% 
lobules affected, with >50% having 10+ cells per lobule centered around the edges of foci 
of cell death plus scattered aggregates of positive cells. 
1the eval/total n represents the number of slides that have been completed of the total 
number of slides that exist for this endpoint. Due to lab closures from COVID-19, data 




Table 5.4 Carotenoid and α-tocopherol accumulation in TRAMP mice fed tomato diets. 
 
 n Lycopene1 Phytoene Phytofluene -Carotene -Tocopherol 
Serum TP-Sham 17 865 ± 84*** 174 ± 12* 834 ± 94 n.d. 67,817 ± 4,711* 
nmol/L TP-Rad 13 456 ± 59 129 ± 11 618 ± 69 n.d. 53,120 ± 3,437  
Liver TP-Sham 11 16.9 ± 2.4 4.64 ± 0.59 27.4 ± 3.2 0.17 ± 0.06   181 ± 21 
nmol/g TP-Rad 12 23.1 ± 2.1 5.10 ± 0.74 31.4 ± 4.4 0.16 ± 0.07 188 ± 23 
Prostate2 TP-Sham 2 0.44 ± 0.07 n.d. 0.40 ± 0.02 n.d. 8.52 ± 0.92 
nmol/g TP-Rad 2 0.72 ± 0.07 n.d. 0.46 ± 0.14 n.d. 4.96 ± 2.14 
Tumor TP-Sham 4 0.28 ± 0.02 2.74 ± 0.77 0.49 ± 0.08** n.d. 18.0 ± 1.9 
nmol/g TP-Rad 4 0.46 ± 0.12 3.26 ± 1.32 0.90 ± 0.07 n.d. 23.0 ± 3.6 
 
1Total lycopene (sum of all trans and cis stereoisomers).  
2Prostate concentrations are means of two pools with 5 anterior prostates (1 lobe per mouse) in each. 
All values represent the mean ± SEM. * means differ, p<0.05 (t-test). ** means differ, p<0.01 (t-test). *** means differ, p<0.001 
(t-test). n.d., not detected. Concentration was below the limit of detection. The limit of detection was 0.015 nmol of each carotenoid 




Chapter 6: Summary and future directions 
Prostate cancer is the most frequently diagnosed cancer among men in the United 
States. Although preventing prostate cancer (PCa) is preferable to treating PCa, patients 
seeking information about foods and supplements might already have cancer. 
Importantly, the prostate microenvironment is not the same prior to cancer initiation, 
during PCa promotion/ progression, and during treatment. There is a growing body of pre-
clinical and epidemiological evidence that suggests that tomato products and compounds 
(such as lycopene) decrease PCa incidence; however, no studies (to our knowledge) 
have evaluated the interactions between the consumption of tomato products and 
common therapeutic approaches for PCa. Elucidating whether dietary approaches can 
improve therapeutic outcomes should positively affect treatment selection and 
recommendations for patients. In this dissertation, we sought to clarify the epidemiological 
associations between tomatoes (and lycopene) and PCa incidence, and to evaluate the 
role of tomato feeding in an animal model that underwent two common treatment 
approaches. More specifically, the aims of this dissertation were to: 
 
1. Evaluate the epidemiological associations between the exposures of tomatoes 
or lycopene and risk of prostate cancer in the epidemiological literature.  
2. Determine the potential of tomato or lycopene interventions to reduce the growth 
and progression of CRPC in the TRAMP model 
3. Evaluate the potential for lyophilized tomato powder to reduce radiation-induced 





 Despite potential benefits that have been reported in the literature, epidemiological 
studies evaluating carotenoids and their role in protection from prostate carcinogenesis 
and progression have yielded mixed results. In Chapters 2 and 3, we aimed to evaluate 
the associations between tomatoes or lycopene and PCa incidence. The development of 
PCa is complex and is influenced by a combination of genetic, hormonal and 
environmental factors.97 Diet is one of the most modifiable risk factors for PCa. Many 
epidemiological studies have investigated tomato products and their association with PCa 
carcinogenesis. Despite much positive data, studies have yielded mixed results. 
Lycopene, a lipophilic carotenoid that gives some fruits and vegetables their red color, is 
a primary bioactive component in tomatoes.44,45 We hypothesized that increased 
consumption of tomato products or lycopene would result in a lower risk of PCa in the 
epidemiological literature. To elucidate these associations, two dose-response meta-
analyses were conducted. 
 The first meta-analysis (Chapter 2) focused on the interactions between tomato 
products and risk of PCa. Thirty studies related to tomato consumption and PCa risk were 
included in the meta-analysis, which summarized data from 24,222 cases and 260,461 
participants. Higher total tomato consumption was associated with a reduced risk of PCa 
(RR=0.81, p=0.001). This association was supported by several dose-response meta-
analyses of tomato products. In particular, we found that bioavailability of lycopene was 
important. Raw tomato consumption was not associated with a decreased risk of PCa 
(p=0.49), while cooked tomatoes and sauces (sources with high lycopene bioavailability) 




The second meta-analysis (Chapter 3) evaluated associations between lycopene 
and PCa incidence. Forty-two studies were included in the analysis, which included 
43,851 cases of PCa reported from 692,012 participants. Similar to the whole food 
product, increased lycopene consumption (RR=0.88, p=0.02) and blood concentrations 
(RR=0.88, p=0.02) were associated with a decreased risk of PCa. These associations 
were also supported by dose-response associations. There was an estimated 9% 
reduced risk of PCa by consuming 100 grams/week of cooked tomatoes in Chapter 2. 
For an equivalent dose of lycopene (22 mg lycopene in 100 grams of tomato puree 
according to the USDA Nutrient Database), tomatoes were more effective than lycopene 
at reducing PCa risk (9% compared to 1.6%). The greater benefit from tomato products 
may be due to interactions between potentially beneficial bioactive compounds in 
tomatoes. These meta-analyses support the hypothesis that tomato products or lycopene 
reduce prostate carcinogenesis. 
Although data from these studies support significant and consistent reductions in 
the risk of developing prostate cancer with higher consumption of tomato products, very 
few studies reported risk associations by stage or grade of PCa. Many studies included 
in our meta-analyses did not include the grade or stage of PCa and contained only a small 
number of cases with advanced stages of PCa. Due to the small number of studies that 
investigated advanced PCa, it is difficult to obtain adequate estimates of the associations 
between tomatoes products and risk of advanced stages of PCa. A pooled analysis of 
prospective cohort studies found that pizza with tomato sauce was significantly 
associated with a reduced risk of lethal PCa.126 Another pooled analysis of prospective 




a reduced risk of advanced PCa.94 Combined, these pooled analyses suggest that tomato 
consumption may be associated with advanced PCa. A better understanding of the 
associations between the stage or grade of PCa and carotenoid status may lead to a 
reduced progression of PCa. More studies are needed in order to elucidate the 
associations and potential benefits of tomato consumption on advanced PCa risk.  
 As the prostate tumor is treated with common approaches, such external beam 
radiation therapy (EBRT) or androgen deprivation therapy (ADT), many changes occur 
within the prostate microenvironment. If PCa is detected early, common therapeutic 
options include: active surveillance, surgery (prostatectomy), radiation therapy and/or 
chemotherapy.11,12 Despite primary treatment, approximately 30% of men suffer tumor 
recurrence.31 These men, along with men diagnosed with advanced or metastatic cancer, 
usually undergo ADT.31,32 This aggressive and often lethal stage of PCa occurs after the 
prostate tumor acquires mutations to sustain growth despite ADT.  
In Chapter 4, we aimed to determine whether dietary lyophilized tomato powder 
(TP) or lycopene would be capable of affecting the growth of castration-resistant prostate 
cancer (CRPC). We hypothesized that tomato or lycopene products would reduce the 
growth and emergence of CRPC. We administered a physiologically relevant dose of a 
commercially available tomato food (Contadina® brand tomato paste), in order to 
maximize translatability of this animal study. A human equivalent dose of 3 mg/kg in mice 
translates to 17 mg per day (0.24 mg/kg).310 This could be achieved with a half serving of 
tomato sauce (1/4 cup, 60 grams) per day. Men accumulate carotenoids in the prostate 
and prostate lycopene concentrations increase similar to blood concentrations.311 




cancer incidence, time to tumor detection, or final tumor weight. This is the first study to 
evaluate the potential for a dietary intervention to modify the growth of CRPC tumors.  
Ultrasound evaluation of the emergence of individual castrate resistant tumors 
over five weeks provided a unique and insightful dimension to our studies. The individual 
growth rates of CRPC tumors were extremely heterogeneous regardless of dietary 
treatment and ranged between 10- and 100-fold. This heterogeneity is similar to the over 
10-fold variation that is seen in the rate of progression for men failing initial ADT.318 
Although the sample sizes of the present experiments are large compared to other 
preclinical studies, this observed variation in tumor growth rates would make it difficult to 
detect modest effects of the dietary treatments on tumor growth rates.  
CRPC tumors that grow despite ADT typically maintain activity of androgen-
mediated pathways, often through sustained androgen receptor signaling.36 There are 
many pathways for PCa to progress to CRPC such as mutations affecting the function of 
the androgen receptor, affinity for alternative ligands, activation complementary growth 
promoting signaling pathways, and others.36,319 It is likely that the specific mutational 
spectrum of individual CRPC lesions underlies the large variation in progression rates. 
Depending on the acquired mutation, some tumors might have been more responsive to 
a dietary tomato or lycopene intervention. A recent systematic review of preclinical studies 
found that most eligible studies reported inhibitory effects of tomato or lycopene treatment 
on androgen-related outcomes.322 Lycopene, and other tomato bioactives may improve 
the effectiveness of ADT by reducing tumor promoting inflammation,104 androgen/growth 




studies are needed that investigate the molecular profiles of CRPC tumors to determine 
if TP or lycopene feeding differentially affects specific molecular subtypes of CRPC.    
Approximately 80% of new PCa cases are eligible for EBRT. In Chapter 5, we 
hypothesized that dietary lyophilized tomato powder (TP) would not reduce the efficacy 
of external beam radiation therapy (EBRT) in the prostate tumor, but would protect 
surrounding tissues from radiation-induced damage. Lycopene and other tomato 
carotenoids are potent antioxidants that may act as a buffer against elevated ROS caused 
by EBRT in normal (non-tumor tissue); however, it is also possible that lycopene and 
other tomato carotenoids may reduce the efficacy of EBRT by quenching ROS in the 
tumor before substantial damage occurs to the DNA.334,335 
Following radiation treatment, circulating levels of lycopene, phytoene, and α-
tocopherol decreased compared to sham treated mice. Supporting our hypothesis, cell 
death and apoptosis scores within the tumor increased with radiation treatments 
compared to sham-treated mice. Contrary to our hypothesis, no changes in apoptosis 
scores occurred in the surrounding prostate. Collectively, these data indicate that 
radiation therapy in TRAMP mice consuming TP was as effective at destroying tumor 
tissue as radiation therapy in mice receiving no TP. However, TP did not affect any of the 
measured endpoints. This is important because many men do not alter their consumption 
of tomato products following diagnosis (unlike other fruits and vegetables). Additional 
studies will be needed to determine whether tomato consumption can improve radiation 
efficacy in the tumor or surrounding tissues when radiation is provided at different doses 




In conclusion, this work has revealed consistent inverse associations with both 
tomato products and lycopene with the risk of prostate cancer incidence within published 
epidemiological studies. Our preclinical studies focusing on the potential of tomato 
products to improve PCa treatments (ADT and EBRT) found that the responses to 
treatment were not modified by a diet containing 10% TP or lycopene. While further work 
in animal models and humans is needed, it is notable that these are the first studies to 
evaluate the interactions between tomato products on common PCa treatments. Further 
studies should expand on these results and evaluate differences within the tumor 
microenvironment to determine if tomato products are more effective for specific subtypes 
or specific clonal populations of PCa. Data from these epidemiological and preclinical 
studies illuminate the importance of healthy dietary patterns throughout the lifespan given 
that it is much easier to modify the risk of developing PCa, rather than successfully 
treating existing PCa. These data are of great interest to patients who are diagnosed with 
PCa that seek out information about the types of foods or supplements that can improve 
their clinical outcomes. In conclusion, this dissertation has contributed novel findings to 
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Appendix A: Supplemental tables for Chapter 1 
Table A.1: Sources of dietary lycopene 
Table A.2: Sources of dietary β-carotene 
Table A.3: Sources of dietary α-carotene 
Table A.4: Sources of dietary β-cryptoxanthin 
Table A.5: Sources of dietary lutein and zeaxanthin 





Table A.1 Sources of dietary lycopene 
Food Portion description Portion weight (g) Lycopene content per 
portion (mg) 
Tomato juice, 100% 1 cup 248 22.4 
Spaghetti sauce ½ cup 130 16.5 
Watermelon, raw 1 medium wedge 286 13.0 
Canned Stewed 
tomatoes 
1 cup 255 10.4 
Tomatoes, raw 1 medium 123 3.2 
Grapefruit, raw 1 medium 256 2.9 
Tomato catsup 1 tablespoon 15 1.8 
Dried Papaya 1 strip 23 0.7 





Table A.2 Sources of dietary β-carotene 
Food Portion description Portion weight (g) β-carotene content per 
portion (mg) 
Carrot juice 1 cup 240 22.3 
Baked sweet potato 1 medium 150 17.2 
Cooked spinach 1 cup 190 13.7 
Kale, cooked 
from frozen 
1 cup frozen 130 11.4 
Mustard greens, 
cooked from fresh 
1 cup 140 10.3 
Carrots, raw 1 cup, NFS 110 9.1 










Table A.3 Sources of dietary α-carotene 
Food Portion description Portion weight (g) α-carotene content per 
portion (mg) 
Carrot juice 1 cup 240 10.4 
Cooked pumpkin 1 cup, NFS 245 6.6 
Carrots, raw 1 cup, NFS 110 3.8 
Cooked winter 
squash 
1 cup, NFS 245 1.7 
Plantain, raw 1 medium 179 0.8 
Pumpkin bread 1 slice 60 0.7 
Mandarin oranges, 
canned 
1 cup 189 0.4 
Dandelion greens  1 cup 55 0.2 





Table A.4 Sources of dietary β-cryptoxanthin 
Food Portion description Portion weight (g) 
β-cryptoxanthin 
content per portion 
(µg) 
Persimmon, raw 1 persimmon 168 2,431 
Papaya, raw 1 medium 304 1,791 
Mandarin oranges, 
canned 
1 cup 189 1,465 
Red peppers, raw 1 medium 119 583 
Tangerine, raw 1 medium 88 358 
Papaya, dried 1 strip 23 224 
Calamondin, raw 1 fruit 19 77 
Kumquat, raw 1 kumquat 19 37 





Table A.5 Sources of dietary lutein and zeaxanthin  
Food Portion description Portion weight (g) 
Lutein and Zeaxanthin 
content per portion 
(mg) 
Spinach, cooked from 
frozen 
1 cup 190 29.7 
Kale, cooked from 
frozen 
1 cup 130 25.4 
Dandelion greens, 
raw 
1 cup 55 7.5 
Chard, raw 1 cup 36 4.0 
Spinach, raw 1 cup 25 3.0 
Kale, raw 1 cup 25 2.0 
Broccoli, raw 1 cup 88 1.2 
Egg yolk, cooked 1 large 17 0.2 





aData from 2015-2016 NHANES. Values represent means ± standard error.  
bData from 2005-2006 NHANES. Values represent means ± standard error. 
cValue represents total lycopene (cis- and trans-isomers) 
dValue represents trans-isomers for β-carotene 








Lycopene 4465 ± 101 43.01 ± 0.25c 0.804 ± 0.005c 
α-carotene 366 ± 13 4.05 ± 0.07 0.075 ± 0.001 
β-carotene 1910 ± 45 
16.53 ± 0.24d 
1.03 ± 0.14e 
0.308 ± 0.004d 
0.019 ± 0.0003e 
Lutein + Zeaxanthin 1409 ± 43 15.78 ± 0.11 0.277 ± 0.002 
β-cryptoxanthin 85.6 ± 2.4 11.19 ± 0.11 0.202 ± 0.002 




Appendix B: Supplemental table and figures for Chapter 2  
 
Table B.1. List of items included in tomato foods category 
 
Figure B.1. Forest plot for cumulative meta-analysis of highest vs lowest quantile 
of overall tomato consumption on PCa risk. This association was indicated as a 
relative risk (RR) estimate with the corresponding 95% confidence interval (CI). 
 
Figure B.2. Funnel plot for publication bias among studies investigating tomatoes 
and PCa risk. (A) total tomato consumption, (B) tomato foods; (C) cooked tomatoes 
and sauces, (D) raw tomatoes, (E) pizza and PCa (F) tomato consumption and risk of 
advanced PCa. 
 
Figure B.3. Forest plot for cumulative meta-analysis of highest vs lowest quantile 
of consumption of tomato foods on PCa risk. This association was indicated as a 
relative risk (RR) estimate with the corresponding 95% confidence interval (CI). 
 
Figure B.4. Forest plot for cumulative meta-analysis of highest vs lowest quantile 
of consumption of cooked tomatoes and sauces on PCa risk. This association was 
indicated as a relative risk (RR) estimate with the corresponding 95% confidence 
interval (CI). 
 
Figure B.5. Forest plot for cumulative meta-analysis of highest vs lowest quantile 
of consumption of raw tomatoes on PCa risk. This association was indicated as a 
relative risk (RR) estimate with the corresponding 95% confidence interval (CI). 
 
Figure B.6. Forest plot for cumulative meta-analysis of highest vs lowest quantile 
of consumption of pizza on PCa risk. This association was indicated as a relative risk 
(RR) estimate with the corresponding 95% confidence interval (CI). 
 
Figure B.7. Dose-response analysis of tomato consumption and PCa risk by 
study type. The solid black line is the nonlinear model curve for published relative risk 
and the two dotted lines are the corresponding 95% confidence intervals. The short-
dashed line is the linear model curve for the published relative risks (RR); (A) cohort 
studies for total tomato consumption and risk of PCa; (B) case-control studies for total 
tomato consumption and risk of PCa; (C) cohort studies for tomato foods and risk of 
PCa; (D) case-control studies for tomato foods and risk of PCa; (E) cohort studies for 
cooked tomatoes & sauces and risk of PCa; (F) case-control studies for cooked 
tomatoes & sauces and risk of PCa; (G) cohort studies for raw tomatoes and risk of 









Appendix B: Supplemental table and figures for Chapter 2 (Continued) 
 
Figure B.8. Dose-response analysis of tomato consumption and PCa risk before 
exclusion of one study. The solid black line is the nonlinear model curve for published 
relative risk and the two dotted lines are the corresponding 95% confidence intervals. 
The short-dashed line is the linear model curve for the published relative risks (RR); (A) 
total tomato consumption and risk of PCa; (B) case-control studies for total tomato 
consumption and risk of PCa; (C) tomato foods and risk of PCa; (D) case-control 









Foods included in tomato foods category 
Darlington, 2007 Tomato juices, raw tomatoes, and ketchup 
Diallo, 2016 Tomato products, specific sources not disclosed 
Er, 2014 Tomato juice, tomato sauce, pizza, and baked beans 
Hodge, 2004 Tomatoes, pizza, and pasta 
Jain, 1999 Tomatoes, tomato soups, and sauces 
Jian, 2005 Tomatoes and tomato products, specific sources not disclosed 
Kirsh, 2006 Raw tomatoes, canned tomatoes, ketchup, spaghetti, tomato sauce, 
tomato juice, pizza, lasagna 
Kolonel, 2000 Tomatoes, pizza, spaghetti sauce, stews, stir-fries, and others (not 
disclosed) 
Li, 2008 Tomatoes (cooked or raw), specific sources not disclosed 
Mills, 1989 Tomatoes, specific sources not disclosed 
Norrish, 2000 Tomatoes (cooked or raw), tomato soup or puree, tomato juice, tomato 
sauce, ketchup, tomato-based pasta dishes 
Salem, 2011 Tomatoes (fresh, extract, and dressing) 
Sonoda, 2004 Tomatoes, specific sources not disclosed 
Stram, 2006 Tomatoes (cooked or raw), tomato sauce, tomato juice, tomato soup, 
spaghetti, ravioli, lasagna, pizza, and Mexican/Spanish rice 
Subahir, 2009 Tomatoes, specific sources not disclosed 
Takachi, 2010 Tomatoes, tomato juice, ketchup 
Villeneuve, 1999 Tomatoes or tomato juice 





Figure B.1 Forest plot for cumulative meta-analysis of highest vs lowest quantile of 
overall tomato consumption on PCa risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure B.2. Funnel plot for publication bias among studies investigating tomatoes and 
PCa risk.  
 
 
(A) total tomato consumption, (B) tomato foods; (C) cooked tomatoes and sauces, (D) 





Figure B.3. Forest plot for cumulative meta-analysis of highest vs lowest quantile of 
consumption of tomato foods on PCa risk.  
 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 






Figure B.4. Forest plot for cumulative meta-analysis of highest vs lowest quantile of 
consumption of cooked tomatoes and sauces on PCa risk. 
 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 






Figure B.5. Forest plot for cumulative meta-analysis of highest vs lowest quantile of 
consumption of raw tomatoes on PCa risk.  
 
This association was indicated as a relative risk (RR) estimate with the corresponding 






Figure B.6. Forest plot for cumulative meta-analysis of highest vs lowest quantile of 
consumption of pizza on PCa risk.  
 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 










Figure B.7 Caption: The solid black line is the nonlinear model curve for published relative 
risk and the two dotted lines are the corresponding 95% confidence intervals. The short-
dashed line is the linear model curve for the published relative risks (RR); (A) cohort 
studies for total tomato consumption and risk of PCa; (B) case-control studies for total 
tomato consumption and risk of PCa; (C) cohort studies for tomato foods and risk of PCa; 
(D) case-control studies for tomato foods and risk of PCa; (E) cohort studies for cooked 
tomatoes & sauces and risk of PCa; (F) case-control studies for cooked tomatoes & 
sauces and risk of PCa; (G) cohort studies for raw tomatoes and risk of PCa; (H) case-




Figure B.8. Dose-response analysis of tomato consumption and PCa risk before 
exclusion of one study  
 
The solid black line is the nonlinear model curve for published relative risk and the two 
dotted lines are the corresponding 95% confidence intervals. The short-dashed line is the 
linear model curve for the published relative risks (RR); (A) total tomato consumption and 
risk of PCa; (B) case-control studies for total tomato consumption and risk of PCa; (C) 






Appendix C: Supplemental figures for Chapter 3 
  
Figure C.1. Funnel plot for publication bias among studies investigating lycopene 
and PCa risk. (A) dietary lycopene and risk of PCa; (B) circulating lycopene 
concentrations and risk of PCa; (C) dietary lycopene and risk of advanced PCa; (D) 
circulating lycopene concentrations and risk of advanced PCa. 
 
Figure C.2 Forest plot for cumulative meta-analysis of highest vs lowest intake of 
lycopene on PCa risk. This association was indicated as a relative risk (RR) estimate 
with the corresponding 95% confidence interval (CI). 
 
Figure C.3. Forest plot for the association of highest vs lowest intake of lycopene 
on PCa after removing one study. This association was indicated as relative risk (RR) 
estimate with the corresponding 95% confidence interval (CI). 
 
Figure C.4. Forest plot for association of highest vs lowest intake of lycopene on 
PCa risk excluding supplemented studies. This association was indicated as a 
relative risk (RR) estimate with the corresponding 95% confidence interval (CI).  
 
Figure C.5. Forest plot for cumulative meta-analysis of highest vs lowest intake of 
lycopene on advanced PCa risk. This association was indicated as a relative risk (RR) 
estimate with the corresponding 95% confidence interval (CI). 
 
Figure C.6. Forest plot for cumulative meta-analysis of highest vs lowest 
circulating lycopene on PCa risk. This association was indicated as a relative risk 
(RR) estimate with the corresponding 95% confidence interval (CI). 
 
Figure C.7. Forest plot for the association of highest vs lowest circulating 
lycopene on PCa after removing one study. This association was indicated as 
relative risk (RR) estimate with the corresponding 95% confidence interval (CI). 
 
Figure C.8. Forest plot for association of highest vs lowest circulating lycopene 
on PCa risk excluding supplemented studies. This association was indicated as a 
relative risk (RR) estimate with the corresponding 95% confidence interval (CI).  
 
Figure C.9. Forest plot for cumulative meta-analysis of highest vs lowest 
circulating lycopene on advanced PCa risk. This association was indicated as a 
relative risk (RR) estimate with the corresponding 95% confidence interval (CI). 
 
Figure C.10. Forest plot for the association of highest vs. lowest circulating 
lycopene on advanced PCa risk excluding supplemented studies. This association 
was indicated as a relative risk (RR) estimate with the corresponding 95% confidence 





Figure C.1. Funnel plot for publication bias among studies investigating lycopene and 
PCa risk. 
 
(A) dietary lycopene and risk of PCa; (B) circulating lycopene concentrations and risk of 
PCa; (C) dietary lycopene and risk of advanced PCa; (D) circulating lycopene 




Figure C.2 Forest plot for cumulative meta-analysis of highest vs lowest intake of 
lycopene on PCa risk.  
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure C.3. Forest plot for the association of highest vs lowest intake of lycopene on 
PCa after removing one study  
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure C.4. Forest plot for association of highest vs lowest intake of lycopene on PCa 
risk excluding supplemented studies. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure C.5. Forest plot for cumulative meta-analysis of highest vs lowest intake of 
lycopene on advanced PCa risk 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure C.6. Forest plot for cumulative meta-analysis of highest vs lowest circulating 
lycopene on PCa risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure C.7 Forest plot for the association of highest vs lowest circulating lycopene on 
PCa after removing one study  
 
This association was indicated as a relative risk (RR) estimate with the corresponding 




Figure C.8 Forest plot for association of highest vs lowest circulating lycopene on PCa 
risk excluding supplemented studies. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure C.9 Forest plot for cumulative meta-analysis of highest vs lowest circulating 
lycopene on advanced PCa risk. 
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Figure C.10 Forest plot for the association of highest vs. lowest circulating lycopene on 
advanced PCa risk excluding supplemented studies.  
 
This association was indicated as a relative risk (RR) estimate with the corresponding 





Appendix D: Supplemental table and figures for Chapter 4  
 
Table D.1. Organ weights at necropsy in castrated TRAMP mice. 
Figure D.1. Body Weights of CRPC animals 
A, Study 1 body weights at euthanasia; individual points indicate individual mice, while 
the bars represent mean ± SEM. B, Study 1 average weekly body weight; data are 
represented as mean ± SEM. C, Study 2 body weights; individual points indicate 
individual mice, while the bars represent mean ± SEM. D, Study 2 average weekly body 
weight; data are represented as mean ± SEM. 
Figure D.2. Individual CRPC tumor growth curves  
Each line represents the in vivo growth of an individual mouse’s tumor from detection 
(week 0) through 4 weeks post-detection. Study 1, top row; Study 2, bottom row. Lines 
which end before the 4th week are due to animals that died prior to completing all tumor 





Table D.1. Organ weights at necropsy in castrated TRAMP mice. 
Study 1 Con-L TP-L TP-Int1 p-value 
Prostate Tumor (g) 2.9 ± 0.5 2.6 ± 0.6 1.9 ± 0.5 0.173 
Prostate2 (mg) 27.8 ± 3.2 19.6 ± 1.5 22.8 ± 2.2 0.248 
     Anterior 18.6 ±2.6 12.8 ± 1.1 15.6 ± 1.8 0.311 
     Dorsolateral 13.0 ± 2.8 6.3 ± 0.7 6.9 ± 0.8 0.076 
     Ventral 4.4 ±0.4 4.6 ± 0.8 7.0 ± 0.8 0.680 
Seminal Vesicles (mg) 13.8 ±0.8 14.2 ± 1.4 17.6 ± 2.7 0.341 
Liver (g) 1.44 ±0.08 1.22 ± 0.07 1.33 ± 0.06 0.071 
Lungs (g) 0.24 ±0.04 0.21 ± 0.03 0.17 ± 0.01 0.059 
Epididymal Adipose Tissue (g) 1.75 ± 0.21 1.87 ± 0.21 2.4 ± 0.25 0.137 
Study 2 Con-Int Lyc-Int TP-Int2 p-value 
Prostate Tumor (g) 1.9 ± 0.3 2.4 ± 0.5 2.1 ± 0.3 0.658 
Prostate2 (mg) 11.6 ± 2.6 7.6 ± 1.3 6.3 ±1.1 0.182 
     Anterior 8.7 ± 2.6 6.5 ± 1.6 4.0 ± 0.7 0.136 
     Dorsolateral 4.5 ± 0.8 4.4± 1.3 4.3 ± 0.8 0.760 
     Ventral 3.6 ± 0.8 2.6 ± 0.3 3.7 ± 1.0 0.553 
Seminal Vesicles (mg) 27.0 ± 3.4 38.2 ± 13.9 27.3 ± 8.4 0.465 
Liver (g) 1.24 ± 0.12 1.15 ± 0.05 1.20 ± 0.03 0.087 
Lungs (g) 0.19 ± 0.02 0.26 ± 0.04 0.21 ± 0.02 0.208 
Epididymal Adipose Tissue (g) 2.03 ± 0.23 1.65 ±0.17 1.72 ± 0.19 0.366 
 
1 There were no statistically significant differences between treatments for any organ at necropsy 
by ANOVA. Values are represented as mean ± SEM. In Study 1, n=26-28 per group (Con-L, n=28; 
TP-L, n=26; TP-Int1, n=26). In Study 2, n=27-29 per group (Con-Int, n=29; TP-Int2, n=29; Lyc-Int, 
n=27). 





Figure D.1. Body Weights of castrated TRAMP mice fed tomato (TP) and lycopene 
(Lyc) containing diets 
 
A, Study 1 mean body weight of TRAMP mice at euthanasia; B, Study 1 mean weekly 
body weight; C, Study 2 mean body weight of TRAMP mice at euthanasia; D, Study 2  
mean weekly body weight. Data are represented as mean ± SEM. Individual points 
indicate individual mice. In Study 1, n=26-28 per group (Con-L, n=28; TP-L, n=26; TP-






Figure D.2. Individual CRPC tumor growth curves 
 
Each line represents the in vivo growth of an individual mouse’s tumor from detection 
(week 0) through 4 weeks post-detection. Study 1, top row; Study 2, bottom row. Lines 
which end before the 4th week are due to animals that died prior to completing all tumor 





Appendix E: Supplemental tables and figures for Chapter 5 
 
Figure E.1. Dose of radiation delivered 
Dose of radiation received. Values are represented as mean ± SEM. The dotted line 
represents the targeted dose of 7.5 gy. * means differ (p<0.0001, t-test) 
Figure E.2. Body weights of TRAMP mice 
A, Pilot study body weights at euthanasia, bars represented as mean ± SEM. B, Pilot 
study mean weekly body weight; data are represented as mean ± SEM. C, Diet study 
body weights; values are represented as mean ± SEM. D, Diet study mean weekly body 
weight; data are represented as mean ± SEM. 
Table E.1. Composition of experimental diets. 






Figure E.1. Dose of radiation delivered 






Values are represented as mean ± SEM (n=3 per group). The dotted line represents the 




Figure E.2 Body weights of TRAMP mice 
 
A, Pilot study body weights at euthanasia, bars represented as mean ± SEM (n=6/group). 
B, Pilot study mean weekly body weight (n=6 per group); data are represented as mean 
± SEM. C, Diet study body weights; values are represented as mean ± SEM (Sham, n=16; 
TP-Sham, n=20; Rad, n=19; TP-Rad, n=18). D, Diet study mean weekly body weight; 







Table E.1 Composition of experimental diets. 
 
  Control 10% Tomato 
Cornstarch 390 363 
Maltodextrin 130 105 
Sucrose 98 97 
Casein 196 177 
Cellulose 49 41 
AIN-93G mineral mix 34 34 
AIN-93G vitamin mix 10 10 
L-Cystine 3.0 3.0 
Choline bitartrate 2.5 2.5 
Soybean oil 70 68 
Lyophilized tomato paste 0 100 
10% Lycopene beadlets 0 0 
Water 18 0 
kcal/g diet1  3.9 3.8 




Table E.2 Organ weights at necropsy 
 
Diet Study Sham TP-Sham Rad TP-Rad  
Prostate Tumor (g) 1.65 ± 0.30 1.73 ± 0.49 1.24 ± 0.30 1.68 ± 0.27 0.58 
Prostate1 (mg) 197 ± 37 203 ± 28 247 ± 24 196 ± 33 0.28 
     Anterior 136 ± 24 119 ± 14 151 ± 15 124 ± 22 0.56 
     Dorsolateral 58 ± 11 78 ± 13 73 ± 9 56 ± 9 0.34 
     Ventral 40 ± 6 36 ± 3 33 ± 3 29 ± 4 0.23 
Seminal Vesicles (g) 0.82 ± 0.13  0.78 ± 0.10 0.96 ± 0.11 0.89 ± 0.12 0.65 
Liver (g) 1.38 ± 0.06  1.39 ± 0.07 1.37 ± 0.07 1.32 ± 0.04 0.76 
Lungs (g) 0.21 ± 0.06 0.15 ± 0.01 0.20 ± 0.04 0.15 ± 0.00 0.53 
Epididymal Adipose (g) 1.25 ± 0.11 1.42 ± 0.12 1.31 ± 0.11 1.33 ± 0.10 0.76 
Heart (mg) 151 ± 5 158 ± 4 160 ± 4 156 ± 3 0.46 
Testes (mg) 239 ± 4 238 ± 4 234 ± 4 231 ± 3 0.13 
Spleen (mg) 88 ± 10a 64 ± 16a 82 ± 6b 44 ± 2b <0.0001 
 
Values are represented as mean ± SEM. In the pilot study, n=6 per group (Sham, n=6; 24-Hours, 
n=6; 72-Hours, n=6). In the Diet Study, n=16-20 per group (Sham, n=16; TP-Sham, n=20; Rad, 
n=19; TP-Rad, n=18). Bolded entries signify a main treatment (radiation) effect of an ANOVA. 
n.a. represents not analyzed due to a low number of samples (n=2) in one of the groups. 
1Represents the combined weight of all lobes of prostate found at necropsy. 
 
Pilot Study Sham 24 Hours 72 Hours p-value 
Prostate Tumor (g) 0.88 ± 0.32 0.53 ± 0.18 0.28 ± 0.05 n.a. 
Prostate2 (mg) 312 ± 110 108 ± 23 257 ± 53 0.06 
     Anterior 137 ± 25 87 ± 16 153 ± 28 0.17 
     Dorsolateral 169 ± 134 25 ± 9 89 ± 22 0.19 
     Ventral 94 ± 48 14 ± 1 20 ± 3 n.a. 
Seminal Vesicles (g) 0.97 ± 0.26 0.76 ± 0.08 1.32 ± 0.24 0.06 
Liver (g) 1.34 ± 0.08a 1.08 ± 0.07b 1.12 ± 0.04ab 0.03 
Lungs (g) 0.14 ± 0.01 0.15 ± 0.01 0.15 ± 0.00 0.69 
Epididymal Adipose (g) 1.03 ± 0.11 0.88 ± 0.16 1.01 ± 0.08 0.61 
Heart (mg) 141 ± 5 140 ± 6 140 ± 5 0.76 
Testes (mg) 231 ± 7a 213 ± 5ab 207 ± 5b <0.01 
Spleen (mg) 83 ± 4a 40 ± 4b 40 ± 4b <0.0001 
